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Background: Diabetic retinopathy screening (DRS) is effective but uptake is suboptimal.
Objectives: To determine the effectiveness of quality improvement (QI) interventions for DRS attendance;
describe the interventions in terms of QI components and behaviour change techniques (BCTs); identify
theoretical determinants of attendance; investigate coherence between BCTs identified in interventions
and determinants of attendance; and determine the cost-effectiveness of QI components and BCTs for
improving DRS.
Data sources and review methods: Phase 1 – systematic review of randomised controlled trials (RCTs)
evaluating interventions to increase DRS attendance (The Cochrane Library, MEDLINE, EMBASE and trials
registers to February 2017) and coding intervention content to classify QI components and BCTs. Phase 2 –
review of studies reporting factors influencing attendance, coded to theoretical domains (MEDLINE,
EMBASE, PsycINFO and sources of grey literature to March 2016). Phase 3 – mapping BCTs (phase 1) to
theoretical domains (phase 2) and an economic evaluation to determine the cost-effectiveness of BCTs or
QI components.
Results: Phase 1 – 7277 studies were screened, of which 66 RCTs were included in the review.
Interventions were multifaceted and targeted patients, health-care professionals (HCPs) or health-care
systems. Overall, interventions increased DRS attendance by 12% [risk difference (RD) 0.12, 95%
confidence interval (CI) 0.10 to 0.14] compared with usual care, with substantial heterogeneity in effect
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size. Both DRS-targeted and general QI interventions were effective, particularly when baseline attendance
levels were low. All commonly used QI components and BCTs were associated with significant improvements,
particularly in those with poor attendance. Higher effect estimates were observed in subgroup analyses for
the BCTs of ‘goal setting (outcome, i.e. consequences)’ (RD 0.26, 95% CI 0.16 to 0.36) and ‘feedback on
outcomes (consequences) of behaviour’ (RD 0.22, 95% CI 0.15 to 0.29) in interventions targeting patients
and of ‘restructuring the social environment’ (RD 0.19, 95% CI 0.12 to 0.26) and ‘credible source’ (RD 0.16,
95% CI 0.08 to 0.24) in interventions targeting HCPs. Phase 2 – 3457 studies were screened, of which
65 non-randomised studies were included in the review. The following theoretical domains were likely to
influence attendance: ‘environmental context and resources’, ‘social influences’, ‘knowledge’, ‘memory,
attention and decision processes’, ‘beliefs about consequences’ and ‘emotions’. Phase 3 – mapping identified
that interventions included BCTs targeting important barriers to/enablers of DRS attendance. However,
BCTs targeting emotional factors around DRS were under-represented. QI components were unlikely
to be cost-effective whereas BCTs with a high probability (≥ 0.975) of being cost-effective at a societal
willingness-to-pay threshold of £20,000 per QALY included ‘goal-setting (outcome)’, ‘feedback on outcomes
of behaviour’, ‘social support’ and ‘information about health consequences’. Cost-effectiveness increased
when DRS attendance was lower and with longer screening intervals.
Limitations: Quality improvement/BCT coding was dependent on descriptions of intervention content in
primary sources; methods for the identification of coherence of BCTs require improvement.
Conclusions: Randomised controlled trial evidence indicates that QI interventions incorporating specific
BCT components are associated with meaningful improvements in DRS attendance compared with usual
care. Interventions generally used appropriate BCTs that target important barriers to screening attendance,
with a high probability of being cost-effective. Research is needed to optimise BCTs or BCT combinations
that seek to improve DRS attendance at an acceptable cost. BCTs targeting emotional factors represent a
missed opportunity to improve attendance and should be tested in future studies.
Study registration: This study is registered as PROSPERO CRD42016044157 and PROSPERO
CRD42016032990.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Antiangiogenic therapy A procedure whereby drugs are injected into the eye to block the factors
associated with the growth and leakage of abnormal blood vessels. Used in the treatment of proliferative
diabetic retinopathy and diabetic maculopathy.
Background diabetic retinopathy The earliest visible change to the retina in diabetes, in which small
blood vessels show signs of damage. They may bulge slightly or leak blood (haemorrhage) or fluid.
Behaviour change technique An observable and replicable component designed to change behaviour.
It is the smallest component compatible with retaining the postulated active ingredients and can be used
alone or in combination with other behaviour change techniques.
Diabetes mellitus A lifelong condition that causes a person’s blood sugar level to become too high.
Diabetic maculopathy A consequence of diabetic retinopathy. Maculopathy is damage to the macula,
the part of the eye that provides us with our central vision.
Diabetic retinopathy A complication of diabetes caused by high blood sugar levels damaging the back
of the eye (retina). It can cause blindness if left undiagnosed and untreated.
Dilated fundus examination A diagnostic procedure that uses eye drops to dilate or enlarge the pupil of
the eye to obtain a better view of the retina.
Laser photocoagulation A procedure used to treat proliferative diabetic retinopathy and maculopathy.
Beams of bright laser light make tiny burns to stop the leaking and to stop the growth of new
blood vessels.
Non-mydriatic A term usually applied to cameras or imaging devices that take an image of the retina.
Non-mydriatic means that eye drops that dilate the pupil of the eye are not needed during the procedure.
Ophthalmologist A medical doctor who has specialised in the diagnosis and treatment of eye diseases.
Optician A person qualified to prescribe and dispense glasses and contact lenses and to detect eye
diseases (optometrist) or to make and supply glasses and contact lenses (dispensing optician).
Optometrist Primary health-care professional trained to examine and detect diseases of the eye.
Proliferative diabetic retinopathy The advanced stage of diabetic retinopathy in which new blood
vessels grow along the inside surface of the retina. These blood vessels are very delicate and bleed easily.
The bleeding (haemorrhage) causes scar tissue that starts to shrink and pull on the retina, leading to it
becoming detached and possibly causing vision loss or blindness.
Slit-lamp biomicroscopy A technique that uses an instrument (slit-lamp biomicroscope) to examine the
front and back (retina) of the eye under magnification.
Type 1 diabetes mellitus Occurs when the body cannot produce insulin, which is needed to control
blood glucose levels.
Type 2 diabetes mellitus Occurs when the body cannot produce enough insulin or the insulin is not
working efficiently enough.
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EPOC Effective Practice and Organisation
of Care
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QI quality improvement
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Plain English summary
People with diabetes mellitus may lose vision as a result of the damaging effects of the disease onsmall blood vessels at the back of the eye (diabetic retinopathy). Screening for diabetic retinopathy
to detect and treat early signs can prevent sight loss. However, screening attendance is variable and
sight-threatening changes may not be detected in good time.
This study investigated the literature to find out if interventions used to improve screening attendance are
effective. We labelled each intervention in terms of the techniques used to encourage attendance and
assessed whether some worked better than others. We then described what factors encourage or prevent
patients from regularly attending for screening and examined whether or not the techniques used target
these factors. We also assessed value for money by comparing the costs and benefits of the interventions
and their component techniques.
We found that interventions aimed at patients and/or health-care professionals were effective at improving
screening attendance. Interventions aimed at improving the general quality of diabetes care worked as
well as those specifically aimed at improving screening for retinopathy. On average, attendance increased
by 12% compared with no intervention. All of the techniques commonly used improved attendance,
especially goal-setting and providing additional social support. The successful techniques were highly likely
to be good value for money, particularly if used in groups who do not usually attend for screening. Linking
techniques to factors influencing attendance showed that the interventions did include techniques that
target these factors. However, techniques addressing emotional barriers to screening attendance and fear
of the consequences of screening were not included in published interventions.
Evidence shows that interventions that target behaviour change do increase screening attendance and
have a good chance of being good value for money. Further studies are required to test how well
techniques addressing emotional barriers to screening work in terms of increasing attendance.
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Scientific summary
Background
Diabetic retinopathy is the most common microvascular complication of diabetes mellitus and is one of
the leading causes of blindness and visual impairment in the UK and throughout the world. However,
despite evidence supporting the effectiveness of diabetic retinopathy screening (DRS) in reducing the risk
of sight loss in people with diabetes, screening uptake is below the recommended levels in many screening
programmes. Research has highlighted that living in an area of high social deprivation, younger age
(< 40 years), having a longer duration of diabetes and belonging to a black, Asian and minority ethnic
group are all associated with lower levels of screening attendance. There is a need to identify the most
effective and cost-effective quality improvement (QI) interventions that increase attendance for DRS in
people with diabetes and to identify the modifiable barriers to/enablers of screening uptake.
Objectives
The specific objectives were as follows.
1. Systematically review the evidence from randomised controlled trials (RCTs) on the effectiveness and
cost-effectiveness of QI interventions that seek to increase attendance for DRS and code descriptions of
the interventions reported in the included RCTs in terms of the QI components and their constituent
behaviour change techniques (BCTs) (with BCTs being the ‘active components’ of interventions that aim
to improve screening attendance).
2. Systematically identify the published and grey literature reporting barriers and facilitators associated
with DRS and code barriers/facilitators according to the Theoretical Domains Framework (TDF) of
behaviour change and the Consolidated Framework for Implementation Research (CFIR) (with domains
being explanatory factors that are proposed to mediate change).
3. Assess BCTs (from objective 1) and barriers and facilitators (from objective 2) in terms of their
theoretical coherence (i.e. whether or not the components of existing DRS interventions target
important determinants of attendance).
4. Use data from objectives 1–3 to estimate the likely cost-effectiveness of interventions to increase
attendance at DRS.
Methods
The study design comprised three phases.
1. Phase 1 (objective 1): a systematic review of RCTs that used any QI intervention to improve attendance
for DRS. Interventions could be directed at patients with diabetes, health-care professionals (HCPs),
the health-care system or any combination thereof. The primary outcome for this review was attendance
for one or more visits for DRS within a 2-year period following randomisation. Secondary outcomes
included ongoing adherence to DRS based on attendance following the initial screening event post
intervention, resources required to deliver interventions and intervention cost-effectiveness. Intervention
content was coded using a classification system to describe the QI components and the BCT taxonomy to
identify the specific BCTs present in each intervention and their effectiveness was analysed by subgroup
analysis and meta-regression.
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2. Phase 2 (objective 2): systematic review of the published and grey literature reporting perceived barriers
and enablers associated with DRS attendance and categorisation of barriers/enablers according to
validated, theory-informed frameworks (TDF and CFIR).
3. Phase 3 (objectives 3 and 4): exploration of theoretical coherence between component BCTs used in
published interventions in the phase 1 review and the TDF domains representing the key barriers to and
enablers of DRS attendance identified in the phase 2 review. This was conducted using two validated
BCT and domain mapping tools. High coherence was defined as the use of BCTs that target important
TDF domains. Low coherence was defined as the use of BCTs that target less important TDF domains.
Missed opportunities for intervention design were noted as infrequent use of BCTs that are theoretically
coherent. A health economic evaluation was conducted using a Markov economic model to estimate
the cost–utility of QI components and BCTs used in interventions. Single BCT components were
compared in the model in terms of their cost-effectiveness. The effectiveness of BCT components was
estimated using multivariable meta-regressions, utilising the data obtained from the phase 1 systematic
review of intervention effectiveness. The costs of BCTs were estimated by assigning a resource use rank
to each intervention in each RCT and conducting a multivariable ordered logit regression. Costs were
assigned to each expected rank. Imprecision in the model was investigated using sensitivity analyses.
Finally, we conducted a formal 1-day knowledge exchange event with stakeholders and end-users to
present the outputs from the evidence synthesis and health economic modelling and discuss the
interpretation and service implications of the findings.
Results
Phase 1: diabetic retinopathy screening intervention effectiveness review
We screened 7277 studies, of which 66 RCTs (n = 352,879 participants) were included in the review
(The Cochrane Library, MEDLINE, EMBASE and trials registers; search date February 2017). Of the included
studies, 50 (75.8%) were of general QI interventions that evaluated their impact across a range of
outcomes (including DRS uptake) and 16 (24.2%) were of interventions that had a primary target of
improving attendance for DRS. The studies were conducted primarily (66.7%) in North America between
1988 and 2013. Thirty-five studies (53%) were parallel-group patient RCTs and 31 (47%) were cluster
RCTs in which the HCP or the health-care setting was the unit of randomisation. Interventions were
multifaceted and incorporated multiple QI components/BCTs targeting patients and HCPs. Fifty studies
compared a variety of QI interventions with usual care. A random-effects meta-analysis of these studies
found a 12% [risk difference (RD) 0.12, 95% confidence interval (CI) 0.10 to 0.14] absolute increase in
DRS attendance for the interventions compared with usual care. Although the pooled effect estimate was
larger for DRS-targeted interventions (RD 0.17, 95% CI 0.11 to 0.22) than for non-targeted interventions,
this difference was not statistically significant. Ten studies compared a less intensive intervention (‘active’
control) with a more intensive intervention. The aim of these studies was to determine whether stepping
up the intensity of an intervention component, or introducing further components, would increase DRS.
The pooled effect estimate for these studies was smaller (RD 0.05, 95% CI 0.02 to 0.09), in favour of
the more intensive intervention, suggesting that it is possible to further enhance the effect size by
increasing intervention intensity. The main comparison in this review (any QI intervention vs. usual care)
was associated with substantial heterogeneity. Heterogeneity was explored using subgroup analysis and
univariate meta-regression. Sufficient studies were available to investigate the impact of 17 BCTs targeting
patients or HCPs. All BCTs were effective in subgroup analysis, with pooled RDs ranging from 0.11 to
0.26. A meta-regression found that certain BCTs were more effective at improving DRS attendance,
including ‘goal-setting (in relation to outcomes or consequences of attending, not attendance itself)’
(regression coefficient 0.162, 95% CI 0.070 to 0.254; p = 0.001), ‘credible source’ (e.g. persuasive
communication from a respected person) (regression coefficient 0.097, 95% CI –0016 to 0.211;
p = 0.092) and ‘restructuring the social environment’ (e.g. introduce diabetes link workers) (regression
coefficient 0.085, 95% CI –0.001 to 0.172; p = 0.053). There was some evidence for larger effect sizes in
populations with lower baseline DRS attendance (regression coefficient –0.208, 95% CI –0.419 to 0.004;
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p = 0.054); however, much of the observed heterogeneity was unexplained. We found no studies
reporting our secondary outcome measure of ongoing adherence to DRS following the initial screening
appointment post intervention and no data on the relative effectiveness of interventions in particular
population subgroups, for example according to socioeconomic characteristics.
Phase 2: barriers/enablers review
We screened 3457 studies, of which 65 were included in the review (MEDLINE, EMBASE, PsycINFO and
sources of grey literature; search date March 2016). Of these, 41 (63%) used quantitative methods only
(e.g. questionnaires, surveys), 18 (28%) used qualitative methods only (e.g. interviews/focus groups) and
six (9%) used mixed methods. The majority (79%) of studies that used quantitative methods in full or as
part of a mixed-method design used a cross-sectional survey design. The majority of studies (79%) that
used qualitative methods in full or as part of a mixed-method design were descriptive and used no specific
analytical or theoretical approach. The studies were conducted primarily in North America (60%), with only
12 studies (18%) conducted in the UK. Fifty studies (77%) reported barriers/enablers from the perspective
of the patients only, 14 studies (21%) reported barriers/enablers from the perspective of both patients and
HCPs and one study (2%) reported barriers/enablers from the perspective of HCPs who were diagnosed
with diabetes. The TDF domains ‘environmental context and resources’, ‘social influences’, ‘knowledge’,
‘memory, attention and decision processes’, ‘beliefs about consequences’ and ‘emotions’ were identified
as representing the most important factors potentially influencing screening attendance. Thematic
synthesis within these six domains resulted in specific content themes at multiple levels, including at the
patient (e.g. fear/anxiety about vision loss, confusion between screening and routine eye care), HCP
(e.g. recommendation to screen, or lack of such recommendation, by the HCP), health-care system
(e.g. inaccurate registers) and wider community (e.g. lack of media coverage) levels. Overall, there were
almost three times as many content themes identified as barriers than as enablers (60 vs. 22). Many of the
themes/subthemes identified within the six TDF domains related to four broad areas: (1) perceptions of
convenience (e.g. transportation, scheduling appointment issues), (2) (lack of) awareness (e.g. of diabetic
retinopathy, screening importance/frequency), (3) comfort and support (e.g. trust in doctors, social support,
negative emotions) and (4) misconceptions that need to be addressed through improved message content
(e.g. DRS not necessary, confusion between attendance at retinopathy screening and routine eye tests).
Recoding the themes from the TDF domains into CFIR constructs did not offer any further insights as the
barriers and enablers reported in the studies were predominantly from the perspective of the patient rather
than the perspective of the organisation or HCP.
Phase 3.1: mapping
Published interventions included a median of four BCTs targeting patients (range 0–16) and three targeting
HCPs (range 0–14). Ten BCTs were frequently identified in intervention arms targeting patients and seven
were frequently identified in intervention arms targeting HCPs. The majority (80%) of frequently used
BCTs in patient intervention arms, and all (100%) frequently used BCTs in HCP intervention arms, were
paired with at least one of the six domains that were identified as important in the review in phase 2,
representing high theoretical coherence. Only two BCTs in the patient intervention arms had a low level
of coherence (i.e. they were paired only with domains of lesser importance): ‘goal-setting (outcome, i.e.
consequences)’ and ‘problem-solving (involving personalised barrier identification together with finding
solutions)’. All frequently used BCTs were effective, regardless of whether they had low or high theoretical
coherence. However, the majority (88%) of effective BCTs were highly coherent. Missed opportunities for
intervention design were identified for all six important theoretical domains, that is, at least one coherent
BCT was not frequently identified in the interventions. Opportunity seized was highest for ‘memory,
attention, and decision processes’ (50% of the theoretically coherent BCTs were frequently used in
interventions), followed by ‘knowledge’ (42% of the theoretically coherent BCTs were frequently used in
interventions). The most missed opportunities were observed for the ‘emotions’ domain; none of the
coherent BCTs paired with this domain were frequently used in existing DRS interventions (range 0–3
intervention arms).
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Phase 3.2: economic modelling
The probability of an intervention being cost-effective at a societal willingness-to-pay threshold of
£20,000 per quality-adjusted life-year was determined using economic modelling that considered the
situation of annual screening, age at screening of 64 years and likelihood of attending screening without
any additional intervention of 70%. The QI component with the highest probability of being cost-effective
was patient education, but in general QI components were unlikely to be considered cost-effective. The
patient-targeted BCTs of ‘goal-setting’, ‘feedback on outcomes of behaviour’ (such as timely treatment),
‘social support’ and ‘information about health consequences’ had extremely high probabilities of being
cost-effective compared with no BCT intervention (≥ 0.975). For the HCP-targeted BCTs, adding objects to
the environment (e.g. reminder systems) had a probability of being cost-effective of > 0.9. The sensitivity
analyses showed that the probability of being cost-effective increased with lower baseline DRS attendance
levels and when the screening interval was increased to biennially or every 3 years.
Conclusions
The results of this study suggest that a number of strategies are likely to improve attendance for DRS.
QI interventions targeted at the person with diabetes, HCPs or the health-care system improve attendance
by 12% on average compared with usual care. There was some evidence to indicate that a larger effect
size could be anticipated in poor attenders. Current interventions are generally using appropriate BCTs that
mediate change in screening behaviour, with a high probability of being cost-effective.
Implications for practice
Including behavioural interventions to support the uptake of DRS services could improve the uptake of DRS.
Such interventions included providing feedback on the consequences of attendance or non-attendance;
encouraging social (interpersonal) support to attend; providing more information on diabetic eye disease,
including information about its health consequences and the process of screening; and introducing
reminder systems or ensuring that patient information is provided by a credible source, such as national
clinical guidelines. These interventions can be delivered at a patient level and at the level of the health
system, including health-care professionals. We identified that these interventions are effective, potentially
cost-effective and also likely to target the important factors associated with attendance at DRS.
For services with lower levels of uptake, the cost-effectiveness evidence and evidence on the effectiveness
of BCTs suggest that providing ‘feedback’ and ‘information about health consequences’ could be worthwhile.
Examples of possible approaches include providing information on diabetic retinopathy, the consequences
and benefits of DRS and explaining the difference between DRS and attendance for regular eye tests. Other
possible approaches include introducing processes to facilitate attendance and improvements in the screening
environment, for example processes to improve convenience for patients such as online management/
booking systems or monitoring tools such as diabetes passports.
Implications for research
The evidence from this study can be used to inform the development of a future RCT to evaluate the
effectiveness and cost-effectiveness of multifaceted interventions for DRS attendance. Intervention
components that target the emotional barriers to and enablers of screening attendance, such as anxiety
regarding the process or outcome of screening, should be considered. Usual care should be specified in
sufficient detail such that BCTs present in the control arm can be identified. Outcome assessment at a
minimum of 24 months is suggested to capture attendance and ongoing attendance at DRS. The evidence
suggests that the target participants should be those who do not regularly attend for DRS. Before carrying
out a trial, a programme of preliminary research is recommended to identify the population with a low
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DRS attendance rate. A qualitative exploration of key determinants of attendance in subgroups of low
attendees and the feasibility of and ethical concerns around targeting population subgroups is needed.
Study registration
This study is registered as PROSPERO CRD42016044157 and PROSPERO CRD42016032990.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the health problem
Globally, an estimated 380 million adults have diabetes mellitus. The majority have type 2 diabetes and the
numbers are predicted to increase because of longer lifespans and rising levels of obesity. The majority
of those affected live in low- or middle-income countries.1 Diabetes and its complications impose a
considerable health and economic burden on individuals, families and health-care systems.2
Diabetic retinopathy is the most common microvascular complication of diabetes and is one of the leading
causes of blindness and visual impairment in the UK and throughout the world.3,4 Although effective
treatments are available for sight-threatening retinopathy in the form of laser photocoagulation5 and, more
recently, the use of antivascular endothelial growth factor inhibitors,6 the success of these interventions is
dependent on early detection and timely referral for treatment. Screening for diabetic retinopathy fulfils
the World Health Organization (WHO) criteria for a screening programme,7 namely diabetes-associated
visual impairment is an important public health problem; potentially sight-threatening retinopathy has a
recognisable latent stage; a universally accepted and effective treatment is available; and screening is
cost-effective compared with no screening in terms of sight-years preserved.8,9 Relatively few countries
have introduced a national population-based diabetic retinopathy screening (DRS) programme. In most
parts of the world screening remains opportunistic, although an annual or biennial retinal examination is
recommended in diabetes clinical practice guidelines in many countries.10–12
Given the value of screening for reducing the risk of sight loss among people with diabetes, it is essential
that screening programmes provide consistent and equitable access for the target population. Furthermore,
an appropriate infrastructure needs to be in place to manage those testing positive, with timely access
to treatment for those who need it. To maximise screening coverage, those people with diabetes who
would benefit from screening need to be identified and receive regular screening as part of their normal
diabetic care.
UK diabetic retinopathy screening programme
Recent developments in digital retinal photography have facilitated the rapid acquisition of high-quality
fundus images that can be stored and subsequently graded. Digital imaging combined with trained graders
has been shown to be an effective screening tool to identify sight-threatening diabetic retinopathy13 and is
increasingly gaining acceptance for population screening.14–17 The UK was the first country in the world to
introduce a national population-based DRS scheme, which was based on annual digital fundus photography
(Figure 1). This was initially introduced in England in 2003 as part of the National Service Framework for
Diabetes18 and by 2008 the scheme had become established throughout the UK. In England, DRS is
overseen by the NHS Diabetic Eye Screening Programme, which offers screening to all people with diabetes
aged > 12 years in approximately 70 local programmes. Screening services in Scotland, Wales and Northern
Ireland are very similar but with slightly different operational procedures. If sight-threatening retinopathy is
identified through the screening service, referral to a specialist eye unit is arranged within a specified time
frame for further assessment and treatment. An early indicator of the success of the Diabetic Eye Screening
Programme, combined with incentives to primary care practitioners to improve the quality of diabetes care,19
comes from a recent longitudinal analysis of the national database of blindness certificates of vision
impairment.4 Over 10 years leading up to 2009–10, the rate of working-age adults in England and Wales
(aged 16–64 years) with blindness certifications attributable to diabetic retinopathy decreased by 3.7%,
such that the condition is no longer the main cause of blindness in working adults.
DOI: 10.3310/hta22290 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 29
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Lawrenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
Variation in attendance for diabetic retinopathy screening
Despite evidence supporting the effectiveness of DRS in reducing the risk of sight loss in people with
diabetes, screening coverage is consistently below recommended levels.20–22 Following a diagnosis of
diabetes, not all of those who are eligible are referred into the retinopathy screening service and further
barriers occur within the screening service itself. Those invited for screening have to receive the invitation,
appreciate the importance of attending for screening and then attend for their appointment. Although a
small proportion of the unscreened population is either excluded or suspended from the screening service,
approximately 20% of those offered screening fail to attend, with wide geographical variation in screening
attendance. Based on the most recently available information from screening programmes in England
(from April 2015 to March 2016) (Figure 2), attendance varied from 71% to 92% of those referred into
the screening service.
Predictors of poor attendance for diabetic retinopathy screening and
quality improvement interventions to increase screening attendance
Following the introduction of the UK NHS Diabetic Eye Screening Programme, published audits have
reported significant inequity in DRS attendance and outcomes. Living in areas of high social deprivation,
a younger age (< 40 years) and having a longer duration of diabetes have been found to be associated
with lower rates of attendance.8,20,23,24 Ethnicity is also an important determinant of DRS attendance and
outcomes. Black, Asian and minority ethnic groups with type 2 diabetes have a higher prevalence of
diabetic retinopathy than white Europeans3 and there is evidence to suggest that these groups are more
likely to present with sight-threatening retinopathy and have higher rates of referral to ophthalmology
following screening.25,26 Despite the associated risk, there is evidence that these ethnic groups are less
likely to attend for screening.20 In addition to the obvious impact on eye health, the high rates of
non-attendance have major financial consequences. For example, from April 2012 to April 2013, in the
London borough of Tower Hamlets, the screening programme invited 13,894 people to participate in DRS.
NHS Diabetic Eye Screening
Programme
Identification of cohort
Invited for routine screening
Routine digital screening
Primary grading
Screen negative
Screen positive
Secondary grading
Referable disease present
Hospital eye services
for treatment
Surveillance
FIGURE 1 NHS Diabetic Eye Screening Programme.
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Of those invited, 4833 (34.7%) failed to attend for their appointment, without rebooking or cancelling.
With each appointment costing £25, the total cost of non-attendance for that year can be crudely
estimated at £120,825 (Tunde Peto, Queen’s University Belfast, 2016, personal communication).
The difference between health-care processes or outcomes observed in practice and those believed to
be achievable has been referred to as the quality gap.27 DRS attendance can be regarded as a quality
improvement (QI) target, which along with other processes of diabetes care can potentially be improved
through the use of one or more QI interventions. A systematic review assessing the effectiveness of
QI interventions to promote DRS was published in 2007.22 This review found evidence that a variety
of intervention components targeting the patient, the health-care professional (HCP) or the health-care
system can be effective in improving screening attendance. Patient-targeted QI components included
(1) educational programmes to increase awareness of diabetic retinopathy and promote self-management
and (2) the use of prompts/reminders. HCP-focused QI components included (1) clinician education
and (2) audit and feedback. Interventions targeting the health-care system included (1) team changes,
(2) establishing electronic registration and recall and (3) the use of telemedicine. In addition to QI
interventions that specifically target DRS, general QI interventions for diabetes care may also be effective
in improving screening coverage. Several systematic reviews of general QI interventions for improving the
quality of diabetes care have included eye-screening outcomes (see Worswick et al.28 for an overview
of these reviews). A systematic review by Tricco et al.29 explored the effectiveness of QI interventions in
diabetes care and included eye screening as an outcome. QI interventions increased the likelihood that
people with diabetes received screening for retinopathy [23 trials; relative risk (RR) 1.22, 95% confidence
interval (CI) 1.13 to 1.32]. Although this review provided information on the relative effectiveness of
different QI interventions, the optimal combination of intervention components remained unclear.
To develop and evaluate QI interventions for improving DRS attendance, it is important to understand the
causal determinants of poor screening attendance. Moreover, it is unclear whether single or multicomponent
interventions are needed, what the optimal combination of components in multicomponent interventions
would be and whether or not interventions need to be adapted to particular patient groups (i.e. based on
socioeconomic factors, comorbidities, reality, etc.). There is overwhelming evidence that behaviour change
plays an important role in people’s health.30 Interventions to improve screening attendance are therefore
likely to be more effective if they target the determinants of behaviour associated with DRS and tailor
behaviour change strategies to specific patient groups.31,32
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FIGURE 2 Percentage of those offered a routine DRS appointment who attend and complete a routine digital
screening event [based on DE1 (Diabetic Eye-Uptake of Digital Screening Encounter) key performance indicator
data submissions from 1 April 2015 to 31 March 2016] across 72 screening programmes. SD, standard deviation.
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Rationale for current evidence synthesis and methodological approach
Although there have been previous systematic reviews33,34 on interventions to optimise adult screening
programmes [including a National Institute for Health Research (NIHR) Health Technology Assessment
(HTA) report35], it is likely that this evidence is not directly transferable to DRS. Screening for diabetic
retinopathy differs from other forms of screening. It is technically a surveillance programme in that those in
the target group have already been identified and have significant contact with the health-care system
because of their underlying diabetes, with life-long monitoring (i.e. annual or biennial surveillance).
However, the UK NHS Diabetic Eye Screening Programme is widely known as a screening programme and,
for consistency, we will refer to screening rather than surveillance throughout this report.
Failure to attend for DRS is not only a UK problem but also a global public health problem. Multiple
interventions have been studied in many countries in a variety of populations and contexts, including
private and publicly-funded screening services. Given the likely complexity of the behavioural determinants
of DRS attendance and the multicomponent nature of the interventions that have been used to increase
screening attendance, it is important to consider evidence from settings outside the UK.
In the subsequent chapters we report an evidence synthesis of the published and grey literature to identify
the effectiveness and cost-effectiveness of QI interventions for improving attendance for DRS globally and
explore the barriers and enablers relating to participation in such activity. We use a validated taxonomy of
behaviour change techniques (BCTs)36 and theoretical frameworks37–39 to specify the components of the
interventions and theoretical determinants of screening behaviour. We assess the theoretical coherence
between intervention components and determinants (i.e. barriers/enablers) associated with attendance for
DRS. We use these data to assess whether or not components of interventions to improve attendance for
DRS represent value for money for the UK NHS. We also report a formal process of knowledge exchange
with stakeholders and end-users to discuss the interpretation and application of the project findings.
BACKGROUND
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Chapter 2 Overview of methods
Aims and objectives
The aim of this project was to determine the most effective and cost-effective components of interventions
that seek to increase attendance for DRS in people with type 1 or 2 diabetes mellitus and to identify likely
determinants of poor uptake and ongoing attendance.
The specific objectives were as follows.
1. Systematically review the evidence from randomised controlled trials (RCTs) on the effectiveness and
cost-effectiveness of QI interventions that seek to increase attendance for DRS.
2. Enrich the data set by contacting authors of included studies to obtain information on missing data
relating to the content of the intervention and/or context.
3. Code descriptions of the interventions reported in the included RCTs in terms of the type of QI
intervention components used in the studies and their constituent BCTs (with BCTs being the ‘active
components’ of interventions).
4. Explore heterogeneity in effect size to identify factors associated with improved effectiveness
(objectives 1–4 reported in Chapter 3).
5. Systematically identify the published and grey literature reporting barriers and facilitators associated
with DRS.
6. Code barriers and facilitators identified in objective 5 into domains from two theoretical frameworks
(with domains being explanatory factors that are proposed to mediate change).
7. Assess whether or not the intervention components (from objective 3) target the proposed mediators
(from objective 5) (objectives 5–7 reported in Chapters 4 and 5).
8. Use data from objectives 1–7 to estimate the potential cost–consequences and cost–utility of
interventions to increase attendance at DRS (see Chapter 6).
9. Integrate the findings (objectives 1–8), with input from stakeholders and end-users, to make
recommendations for practice and future research aiming to improve the attendance for DRS in areas
or population subgroups with low uptake of screening (see Chapter 7).
The study plan is detailed in Figure 3. The design used a validated taxonomy of BCTs36 to code the
components of QI interventions used in RCTs seeking to improve DRS attendance. We also applied a
validated, theory-informed framework [Theoretical Domains Framework (TDF)]37,39 to code the barriers to,
and enablers of, screening behaviour in the studies identified from a systematic review of the published
and grey literature. By employing established mapping tools, we assessed the extent to which BCTs used in
existing interventions target the important theoretical determinants of DRS attendance. In parallel, a health
economic evaluation provided data on the relative cost-effectiveness of the QI interventions, and their
active components (BCTs), for increasing DRS attendance and determined the trade-off between the cost
of the QI interventions and their effectiveness.
Patient and public involvement
Patient and public involvement was integral to the project. Patient and public representatives were actively
involved in the development of the protocols for the phase 1 and phase 2 systematic reviews through our
stakeholder advisory group. The input of this group ensured that all important outcomes relevant to the
study question were included in the evidence synthesis. The stakeholder advisory group (see Appendix 1)
included representatives of retinopathy screening services throughout the UK, the Public Health
Development Manager and the Health Equalities Officer from the Royal National Institute of Blind People
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(RNIB) (who had been actively involved in community engagement projects to improve the uptake of DRS
in minority ethnic groups); and the Director of Health Intelligence and Professional Liaison at Diabetes UK.
The stakeholder advisory group also provided valuable intelligence on the problems of non-attendance
for screening and directed the team towards relevant grey literature on barriers to attendance and local
initiatives to improve attendance.
We conducted a formal 1-day knowledge exchange event with stakeholders and end-users to present the
outputs from the evidence synthesis and health economic modelling and discussed their interpretations and
service implications of the findings (phase 3). The event was attended by people with diabetes, representatives
of leading charities (Diabetes UK, RNIB), screening providers from the screening programmes of the four
nations and HCPs (representing ophthalmology, optometry and general medical practice). Before the event,
all participants received a summary of the results of the project. On the day, members of the research team
presented their research findings, which generated a lively debate. This was followed by three small discussion
groups to reflect more deeply on the project results. These groups were facilitated by consultants who were
independent of the research team. After the event, we prepared a formal report that included the themes
that emerged across the three discussion groups and a discussion of the implications for UK screening
programmes and for future research. A copy of the report was sent to participants for comments and
amendments (see Appendix 2). The outputs from the knowledge exchange event were used to inform the
conclusions of, and recommendations originating from, this project.
Phase 1: systematic review of interventions to increase
uptake and ongoing attendance for DRS. Coding of 
interventions using BCT taxonomy
Phase 2: identification of barriers and enablers associated
with attendance for DRS. Coding of behavioural 
determinants associated with poor attendance 
using theoretical frameworks
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Phase 3: integration of findings of evidence syntheses from
phases 1 and 2. Estimation of potential cost-effectiveness 
of ‘active’ BCTs. Knowledge exchange with end-users to 
discuss implications for current screening programmes and 
future research
FIGURE 3 Study plan.
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Chapter 3 Interventions to increase attendance for
diabetic retinopathy screening: systematic review and
meta-analysis
Background
The majority of studies assessing the effectiveness of QI interventions to improve diabetes care (including
those delivered specifically to improve DRS) involve multicomponent interventions that attempt to change
the behaviour of HCPs (e.g. advising patients to attend DRS) or patients (e.g. actually attending) or
both. As there is no consistent association between the number of intervention components and their
effectiveness,40,41 the ‘ideal’ number of components in such programmes is unknown. Furthermore, given
the complexity of interventions tested to date, it is not always clear which specific components are the
effective elements of these interventions (i.e. the ‘active ingredients’). Hence, the content of complex
behaviour change interventions and the mechanisms through which they have their effect has been
referred to as a ‘black box.42 Therefore, identification of effective interventions for increasing attendance for
DRS first requires clarity about intervention content and the functional relationship between components of
interventions and the intended outcomes. The Cochrane Effective Practice and Organisation of Care (EPOC)
Group has developed a taxonomy that can be used to classify intervention content in systematic reviews.43
Although the EPOC Group taxonomy provides a common language and a useful summary description of
interventions, the taxonomy may not be sufficiently detailed to specify intervention components in sufficient
detail to facilitate replication.44 A complementary approach is to provide a comprehensive categorisation of
the ingredients of interventions in terms of the BCTs used. BCTs are defined as the ‘observable, replicable
and irreducible components of an intervention that are designed to alter or redirect causal processes
regulating behaviour’.36 Recently, a taxonomy of 93 BCTs has been published (co-developed by team member
JJF) to provide a common, consistent terminology [Behaviour Change Technique Taxonomy version 1 (BCTTv1)36
by which the component BCTs in complex interventions may be identified and described. Examples of BCT
labels in this taxonomy include ‘goal-setting (outcome)’, ‘self-monitoring of behaviour’, ‘feedback on
behaviour’ and ‘problem-solving’. Review team members (JP, NMI and JMG) have demonstrated the
feasibility of using the BCT taxonomy within trials of QI interventions for diabetes care.44
Given the potential of screening for reducing the risk of sight loss among people with diabetes, it is
essential that attendance for DRS is maximised as far as available resources allow. Wide geographical
variation in screening coverage has been reported, with associated inequalities in outcomes. Furthermore,
given the incremental costs (resource use) and benefits (effects) associated with interventions to improve
attendance for DRS, it is important to consider whether or not such strategies are worthwhile. By identifying
the active components of interventions that increase attendance for screening, this review contributes
to the identification of implementation strategies for early detection of sight-threatening retinopathy.
Furthermore, by exploring the differential effects of interventions in particular subgroups, the results may
provide insight to help reduce inequalities in screening attendance and determine the impact of inequity on
intervention effectiveness and efficiency.
Objectives
1. Systematically review the evidence from RCTs for the effectiveness and cost-effectiveness of QI
interventions that seek to increase attendance for DRS.
2. Enrich the data set by contacting authors of included studies to obtain information on missing data
relating to the content of the intervention and/or context.
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3. Code descriptions of the interventions reported in the included RCTs in terms of the type of QI
interventions used and their constituent BCTs.
4. Explore heterogeneity in effect size using conventional and innovative meta-analytic methods to identify
factors (including BCTs) associated with greater effectiveness.
Methods
The protocol for this review was published as a Cochrane protocol in The Cochrane Library on 11 August 2016
(PROSPERO CRD42016044157).45 The economics aspects of the review were carried out according to the
recently updated methodology for incorporating economic evidence into Cochrane intervention reviews.
Types of studies
We considered RCTs, both individually randomised and cluster RCTs, conducted in a primary or a secondary
care setting. To investigate cost-effectiveness, we included full economic evaluations (cost-effectiveness
analyses, cost–utility analyses and cost–benefit analyses), cost analyses and comparative resource utilisation
studies conducted alongside or as part of an included RCT.
Types of participants
We included participants with type 1 and type 2 diabetes mellitus who were eligible for DRS.
Types of interventions
We included RCTs that used any planned strategy or combination of strategies to improve attendance for
DRS targeted at individuals with diabetes, HCPs or the health-care system. Interventions included those
specifically targeting DRS as well as those that were part of a general QI intervention for diabetes care.
Comparator interventions were as specified in the included studies.
Types of outcome measures
Primary outcome
The primary outcome was one or more visits for DRS within a 2-year period following randomisation.
This could be based on self-reports, medical insurance claims databases or health record audits.
Secondary outcomes
We considered the following secondary outcomes:
l ongoing adherence to DRS based on attendance for screening following the initial screening
post intervention
l economic outcomes
¢ resources (staff time, equipment, consumables) required to deliver interventions to increase
attendance for screening
¢ costs of staff used to provide interventions, costs of treatment and care, costs of primary care,
lost wages and lost productivity (work output)
¢ cost-effectiveness [incremental cost-effectiveness ratios (ICERs), incremental cost per quality-adjusted
life-year (QALY), incremental cost per disability-adjusted life-year, incremental cost–benefit ratios
and net benefits].
INTERVENTIONS TO INCREASE SCREENING ATTENDANCE
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Search methods for identifying studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the NHS Economic
Evaluation Database (NHS EED) on The Cochrane Library, Ovid MEDLINE, Ovid MEDLINE In-Process & Other
Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to February 2017), EMBASE
(January 1980 to February 2017), PsycINFO (1967 to February 2017), the Web of Science Conference
Proceedings Citation Index – Science (CPCI-S) (January 1990 to February 2017) and Emerging Sources Citation
Index (ESCI) (January 2015 to February 2017), ProQuest Family Health (January 1987 to February 2017) and
OpenGrey (January 1980 to February 2017). We searched the following trials registers: International Standard
Randomised Controlled Trial Number (ISRCTN) registry, ClinicalTrials.gov and the WHO International Clinical
Trials Registry Platform (ICTRP). We did not use any date or language restrictions in the electronic searches.
Appendix 3 provides an example search strategy, with full details provided in Report Supplementary Material 1
(see Search strategies for phase 1 systematic review).
Searching other resources
We searched the reference lists of included studies to identify additional relevant references. In particular,
we used the reference list of a 2012 systematic review29 co-authored by members of the current review team
(NMI, JMG) that investigated the effectiveness of QI strategies for the management of diabetes. We also
identified further studies from the review authors (NMI, JMG), who are currently updating this review.46 As
the review of general QI interventions included only components directed at patients in conjunction with an
intervention targeting HCPs,29 we also screened the list of excluded studies, which was obtained from the
review team.
Study selection and data extraction
Two review authors (JGL and JMB) independently screened the titles and abstracts of studies identified in
the electronic searches. We obtained full copies of research papers in cases of uncertainty and resolved any
differences of opinion between review authors by discussion. Two review authors (JGL and EGR) worked
independently to extract data from the included studies using a modified version of the EPOC Group data
collection form,47 which incorporates information on study design, type and duration of interventions,
participants, setting, methods, outcomes and results. For the extraction of data on the sociodemographic
characteristics of participants that are known to be important from an equity perspective, we used the
PROGRESS (place, race, occupation, gender, religion, education, socioeconomic status, social status)
framework48 and also recorded whether or not any interventions were aimed at disadvantaged or low- and
middle-income country populations (defined using the World Bank Atlas Method – Detailed Methodology49).
Studies judged to potentially include economic data were identified and further assessed by an economics
reviewer (PA). Data from included economic evaluations were extracted by one reviewer (PA) and checked
by a second reviewer. Data collection was adapted from the format and guidelines used to produce the
structured abstracts of full economic evaluations for inclusion in the NHS EED,50 which were redesigned to
accommodate specific data required for the review. Economic evaluations were classified based on their
analytical framework and were coded appropriately.
Coding of intervention content
We coded intervention descriptions from all of the included studies using a validated taxonomy to characterise
the constituent components of each intervention. The Cochrane EPOC Group has developed a comprehensive
taxonomy to classify interventions for use in systematic reviews.43 We used a subset of the EPOC taxonomy
that had been previously used by members of the review team in a review of the effectiveness of general
QI implementation strategies for diabetes care29 (see Appendix 4). This adapted taxonomy incorporates
12 components that target health-care systems (case management, team changes, electronic patient registry,
facilitated relay of information to clinicians, continuous QI), clinicians (audit and feedback, clinician education,
clinician reminders, financial incentives) or patients (patient education, promotion of self-management and
reminder systems). Two review authors (JGL and EGR) independently coded QI components as ‘present’ or
‘absent’ for all intervention and control arms. Any discrepancies were resolved by discussion.
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To better characterise intervention content we also coded BCTs within interventions using the BCTTv1.36
Describing an intervention in terms of BCTs (i.e. ‘active ingredients’) provides a useful level of detail for
synthesis and comparison44 (see Appendix 5 for a description of the BCTs identified in the included
studies). We coded BCTs as ‘present’ or ‘absent’ separately for patient and HCP recipients.44 We contacted
all authors of included studies to ask for further information on the content of the intervention (e.g. a trial
protocol, letters sent to patients, written or audio-visual materials) to clarify the BCT coding. We coded
these materials using the BCT taxonomy in the same manner as for the corresponding published reports.
Two review authors independently conducted BCT coding (EGR and FL), resolving discrepancies by
discussion and, when necessary, by the involvement of a third reviewer (JJF).
Resource requirement needed to deliver interventions
We developed an ordered ranking scale to quantify the level of resource needed to deliver each intervention,
based on the description of the intervention components in each included study (see Chapter 6 for further
details of the methodology). To determine the feasibility of this approach, we initially piloted the scale on a
sample of 10 included studies using two members of the review team. Each intervention was initially graded
between 1 (least resource intensive) and 5 (most resource intensive), or as 0 (unable to determine), with a
record of how the reviewer graded each study also provided.
An algorithm was developed to derive the ordered rank. This mapped resource components and their
intensity to the ordered rank. The following resource components were incorporated into the algorithm:
l face-to-face minutes
l telephone calls
l patient home visits
l printed materials/software
l training.
We defined, a priori, a criterion for success of the ranking scale as reviewer scores from nine out of 10 studies
being within one grade of each other following discussion. This criterion was achieved and the notes about
how each study was graded were used to produce a reproducible description of the resource input associated
with each grade on the ranking scale. The resource components and their intensity levels were then used to
extract the resource use required to deliver the interventions in all included studies. This was conducted by
two reviewers independently (JGL and EGR).
For the algorithm that mapped resource use onto the ordered ranking, the weights given to each resource
component and their intensity were subsequently revised based on cost analyses (see Chapter 6). The
revised grading system produced 18 ranks and these were recategorised into five ordered categories for
the purposes of analysis.
Assessment of risk of bias
Two review authors (JGL and JMB) independently assessed study quality using the EPOC Group risk-of-bias
tool,51 which uses nine standard criteria.
1. Was the allocation sequence adequately generated?
2. Was the allocation adequately concealed?
3. Were baseline outcome measurements similar?
4. Were baseline characteristics similar?
5. Were incomplete outcome data adequately addressed?
6. Was knowledge of the allocated interventions adequately prevented during the study?
7. Was the study adequately protected against contamination?
8. Was the study free from selective outcome reporting?
9. Was the study free from other risks of bias?
INTERVENTIONS TO INCREASE SCREENING ATTENDANCE
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For cluster RCTs we considered particular biases, including (1) recruitment bias, (2) baseline imbalance,
(3) loss of clusters and (4) unit of analysis errors. For each domain, two review authors performed the
risk-of-bias assessment independently and assigned a judgement of low risk, high risk or unclear risk of
bias. The review authors resolved any discrepancies between them by discussion.
The reliability of the data outputs from any full economic evaluation are in part predicated on the reliability
of the estimates of the relative treatment effects (for benefits or harms) of the alternative courses of action
[i.e. intervention(s) and comparator(s)) under investigation]. As the identified economic studies were a subset
of the studies included in the review, the risk of bias was already assessed. However, assessment of the
overall methodological quality of the economic component was still required and was carried out by one
reviewer (PA) using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement52
together with the Consensus on Health Economic Criteria (CHEC).53 In assessing the methodological quality
of economic evaluations, the main objective is to assess the applicability of the scope of the analysis in terms
of costs and outcomes. This helps to highlight the applicability and relevance of each economic evaluation.
The checklists used differed from those that were originally included in our published Cochrane protocol
because of the recent updates of the methods for the incorporation of economic evidence into Cochrane
intervention reviews (see Report Supplementary Material 1, Completed checklists for methodological quality
assessment of economic evaluations, for the completed checklists for each included economic evaluation).
Data synthesis
Attendance at screening post intervention is a dichotomous outcome and our measure of intervention effect
was the risk difference (RD), that is, the actual difference in the observed events between experimental
and control interventions. For individual RCTs the unit of analysis was the individual participant. For cluster
RCTs we analysed data after adjustment for clustering. In the case of cluster RCTs, when outcomes were
presented at the patient level, we used an established method to adjust for clustering.54 This involved
dividing the original sample size by the design effect, which was calculated from the average cluster size
and the intraclass correlation coefficient (ICC). When the ICC was not reported, we imputed the most
commonly reported value from studies in which it was reported. We contacted authors of included studies
when important data were missing; we did not impute missing data if data were not available.
We conducted meta-analyses in Review Manager 5 (The Cochrane Collaboration, The Nordic Cochrane
Centre, Copenhagen, Denmark) using random-effects models to estimate the pooled RD across studies.
Data from patient RCTs and cluster RCTs that were adjusted for clustering were included in the same
meta-analyses. In the case of multiple intervention groups, as recommended in the Cochrane Handbook
for Systematic Reviews of Interventions,55 we combined groups to create a single pairwise comparison.
A summary of the results of the included economic evaluations is available in Report Supplementary Material 1
[see Further details of the review of economic evidence (phase 1 review)]; this is supplemented by a narrative
description in the results and discussion sections. Costs for each study were adjusted to 2016 UK pounds using
a web-based conversion tool based on implicit price deflators for gross domestic product (GDP), a measure of
the wealth of a country, and GDP purchasing power parities.56 The tables in Report Supplementary Material 1
[see Characteristics of included, ongoing and excluded studies (phase 1 review)] present the original currency
and price year used in each included study. Users of this review who might want to adjust costs to another
currency and price year suitable for their needs should use the costs for each study presented in Report
Supplementary Material 1 and not the adjusted costs presented in the main text of this report.
Assessment of heterogeneity
We assessed heterogeneity between studies by visual inspection of forest plots and by formal statistical
tests of heterogeneity (chi-squared test and the I2 statistic). The I2 statistic is the proportion of variation
between studies not due to chance and can take a value from 0% to 100%. Heterogeneity may be the
result of variation in the ‘true’ effects underlying the studies but may also be the result of clinical diversity
(participants, interventions, outcomes) and methodological diversity (varying degrees of bias).
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We performed the following prespecified subgroup analyses to investigate whether or not the presence or
absence of a particular covariant explained the variability in effect size:
l QI intervention components/BCTs
l resource requirements to deliver the intervention.
In our analyses, QI components (coded using the modified EPOC Group taxonomy) and BCTs of each
intervention were assessed separately. When a study used multiple QI components and/or BCTs, the same
effect size was applied to each component for the analysis. We compared effect estimates for subsets of
studies that used a particular QI component/BCT or resource intensity and calculated a pooled effect size.
We further investigated associations between DRS attendance and effect size by meta-regression for a
number of covariates including type of study design (individual/cluster RCT), baseline DRS attendance and
QI component/BCT used in the intervention. For meta-regression we used a prespecified random-effects
model and compared the RD of studies containing a particular explanatory variable with that of studies in
which the variable was absent.
Subgroup analyses and meta-regression were conducted using Stata® 14 (StataCorp LP, College Station,
TX, USA) using the metan and metareg commands. We performed a sensitivity analysis to determine the
impact on the pooled effect estimate of imputing the lower and upper range values for the ICC.
Methods used to assess the quality of the evidence for outcomes included in the
summary of findings tables
We assessed the quality of the evidence using the evidence grading system developed by the Grading of
Recommendations Assessment, Development and Evaluation (GRADE) collaboration57 and described in
section 12.2 of the Cochrane Handbook for Systematic Reviews of Interventions.55 One review author (JGL)
initially applied the GRADE evidence rating system and discussed the rating with other members of the
review team. A final decision was reached by discussion and consensus.
We took the following into account when deciding whether or not to downgrade the quality of evidence
for each outcome:
l risk of bias
l inconsistency of results
l indirectness of evidence
l imprecision of results
l publication bias.
Results
Study selection
The database searches yielded 7244 titles and abstracts. We identified a further 33 studies from additional
sources. After removing duplicates we screened 7277 studies and reviewed 130 full-text articles. We
excluded 64 studies with reasons [see Report Supplementary Material 1, Characteristics of included, ongoing
and excluded studies (phase 1 review)] and included 66 studies that met our inclusion criteria [Figure 4
provides a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram].
Of the included studies, 5058–107 (75.8%) reported general QI interventions and evaluated the impact of the
interventions across a range of outcomes, including DRS uptake; in 16 studies108–123 (24.2%), the primary
target of the intervention was to improve attendance for DRS. From the search of trials registers we identified
nine ongoing studies [see Report Supplementary Material 1, Characteristics of included, ongoing and
excluded studies (phase 1 review)].
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From the database searches we identified 22 references containing potential economic evaluations.
Following full-text review, eight58,83,94,103,114,115,122,123 of these references were excluded and 14
references59,62,67,69,70,85,87,89,95,105,117,124–126 reporting economic outcomes were included in the review.
Characteristics of included studies
The included studies were conducted between 1988 and 2013. Thirty-five studies (53%) were
parallel-group patient RCTs enrolling 237,025 patients59,61–63,71,72,75,80,82,85–89,95,96,98,99,102,103,107–109,111–122 and
31 (47%) were cluster RCTs in which the HCP or the health-care setting was the unit of randomisation.58,60,64–70,
73,74,76–79,81,83,84,90–94,97,100,101,104–106,110,123 These included 6126 clusters (range 6–4125 clusters). Fifty-nine studies
(89%)58–63,65–78,80–93,95–105,107–116,118,120–122 had two arms, six studies (9%)64,79,94,106,117,119 had three arms and one
study (2%)123 had more than three arms. An overview of the included studies is provided in Table 1 [for further
details see Report Supplementary Material 1, Characteristics of included, ongoing and excluded studies
(phase 1 review)].
Types of participants
Participant characteristics are reported in Table 1. We used PROGRESS elements to describe the
characteristics of participants in the included studies that could have an impact on equity of access to
health services. With the exception of gender (reported in 93.9% of studies) and ethnicity (reported in
56.1% of studies), the characteristics of participants were poorly described and the relative effectiveness of
the interventions in subgroups in terms of PROGRESS elements was never reported. Seventeen studies
(25.8%)60,62,63,68,72,75,91,96,107–110,112,113,116,120,121 were conducted in disadvantaged populations and no studies
were carried out in low- or middle-income countries.
Types of setting
Details of study location and setting are given in Table 1.
Records identified through
database searching
(n = 7244)
Additional records identified
through other sources
(n = 33)
Records screened
(n = 7277)
Records excluded
(n = 7147)
Full-text articles
assessed for eligibility
(n = 130)
Full-text articles excluded
(n = 64)
• Retinopathy screening
   attendance not reported, n = 36
• Not RCT, n = 16
• Systematic review (references
   screened), n = 8
• Qualitative study, n = 2
• Vignette study, n = 1
• No control group data, n = 1
Studies included in quantitative
synthesis (meta-analysis)
(n = 66)
FIGURE 4 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
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Intervention content in terms of quality improvement components (coded using the
modified Effective Practice and Organisation of Care Group taxonomy)
Interventions either were specifically targeted at improving attendance for DRS (n = 16) or were part of a
general QI intervention to improve diabetes care (n = 50). For studies comparing any intervention with
usual care, the majority of studies provided no description of usual care, which precluded coding of the
comparator arm. All 12 QI intervention components, as defined by the modified EPOC taxonomy, were
used in at least one study. Generally, interventions were multifaceted with several QI components per
TABLE 1 Characteristics of included studies
Study characteristic
Target: DRS attendance
(n= 16)
Target: general QI in
diabetes care (n= 50) Total (n= 66)
Study design Individual RCT, n= 14
(87.5%); cluster RCT, n = 2
(12.5%)
Individual RCT, n = 21
(42.0%); cluster RCT, n= 29
(58.0%)
Individual RCT, n= 35
(53.0%); cluster RCT, n = 31
(47.0%)
Two arms, n= 13; three arms,
n= 2; more than three arms,
n= 1
Two arms, n= 46; three
arms, n = 4
Two arms, n= 59 (89.4%);
three arms, n = 6 (9.1%);
more than three arms, n= 1
(1.5%)
Location USA, n= 12 (75.0%);
Canada, n= 1 (6.3%); China,
n= 1 (6.3%); Germany, n= 1
(6.3%); and the UK, n = 1
(6.3%). Conducted between
1995 and 2013
USA, n= 29 (58.0%);
Canada, n = 2 (4.0%);
Netherlands, n= 4 (8.0%);
Australia,: n = 3 (6.0%); the
UK, n = 2 (4.0%); and other,
n = 10 (20.0%). Conducted
between 1988 and 2013
USA, n = 41 (62.1%);
Canada, n= 3 (4.6%);
Netherlands, n= 4 (6.1%);
Australia, n = 3 (4.6%); the
UK, n= 3 (4.6%); and other,
n= 12 (18.2%). Conducted
between 1985 and 2013
Setting Primary care, n= 11 (68.8%);
outpatient clinics, n = 4
(25.0%); unclear, n= 1
(6.3%)
Primary care, n = 40
(80.0%); outpatient clinics,
n = 3 (6.0%); unclear, n= 7
(14.0%)
Primary care, n= 51
(77.3%); outpatient clinics,
n= 7 (10.6%); unclear,
n= 8 (12.1%)
Diabetes type Type 2, n = 4 (25.0%); types
1 and 2, n = 3 (18.8%); not
reported, n= 9 (56.3%)
Type 2, n= 34 (68.0%);
types 1 and 2, n = 7
(14.0%); not reported, n= 9
(18.0%)
Type 2, n = 38 (57.6%);
types 1 and 2, n= 10
(15.2%); not reported,
n= 18 (27.3%)
Number of participants
recruited
Individual RCT, n= 38,273;
cluster RCT, n= 4135 clusters
(182,513 patients); total,
n= 220,786 (patients
included)
Individual RCT, n = 198,752;
cluster RCT, n = 1991
clusters (78,276 patients);
total, n = 277,028 (patients
included)
Individual RCT, n= 237,025;
cluster RCT, n= 6126
clusters (260,789 patients);
total, n= 497,814 (patients
included)
Age (years), median
(range)
60.7 (51.1–72.7), n= 9
studies
60.6 (46.8–74), n = 34
studies
60.7 (46.8 to 74), n= 43
studies
Gender (% male),
median (range)
38.9 (25–98), n = 12 studies 49.8 (25–97), n= 35 studies 48 (25–98), n= 47 studies
Type of screening Retinal examination, n= 12
(75.0%); grading of digital
retinal images, n= 4 (25.0%)
Retinal examination, n= 49
(98.0%); grading of retinal
images, n= 1 (2.0%)
Retinal examination, n= 61
(92.4%); grading of retinal
images, n= 5 (7.6%)
Baseline screening
attendance (in previous
12 or 24 months) (%),
median (range)
0 (0–48.4), n= 7 studies 37.1 (0–88), n = 36 studies 35.4 (0–87.8), n= 43 studies
Longest duration of
follow-up (months),
median (range)a
6 (3–48), n= 14 studies 12 (1–30), n= 49 studies 12 (1–48), n = 63 studies
a Mansberger et al.116 reported follow-up data to 48 months but intervention offered to intervention and control group
after 18 months and data reported at 12 and 24 months.
For further details see Report Supplementary Material 1.
Reproduced from Lawrenson et al.,127 with permission from John Wiley & Sons, Ltd. Copyright © The Cochrane
Collaboration. Published by John Wiley & Sons, Ltd.
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intervention arm (median 3, range 1–7). For interventions specifically targeting DRS attendance, the most
commonly used QI components were ‘patient reminders’ (56% of studies) and ‘patient education’ (75%)
(Figure 5). For general QI interventions, a greater number and range of strategies were used, including
‘patient education’ (48% of studies), ‘promotion of self-management’ (40%), ‘case management’ (40%),
‘clinician education’ (38%) and ‘team changes’ (36%).
Intervention content in terms of behaviour change techniques (coded using the
Behaviour Change Technique Taxonomy version 136)
Overall, 39 out of the possible 93 BCTs (42%) were identified as targeting change in patient or HCP
behaviour in at least one trial. Interventions specifically targeting DRS primarily used techniques aimed at
patients, particularly ‘instruction on how to perform the behaviour’ (75% of studies), ‘prompts/cues’ (69%)
and ‘information about consequences’ (56%) (Figure 6). Relatively few of these studies used BCTs that
were aimed at HCPs (Figure 7). By contrast, the following HCP-directed strategies were more widely used in
general QI interventions, in particular ‘instruction on how to perform the behaviour’ (66%), ‘restructuring
the social environment’ (52%) and ‘feedback on outcomes of behaviour’ (36%). Table 2 provides definitions
and illustrative quotations for each BCT.
For studies comparing any intervention with usual care, the majority of studies provided no description of
usual care, which precluded coding of the comparator arm.
Outcome measures
In 12 (75%)96,108,109,111,113,114,117,119–123 of the 16 studies in which the primary target of the intervention was
to improve attendance for DRS, the outcome was a dilated fundus examination (DFE) conducted by an
ophthalmologist or optometrist during the follow-up period post intervention (median follow-up 12 months).
The DFE was confirmed by medical record audit, from a health claims database or by eye-care professional
examination. In four studies (25%)110,112,115,116 DRS consisted of screening of digital retinal images.
In the 50 studies in which DRS attendance was reported as part of a general QI intervention, DRS was
usually listed as part of a number of processes of care based on diabetes guideline recommendations.
DRS was variously described as a DFE/diabetic eye examination/retinal examination/eye examination in
49 studies (98%) and involved grading of retinal images in one study.107 DRS was confirmed by medical
record audit, from health claims databases or from patient self-reports (both validated and unvalidated by
an eye-care professional). The median duration of follow-up was 12 months (range 1–48 months).
Audit and feedback
Case management
Team changes
Electronic patient registry
Clinician education
Clinician reminders
Facilitated relay
Patient education
Promotion of self-management
Patient reminders
Continuous quality improvement
Financial incentives
0 20 40 60 80
Studies (%)
DRS %
GQI %
FIGURE 5 Quality improvement components used in the intervention arms of included studies. GQI, general
quality improvement. Reproduced from Lawrenson et al.,127 with permission from John Wiley & Sons, Ltd.
Copyright © The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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In terms of economic outcomes, five studies reported a full economic evaluation.67,117,124–126 Three of these
were cost-effectiveness analyses124–126 and two were cost–consequence analyses.67,117 Nine studies reported
partial economic evaluations: five were resource utilisation studies62,69,85,89,95 and four were cost outcome
descriptions.59,70,87,105 The full text of one of the cost-effectiveness studies could not be retrieved but the
abstract124 provided some information required for review alongside the clinical effectiveness report.63
Excluded studies
See Report Supplementary Material 1, Characteristics of included, ongoing and excluded studies
(phase 1 review).
Ongoing studies
See Report Supplementary Material 1, Characteristics of included, ongoing and excluded studies
(phase 1 review).
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FIGURE 6 Behaviour change techniques targeting patients used in the intervention arms of included studies.
GQI, general quality improvement. Reproduced from Lawrenson et al.,127 with permission from John Wiley & Sons,
Ltd. Copyright © The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Risk of bias in included studies
A risk-of-bias assessment was conducted using the Cochrane EPOC Group risk-of-bias tool (Figure 8).51
Overall, trials were judged to be at low or unclear risk of bias. However, 33 studies (48.5%)58–60,62,65,68,69,71,72,
74,76,78,81–84,88,91–97,99,100,103–107,119,121 were judged to be at high risk of bias in at least one domain. The domains
most commonly at high risk of bias were ‘incomplete outcome data addressed’ [15 studies65,68,72,76,78,81–84,88,93,
94,100,103,105 (22.7%)], ‘protected against contamination’ [seven studies60,62,96,99,104,107,119 (10.6%)] and ‘similar
baseline outcome measurements’ [five studies58,69,92,95,106 (7.6%)]. It was possible to judge if a study was free
from selective outcome reporting for only 17 studies (25.7%)58,59,63,64,67,69,72,77,78,83,84,94,96,99,100,121,123 because of
a lack of availability of a prospectively published trial registration or protocol. Although studies were rarely
judged to be at a high risk of bias for adequate sequence generation and adequate allocation concealment,
the methods associated with these domains were frequently poorly reported.
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FIGURE 7 Behaviour change techniques targeting HCPs used in the intervention arms of included studies.
GQI, general quality improvement. Reproduced from Lawrenson et al.,127 with permission from John Wiley & Sons,
Ltd. Copyright © The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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TABLE 2 Definitions of and illustrative quotations for BCTs identified in the included studies
BCTs, abbreviated definitions and DRS-specific examples
Illustrative quotation from existing DRS
interventions
Goals and planning
Goal-setting (behaviour) Practice nurses planned independent consultations
with patients. The monitoring tool guided them
through the consultations, and provided the
opportunity to help the patient in selecting
appropriate, concrete, behavioural goals
Frei et al.69 (pp. 1040–1)
Set or agree a goal defined in terms of the behaviour to
be achieved (e.g. set targets for how often patients should
attend DRS, or general diabetes self-management, such as
the frequency of blood glucose testing or the amount of
carbohydrates to consume at each meal)
Problem-solving the health educator . . . offered one-on-one,
interactive education and counselling. Having
established rapport, she worked to identify and
understand each subject’s reasons for and/or barriers
to having a dilated retinal examination. Focused
problem-solving then guided the subject toward
making an informed choice about receiving an
ophthalmic examination
Basch et al.109 (p. 1879)
Analyse, or prompt the person to analyse, factors
influencing the behaviour and generate or select strategies
that include overcoming barriers and/or increasing
facilitators (e.g. support patients to identify reasons for
wanting or not wanting to attend DRS and help them
select potential strategies for overcoming these barriers to
screening attendance)
Goal-setting (outcome) During the case management sessions, patients and
providers set management goals that were reasonable
to achieve
Barceló et al.60 (p. 147)
Set or agree a goal defined in terms of a positive outcome
of wanted behaviour (e.g. agree with the patient target
glycated haemoglobin level, blood pressure or cholesterol
levels or target range for blood glucose levels)
Action-planning Behavioural activation for diabetic retinopathy
prevention combined the principles of education
about diabetes mellitus, behavioural therapy, and
the health belief model to assist participants in
identifying barriers to obtaining DFEs [dilated fundus
examinations], problems-solving solutions to
surmounting barriers, formulating action plans to
facilitate DFEs, and gauging the success of action plans
Weiss et al.121 (p. 1007)
Prompt detailed planning of performance of the behaviour
(e.g. support the patient to develop a plan for how often
they will attend DRS, where the DRS will occur and how
they will get to their appointment)
Review behaviour goals Care managers were trained to use a patient-centred
self-management approach that included review of
the medical care needs and self-care goals that the
patient identified and brainstorming additional
strategies that patients could use to overcome barriers
to their goals
Glasgow et al.73 (p. 35)
Review behaviour goal(s) jointly with the person and
consider modifying goal(s) or the behaviour change
strategy in light of achievement [e.g. during scheduled
diabetic review consultations, discuss with patients how
they are progressing with their agreed self-management
behavioural goals (e.g. frequency of blood glucose testing,
attendance for DRS); when patients are not meeting
agreed goals, either discuss how to adjust goals if needed
to increase feasibility or engage in problem-solving to
overcome any barriers to goal attainment]
Discrepancy between current behaviour and goals Physicians in the IG [intervention group] received a
monthly report of their care quality with the top 10%
quality of diabetes care score for all physicians being
the achievable benchmark
Hayashino et al.77 (p. 599)
Draw attention to discrepancies between a person’s
current behaviour and the person’s previously set outcome
goals, behaviour goals or action plans (e.g. provide
feedback to HCPs on the proportion of patients who have
received DRS in the previous 12 months and compare this
against a gold standard for clinical practice based on
clinical guidelines)
Review outcome goal(s) The telephone call was structured to first review the
patient’s goals, followed by medication use,
symptoms, glucose monitoring, blood pressure
monitoring and self-management/care activities
Taylor et al.102 (p. 1059)
Review outcome goal(s) jointly with the person and
consider modifying goal(s) in light of achievement
(e.g. review or alter target blood glucose levels towards
a more feasible/achievable intermediate target)
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TABLE 2 Definitions of and illustrative quotations for BCTs identified in the included studies (continued )
BCTs, abbreviated definitions and DRS-specific examples
Illustrative quotation from existing DRS
interventions
Behavioural contract Care guides asked patients to sign a contract (which
was scanned into the EHR [electronic health record])
agreeing to work toward their disease-specific goals
Adair et al.59 (p. 176)
Create a written specification of the behaviour to be
performed, agreed by the person and witnessed by
another (e.g. ask the person with diabetes to sign a
contract in their self-management plan or diary,
undertaking to attend DRS once)
Commitment The initial goal was to elicit a verbal commitment to
schedule an eye examination
Basch et al.109 (p. 1879)Ask the person to affirm or reaffirm the statement
indicating commitment to change the behaviour (e.g. ask
the person with diabetes to verbally affirm or reaffirm that
they are committed to attending DRS at the agreed
frequency and location)
Feedback and monitoring
Monitoring of behaviour by others without feedback Foot examinations, blood pressure, and eye examinations
were recorded on the reminder by clinic staff, collected
after the patient visit and entered manually
Peterson et al.58 (p. 2239)
Observe or record behaviour with the person’s knowledge
as part of a behaviour change strategy (e.g. record the
proportion of patients who attend for a DRS examination
as part of clinical audit, but do not feed back the results to
the HCPs whose practice has been audited)
Feedback on behaviour In addition, diabetic members who did not have a
record of a diabetic retinopathy exam received
educational materials and a report of their current DRE
[diabetic retinal examination] status directly from the
HMO [health maintenance organisation] 2 weeks later
Halbert et al.114 (p. 753)
Monitor and provide information or evaluative feedback
on performance of the behaviour (e.g. form, frequency,
duration, intensity) (e.g. provide a feedback report to
HCPs, stating the proportion of their patients who have
attended a DRS examination, had their blood pressure
taken and had a foot examination)
Self-monitoring of behaviour We prepared feedback sheets for adherence to these
eight indicators using data from the physicians’
self-report forms, as the physicians monitored and
promoted these indicators to improve adherence
Hayashino et al.77 (p. 601)
Establish a method for the person to monitor and record
his or her behaviour(s) as part of a behaviour change
strategy (e.g. a person with diabetes maintains a self-
management diary in which they record their daily food
intake and exercise and tick off on a checklist when they
have attended the annual DRS examination)
Self-monitoring of outcomes of behaviour In general, case managers were directed to encourage
patient self-management, including diet and exercise,
provide reminders for recommended screening/tests,
help with appointment scheduling; monitoring home
glucose and blood pressure levels
Krein et al.85 (p. 734)
Establish a method for the person to monitor and record
the outcome(s) of their behaviour as part of a behaviour
change strategy (e.g. a person with diabetes records in
their self-management diary the results of their latest
glycated haemoglobin test and DRS examination)
Monitoring of outcomes of behaviour by others without
feedback
The nurse case manager used behavioural goal
setting, established individualized care plan, provide
patient self-management education and surveillance
of patients . . . ordered protocol-driven laboratory
tests, tracked the outcomes using the computerized
data registry
Gabbay et al.71 (p. 30)
Observe or record outcomes of behaviour with the
person’s knowledge as part of a behaviour change
strategy (e.g. a person attends a DRS examination but is
not provided with the results of the examination)
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TABLE 2 Definitions of and illustrative quotations for BCTs identified in the included studies (continued )
BCTs, abbreviated definitions and DRS-specific examples
Illustrative quotation from existing DRS
interventions
Feedback on outcomes of behaviour All persons who attended the screening clinics
received a dilated eye exam by a volunteer
community-based ophthalmologist. The eye exam
included visual acuity . . . and a fundus examination
through a dilated pupil . . . immediately after receiving
the dilated eye exam, the patient was told the results
by the examination ophthalmologist
Anderson et al.108 (p. 41)
Monitor and provide feedback on the outcome of
performance of the behaviour [e.g. informing the person
with diabetes of the results of the DRS examination
(i.e. presence/absence of retinopathy)]
Biofeedback Immediately after receiving the dilated eye exam,
the patient was told the results by the examination
ophthalmologist
Anderson et al.108 (p. 41)
Provide feedback about the body (e.g. physiological or
biochemical state) using an external monitoring device as
part of a behaviour change strategy
Social support
Social support (unspecified) Overall, the intervention included . . . and self-
management support (provided by the practice nurse)
Frei et al.69 (p. 1041)Advise on, arrange or provide social support (e.g. from
friends, relatives, colleagues, ‘buddies’ or staff) or
non-contingent praise or reward for performance of the
behaviour – includes encouragement and counselling
(e.g. provide general encouragement or reassurance to a
person with diabetes to attend their DRS appointment)
Social support (practical) Referrals were facilitated to other clinicians when
indicated, including ophthalmology, podiatry, nutrition
and primary care for follow-up of acute or other
chronic issues or when requested by patients
Jacobs et al.82 (p. 616)
Advise on, arrange or provide practical help (e.g. from
friends, relatives, colleagues, ‘buddies’ or staff) for
performance of the behaviour (e.g. provide practical help
for a patient with diabetes to attend DRS; this can include,
for example, arranging a referral to DRS, arranging or
providing transport to the clinic)
Shaping knowledge
Instruction on how to perform the behaviour A direct mail reminder was sent to patients to
reinforce the importance of annual eye examinations
and included the following text:
If you don’t have an eye doctor, ask your regular
doctor to refer you to one
Prela et al.118 (p. 258)
Advise or agree on how to perform the behaviour
(includes ‘skills training’) (e.g. provide advice to a person
with diabetes on how often guidelines recommend
attending DRS, where they can obtain DRS and how to
schedule an eye examination)
Natural consequences
Information about health consequences A tailored telephone intervention was delivered by
bilingual interventionists:
Risk communications, such as the frequent lack of
symptoms of retinopathy and that early treatment
for retinopathy decreases the risk of blindness,
were included
Walker et al.120 (p. 187)
Provide information (e.g. written, verbal, visual) about the
health consequences of performing the behaviour (e.g.
provide advice to the person with diabetes on the negative
health consequences of retinopathy and the benefits of
early detection.)
Salience of consequences The videotape used emotional appeals through
storytelling to increase motivation to have a yearly
dilated retinal examination
Basch et al.109 (p. 1879)
Use methods specifically designed to emphasise the
consequences of performing the behaviour with the aim of
making them more memorable (e.g. give a person with
diabetes a leaflet containing testimonials from other
people with diabetes who suffer from retinopathy to
emphasise the benefits of attending DRS and of early
detection)
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TABLE 2 Definitions of and illustrative quotations for BCTs identified in the included studies (continued )
BCTs, abbreviated definitions and DRS-specific examples
Illustrative quotation from existing DRS
interventions
Information about social and environmental consequences A take-home reminder (aimed at patients, to remind
them to make an appointment for an eye examination),
to be given to patients by their family practitioner,
included the following text:
OHIP [Ontario Health Insurance Plan] covers annual
eye checks for patients with diabetes so you will not
have to pay
Zwarenstein et al.123 (p. 90)
Provide information (e.g. written, verbal, visual) about the
social and environmental consequences of performing the
behaviour (e.g. provide information on the costs of having
a DRS examination)
Information about emotional consequences Group visit content, though patient-guided, was
physician-directed to cover educational topics . . . and
the emotional aspects of diabetes
Clancy et al.62 (p. 621)
Provide information (e.g. written, verbal, visual) about the
emotional consequences of performing the behaviour (e.g.
provide a leaflet recognising the potential negative effects
on emotional and mental health of managing a chronic
illness such as diabetes)
Comparison of behaviour
Demonstration of the behaviour The newsletter consisted of six sections, including a
testimonial designed to model eye examination
behaviour
Ellish et al.113 (p. 1593)
Provide an observable sample of the performance of the
behaviour, directly in person or indirectly (e.g. through
film, pictures), for the person to aspire to or imitate
(e.g. play a video demonstrating the DRS procedure)
Social comparison The system presented register data on their Type 2
diabetes population, giving them the option either to
use the data during individual diabetes consultations
or to gain an overview of the quality of their diabetes
care and compare it with the corresponding quality in
their colleagues’ practices
Guldberg et al.74 (p. 326)
Draw attention to others’ performance to allow
comparison with the person’s own performance (e.g.
provide HCPs with feedback on the proportion of their
patients who have had a DRS examination and benchmark
this in comparison to other hospitals or HCPs)
Information about others’ approval One of the messages in the targeted newsletter read:
Even though you’ve been thinking about getting a
dilated eye exam, we hope you’ll make the call now
Ellish et al.113 (additional information provided by
the author)
Provide information about what other people think about
their behaviour. The information clarifies whether others
will like, approve of or disapprove of what the person is
doing or will do (e.g. tell the person with diabetes that
their family members would likely be keen for them to
attend their DRS appointment)
Associations
Prompts/cues For those who made an appointment, a reminder
letter was mailed 3 weeks prior to the scheduled
appointment. Additionally, there was an automated
reminder call the day before the scheduled
appointment
Pizzi et al.117 (p. 255)
Introduce or define environmental or social stimulus
with the purpose of prompting or cueing the behaviour
(e.g. telephone the person with diabetes to remind them
of their upcoming DRS appointment)
Reduce prompts/cues Recommendations for regular telephone follow-ups
for diabetes patients, which will be monthly in the 1st
half year and then will probably decrease
Jansink et al.83 (coded from protocol128)
Withdraw gradually prompts to perform the behaviour
[e.g. decrease the frequency with which a person with
diabetes is sent a reminder about their DRS attendance
(i.e. from weekly to fortnightly, to monthly, to quarterly
reminders)]
continued
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TABLE 2 Definitions of and illustrative quotations for BCTs identified in the included studies (continued )
BCTs, abbreviated definitions and DRS-specific examples
Illustrative quotation from existing DRS
interventions
Repetition and substitution
Behavioural practice/rehearsal During a 2-day training session, case managers
received instruction on collaborative goal setting, with
case examples and role-playing used to familiarize
them with the treatment algorithms
Krein et al.85 (p. 734)
Prompt practice or rehearsal of the performance of the
behaviour one or more times in a context or at a time
when the performance may not be necessary, to increase
habit and skill (e.g. provide an opportunity for trainee
HCPs to practise delivering a DRS examination to an actor
role-playing a patient with diabetes)
Graded tasks Theoretically, this form of facilitation should be
necessary for only a relatively short period of time,
with the practice improvement team progressively
assuming responsibility for the ongoing improvement
efforts after the initial facilitation
Dickinson et al.64 (p. 10)
Set easy-to-perform tasks, making them increasingly
difficult, but achievable, until the behaviour is performed
(e.g. initially allocate a HCP responsibility for one
component of the DRS examination and progressively
increase their level of responsibility)
Comparison of outcomes
Credible source Participants in the print-intervention group received a
mailing of a colourful, 14-page booklet on preventing
diabetes eye problems called Keep Your Eyes Healthy,
in English or Spanish, developed by the National
Institutes of Health
Walker et al.120 (p. 187)
Present verbal or visual communication from a credible
source in favour of or against the behaviour (e.g. include
the logos for national health institutes or cite published
clinical guidelines to endorse information provided in
leaflets regarding DRS)
Reward and threat
Material incentive (behaviour) The automated system offered a live telephone call
back to assist in scheduling test and also offered to
send participants the following items: 1) a voucher
that would allow the provider to waive the
co-payment for a dilated eye examination . . .
Simon et al.98 (p. 1452)
Inform that money, vouchers or other valued objects will
be delivered if and only if there has been effort and/or
progress in performing the behaviour (e.g. advise the
person with diabetes that they will receive a shopping
voucher if they attend their upcoming DRS appointment)
Social reward When a subject reported having a dilated retinal
examination a congratulatory letter was sent
Basch et al.109 (p. 1879)Arrange a verbal or non-verbal reward if and only if there
has been effort and/or progress in performing the
behaviour (e.g. verbally praise the person with diabetes if
they attend their DRS appointment)
Non-specific reward CME [continuing medical education] credits were
given to the participating physicians in the workshops
Vidal-Pardo et al.104 (p. 752)Inform that a reward will be delivered if and only if there
has been effort and/or progress in performing the
behaviour (e.g. inform the HCP that they will be rewarded
for conducting a DRS examination with a target proportion
of their patients)
Antecedents
Restructuring the physical environment Care guide workstations were located in the clinic
waiting rooms, to facilitate face-to-face interactions
with patients, providers, and nurses
Adair et al.59 (p. 177)
Change, or advise changing, the physical environment to
facilitate performance of the wanted behaviour or create
barriers to performance of the unwanted behaviour (e.g.
introduce mobile DRS vans in geographically remote areas
to increase access to screening facilities)
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We explored publication bias using a funnel plot for the main comparison of any intervention with usual
care (56 studies58–63,65–72,74–78,80–89,92–105,108–112,115–118,120–123). Although there were few data points for the less
precise studies, those with greater precision were evenly distributed.
The studies that reported economic outcomes are a subset of the studies included in the systematic review
and the risk of bias of these studies was very similar to the risk of bias of the main body of included studies.
With respect to methodological quality, only five67,117,124–126 of the 14 included economic studies reported
full economic evaluations. One of these studies124 was published as an abstract and lacked important
TABLE 2 Definitions of and illustrative quotations for BCTs identified in the included studies (continued )
BCTs, abbreviated definitions and DRS-specific examples
Illustrative quotation from existing DRS
interventions
Restructuring the social environment Three multi-lingual Link Workers already employed by
Coventry Primary Care Trust (PCT) were trained in
diabetes management and care and assigned to work
with specific intervention GP [general practice] surgeries
Bush et al.110 (p. 295)
Change, or advise changing, the social environment to
facilitate performance of the wanted behaviour or create
barriers to performance of the unwanted behaviour
(e.g. change a health-care team and team working,
such as introducing a new specialist diabetes nurse role
responsible for monitoring screening rates and telephoning
people with diabetes to remind them to attend their DRS
appointment)
Adding objects to the environment In addition 4500 diabetes passports were made
available at the four hospitals
Dijkstra et al.65 (p. 128)Add objects to the environment to facilitate performance of
the behaviour (e.g. introduce new computerised software
to a general practice to help monitor and remind HCPs
about which patients need to be prompted to attend DRS)
Scheduled consequences
Behaviour cost We were interested to find out whether a small
copayment would be an important deterrent to the
uptake of screening for diabetic retinopathy (DR) . . .
We conducted a randomized trial in which one group
was charged a small fee for DR screening and the
other was provided with free access
Lian et al.115 (p. 1247)
Arrange for withdrawal of something valued if and only if
an unwanted behaviour is performed (e.g. charging people
with diabetes a fee for failing to attend a DRS examination)
Self-belief
Verbal persuasion about capability Diabetes is a serious, lifelong condition, but there is so
much that you can do to protect your health. Take
charge of your health, not only for today, but also for
the years to come
Lafata et al.86 (p. 523)
Tell the person that they can successfully perform the
wanted behaviour, arguing against self-doubts and
asserting that they can and will succeed (e.g. encourage or
reassure the patient to attend a DRS examination, providing
information as needed to address any concerns or
self-doubts that they may have about attending for DRS)
Focus on past success A comprehensive programme that integrated lifestyle
counselling based on motivational interviewing
principles was integrated into structured diabetes care
Jansink et al.83 (p. 119)
In additional file 2, which is linked to the protocol for
this study,128 the authors describe the staff training
programme. Within the text they explain that one
guiding principle of motivational interviewing is to
‘support self-efficacy’. They state that ‘self-efficacy can be
strengthened by affirming past success (i.e. reinforcement)’
Advise thinking about or listing previous successes in
performing the behaviour (or parts of it) (e.g. help the
person with diabetes to remember the last time that they
attended DRS and use this as an opportunity to reassure
them of the benefits of attending)
Reproduced from Lawrenson et al.,127 with permission from John Wiley & Sons, Ltd. Copyright © The Cochrane
Collaboration. Published by John Wiley & Sons, Ltd.
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methodological details. Only three96,117,125 of the studies with full economic evaluations reported a sensitivity
analysis to explore changes in the costs and outcomes under different scenarios. Discounting in economic
evaluations is necessary to adjust future costs and outcomes of an intervention to their present values
but was reported in only one96 of the full economic outcomes. Its use would have been appropriate in
those other studies with a stated follow-up of > 12 months.67,70,85,89,105 The methodological quality of the
full economic evaluations was considered to be moderate. Full details of the methodological quality
assessment for each of the included economic evaluations are available in Report Supplementary Material 1
[see Further details of the review of economic evidence (phase 1 review)].
Effects of the interventions
Primary outcome
One or more visits for diabetic retinopathy screening within a 2-year period following
implementation of the intervention
All 66 trials provided data for this outcome. There were two types of comparison: 56 (85%)58–63,65–72,74–78,
80–89,92–105,108–112,115–118,120–123 of the 66 studies compared an intervention against current usual care whereas
10 (15%) studies64,73,79,90,91,106,107,113,114,119 compared a more intensive QI intervention or group of QI
interventions against a less intensive intervention. As these addressed different questions, meta-analyses
were conducted separately on the 56 and 10 studies.
Thirty-one (47%)58,60,64–70,73,74,76–79,81,83,84,90–94,97,100,101,104–106,110,123 of the 66 trials were cluster RCTs. Only
nine65,67,69,70,73,83,93,101,123 of these reported an ICC and the ICC reported typically did not relate specifically to
DRS outcomes. Of the nine cluster RCTs reporting an ICC, the most commonly reported value was 0.05
and so this was the value imputed for studies with no estimates of ICCs. The smallest value reported was
0.01 and the largest value was 0.2. A sensitivity analysis was conducted to investigate the impact on the
computed effect estimates of using the lower and upper range values.
Comparison A: any quality improvement intervention compared with usual care Of the 56 studies
that compared any intervention against usual care, 13 (23%)108–112,115–118,120–123 evaluated interventions
specifically targeting DRS. The remaining 43 studies (77%)58–63,65–72,74–78,80–89,92–105 evaluated interventions
directed towards improving the general quality of diabetes care (including DRS attendance). Although
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FIGURE 8 Risk-of-bias graph.
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there was substantial heterogeneity in the intervention effects (I2 > 90%), 48 out of the 56 studies showed
an improvement in DRS attendance (Figure 9). As it may be argued that it is better to examine clinical
differences in a meta-analysis rather than use them as a reason for not conducting one, we computed
pooled estimates for each of these subgroups. A random-effects model was adopted, which can
accommodate statistical heterogeneity between studies by assuming that different studies have different
true effect sizes (Figure 9), but we acknowledge that use of the random-effects model does not in itself
deal with heterogeneity. We assessed whether or not there was evidence of a subgroup effect and, as
there was not (p = 0.15), subsequent analyses were conducted on the 56 studies. The pooled RD for
comparisons between the intervention and usual care was 0.12 (95% CI 0.10 to 0.14). This corresponds to
a 12% absolute increase in DRS attendance.
Comparison B: more intensive (stepped) intervention compared with less intensive
intervention Examples of studies in this comparison included a tailored (individualised) newsletter
compared with a generic patient education newsletter113 and a comparison between audit and feedback to
HCPs and audit and feedback combined with a diabetes outreach service.91 Ten studies64,73,79,90,91,106,107,113,114,119
contributed to this analysis (Figure 10). Three (30%)113,114,119 evaluated interventions specifically targeting DRS,
whereas seven (70%)64,73,79,90,91,106,107 evaluated interventions directed towards improving the general quality
of diabetes care. The pooled RD for comparisons between a more intensive (stepped) intervention and a less
intensive intervention was 0.05 (95% CI 0.02 to 0.09). This corresponds to a 5% absolute increase in DRS
attendance for participants receiving the stepped intervention.
Secondary outcomes
Ongoing adherence to diabetic retinopathy screening based on attendance for screening
following the initial screening post intervention
It was not possible to extract data on ongoing adherence to DRS (based on attendance for screening
following the initial screening post intervention) because either it was not possible to identify unique
screening episodes from pooled data reported at two time points or, in one study,116 the intervention was
offered to the comparator arm 18 months post randomisation.
Economic outcomes
Resources (staff time, equipment, consumables) required to deliver interventions to
increase attendance for diabetic retinopathy screening
Resource utilisation was scored on a 1–5 ordered ranking scale, with 1 representing the least amount of
resources used and 5 representing the most amount of resources used. Chapter 6 provides a description of
the ordered ranking scale and the justification for using an ordered ranking scale (see The ordered ranking
score in Report Supplementary Material 4, Economic model). The percentage of studies in each resource
grouping for the 56 studies comparing any intervention with usual care was as follows: 1 = 48.2%,
2 = 10.7%, 3 = 8.9%, 4 = 19.6% and 5 = 12.6%.
Costs of staff used to provide interventions, treatment and care, primary care, lost wages
and lost productivity (work output)
All costs reported were converted to 2016 UK pounds and are summarised for each study in Appendix 6.
Only two studies67,126 reported both the direct and the indirect costs (productivity loss) of the interventions.
In all other studies, the costs reported covered just the direct costs of providing the intervention. Five
studies59,62,70,117,126 reported the total direct costs of the intervention but the resources that they considered
relevant and how they combined them to estimate total costs varied between studies. The components of
the total cost for each intervention are reported in Appendix 6.
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FIGURE 9 Meta-analysis of any QI interventions compared with usual care. df, degrees of freedom;
M-H, Mantel–Haenszel.
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FIGURE 10 Meta-analysis of stepped QI interventions compared with less intensive QI interventions. df, degrees of freedom; M-H, Mantel–Haenszel.
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The types of resources included in the cost calculations for each study varied; hence, it is difficult to
compare directly across the studies. The estimated training cost differed between the few studies that
reported this information. In terms of the costs of treatment and care of diabetes, there was no obvious
difference in between the intervention and the comparator in the studies that reported these data,
primarily reflecting an absence of evidence.
Incremental cost-effectiveness ratio
Only three studies conducted in the USA124–126 reported this outcome. Davis and Mayer-Davis124 reported
an incremental cost per QALY of £13,154 over 1 year for a diabetes telecare intervention compared with
no intervention. However, it is unclear what tool was used to estimate QALYs. Prezio et al.126 used an
established whole-disease model, the Archimedes model simulator, to estimate the incremental cost per
QALY. Using a discount rate of 3% and programme effectiveness of 100%, the incremental cost per
QALY was £73,683 over 5 years and £261 over 20 years for the intervention (a culturally tailored diabetes
education programme delivered by a community health worker) compared with usual care. Schechter
et al.125 also reported an ICER. In this study, the unit of effectiveness was the number of DFEs gained, which
was associated with the number of diabetic retinopathies diagnosed. The incremental cost per DFE gained
for a telephone intervention compared with a mailed/printed intervention was £333. Pizzi et al.117 reported
an ICER for a telephone intervention of £18.77 per additional patient attending a DFE compared with usual
care. The ratio was not calculated for a mailed intervention because it was dominated by usual care.
Further details of these outcomes are reported in Report Supplementary Material 1 [see Further details of
the review of economic evidence (phase 1 review)].
Exploration of heterogeneity
Substantial heterogeneity was observed (I2 > 90%), which was investigated by subgroup analysis and
meta-regression.
Subgroup analysis
Comparisons of studies grouped according to the QI component/BCTs present in the intervention arm
were conducted as well as comparison of studies at high compared with low risk of bias and according to
the resource intensity scale.
Although we attempted to code for the QI component/BCT in the control arm in all studies, we did not
adjust for this in the analysis as, for the majority of these studies, usual care was not specified and
therefore could not be coded.
Quality improvement components A sufficient number of studies were available to investigate the
effectiveness of nine out of the possible 12 QI components (see Appendix 4 for definitions of the QI
components). Insufficient data were available to analyse ‘continuous quality improvement’, ‘financial
incentives’ and ‘facilitated relay of information to clinicians’. Interventions incorporating all nine QI
components evaluated in the subgroup analysis were associated with improvements in DRS attendance,
with higher pooled effect estimates for interventions directed at patients (promotion of self-management
and patient education) or the organisation of the health system (team changes or the establishment of an
electronic patient registry) (Figure 11).
Component behaviour change techniques Sufficient studies were available to investigate the
effectiveness of interventions containing particular BCTs (including 10 BCTs aimed at patients and seven
aimed at HCPs) (Figures 12 and 13). Interventions incorporating all 17 BCTs included in the subgroup
analysis were all shown to be effective at improving DRS attendance. For BCTs aimed at patients, higher
pooled effect estimates were found for ‘goal-setting (outcome)’ and ‘credible source’; for BCTs aimed at
HCPs, higher pooled effect estimates were found for ‘restructuring the social environment’ and ‘credible
source’ (see Table 2 and Appendix 5 for BCT descriptions).
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Resource utilisation Analysis of subgroups according to resource intensity did not show a relationship
between effect size and increasing resource intensity (Figure 14).
Meta-regression
The results of the meta-regression analysis are provided in Tables 3–5. There was some evidence of an
association between effect size and baseline risk, with larger effects in studies with poorer baseline DRS
attendance (Figure 15). Because of regression to the mean, this association might be spurious, so a
permutation test was conducted to allow for this (with 1000 permutations; p = 0.055).
20 30 40100
Risk difference (%)
Patient reminders (n = 16 trials)
Audit and feedback (n = 11 trials)
Clinician reminders (n = 10 trials)
Case management (n = 18 trials)
Clinician education (n = 16 trials)
Patient education (n = 30 trials)
Electronic patient registry (n = 10 trials)
Promotion of self management (n = 21 trials)
Team changes (n = 19 trials)
FIGURE 11 Subgroup analysis of QI components.
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Prompts/cues (n = 25 trials)
Information about health consequences (n = 19 trials)
Social support (practical) (n = 20 trials)
Instruction on how to perform behaviour (n = 34 trials)
Restructuring the social environment (n = 17 trials)
Problem-solving (n = 10 trials)
Social support (unspecified) (n = 14 trials)
Feedback on outcomes of behaviour/biofeedback (n = 15 trials)
Credible source (n = 10 trials)
Goal-setting (outcome) (n = 14 trials)
FIGURE 12 Subgroup analysis of BCTs aimed at patients.
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The effect sizes from studies at high risk of bias were slightly (but not statistically significantly) higher than
those from studies at low risk of bias. Similarly, no statistically significant difference was found between
individual RCTs and cluster RCTs (p = 0.268).
For the meta-regression analyses comparing studies containing particular QI components/BCTs with
studies not including these components, no statistically significant differences were found, although
there was evidence of an association for ‘team changes’ (p = 0.052) and ‘promotion of self-management’
(p = 0.055). The patient-targeted BCT ‘goal-setting (outcome)’ was associated with a significantly greater
improvement in DRS attendance than in studies without this BCT (p = 0.001) and there was some evidence
of an association for the HCP-targeted BCT ‘restructuring the social environment’ (p = 0.053).
20 30 40100
Risk difference (%)
Restructuring the social environment (n = 23 trials)
Credible source (n = 13 trials)
Adding objects to the environment (n = 15 trials)
Instruction on how to perform behaviour (n = 30 trials)
Social support (practical) (n = 10 trials)
Prompts/cues (n = 15 trials)
Feedback on outcomes of behaviour/biofeedback (n = 17 trials)
FIGURE 13 Subgroup analysis of BCTs aimed at HCPs.
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Resource level 5 (n = 7 studies)
Resource level 4 (n = 11 studies)
Resource level 3 (n = 5 studies)
Resource level 2 (n = 6 studies)
Resource level 1 (n = 27 studies)
FIGURE 14 Subgroup analysis based on resource utilisation.
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TABLE 3 Results of the meta-regression analysis of type of QI intervention
Explanatory variable Regression coefficient (95% CI) p-value Residual I2 (%)
Baseline DRS attendance –0.208 (–0.419 to 0.004) 0.054 94
High vs. low risk of bias 0.008 (–0.136 to 0.094) 0.079 92
Cluster vs. individual RCT –0.049 (–0.136 to 0.039) 0.268 93
QI component
Audit and feedback –0.029 (–0.136 to 0.079) 0.597 92
Case management 0.001 (–0.092 to 0.095) 0.979 93
Team changes 0.089 (–0.001 to 0.178) 0.052 91
Electronic patient registry 0.051 (–0.061 to 0.164) 0.363 92
Clinician education –0.011 (–0.107 to 0.085) 0.822 93
Clinician reminders –0.012 (–0.127 to 0.103) 0.835 92
Patient education 0.075 (–0.009 to 0.160) 0.081 92
Promotion of self-management 0.085 (–0.002 to 0.172) 0.055 93
Patient reminders –0.033 (–0.128 to 0.063) 0.493 93
Resource requirement 0.013 (–0.015 to 0.042) 0.356 93
TABLE 4 Results of the meta-regression analysis of BCTs aimed at HCPs
Explanatory variable (HCP-BCTs) Regression coefficient (95% CI) p-value Residual I2 (%)
Feedback on outcomes of behaviour/biofeedback –0.035 (–0.129 to 0.060) 0.465 92
Social support (practical) –0.013 (–0.128 to 0.102) 0.821 93
Instruction on how to perform the behaviour –0.022 (–0.110 to 0.066) 0.622 93
Prompts/cues –0.029 (–0.126 to 0.069) 0.559 92
Credible source 0.028 (–0.075 to 0.132) 0.586 93
Restructuring the social environment 0.085 (–0.001 to 0.172) 0.053 91
Adding objects to the environment –0.003 (–0.102 to 0.095) 0.946 92
TABLE 5 Results of the meta-regression analysis of BCTs aimed at patients
Explanatory variable (patient BCTs) Regression coefficient p-value Residual I2 (%)
Problem-solving 0.042 (–0.073 to 0.158) 0.466 92
Goal-setting (outcome) 0.162 (0.070 to 0.254) 0.001 90
Feedback on outcomes of behaviour/biofeedback 0.081 (–0.016 to 0.179) 0.102 92
Social support (unspecified) 0.063 (–0.037 to 0.162) 0.211 91
Social support (practical) 0.012 (–0.079 to 0.103) 0.789 92
Instruction on how to perform the behaviour 0.031 (–0.059 to 0.120) 0.497 92
Information about health consequences –0.023 (–0.114 to 0.069) 0.624 93
Prompts/cues –0.050 (–0.137 to 0.037) 0.251 93
Credible source 0.097 (–0.016 to 0.211) 0.092 92
Restructuring the social environment 0.051 (–0.043 to 0.145) 0.284 93
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Sensitivity analysis
The main meta-analysis for any intervention compared with usual care was repeated using the lower and
upper range values for the ICCs to evaluate the impact on the computed effect estimates (Table 6).
Overall quality of the evidence
The summary of findings for the primary outcome of this review is presented in Table 7. For the main
comparison (any intervention vs. usual care), as most of the information came from studies at low or
unclear risk of bias, we did not downgrade for risk of bias. We downgraded one step for inconsistency as
there was substantial unexplained heterogeneity between the studies. We found no reasons to downgrade
the evidence on the basis of indirectness, imprecision or publication bias. Figure 16 provides a funnel plot
for the main comparison.
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FIGURE 15 Bubble plot showing the relationship between the RD and the baseline percentage screened. The RD
represents the difference in DRS attendance between the intervention arm and the control arm. Each bubble
corresponds to a different study and the size of the bubble reflects the number of participants. The regression
line shows a trend towards reduced screening attendance with increasing baseline compliance. Reproduced from
Lawrenson et al.,127 with permission from John Wiley & Sons, Ltd. Copyright © The Cochrane Collaboration.
Published by John Wiley & Sons, Ltd.
TABLE 6 Sensitivity analysis of imputed ICCs
Model
ICC
0.05 0.01 0.2
RD (95% CI) RD (95% CI) RD (95% CI)
DRS 0.17 (0.11 to 0.22) 0.17 (0.11 to 0.22) 0.17 (0.11 to 0.22)
GQI 0.12 (0.09 to 0.15) 0.12 (0.09 to 0.16) 0.11 (0.08 to 0.15)
Combined 0.12 (0.10 to 0.14) 0.13 (0.11 to 0.15) 0.12 (0.10 to 0.14)
GQI, general quality improvement.
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TABLE 7 Summary-of-findings table
Outcomes
Anticipated absolute effectsa (95% CI)
Relative effect
(95% CI)
Number of
participants
(studies)
Quality of
the evidence
(GRADE) Comments
Attendance
with usual care
Attendance with
any QI intervention
Any QI intervention compared with usual care for DRS
Proportion of patients attending
screening
472 per 1000 580 per 1000
(557 to 604)
RR 1.23
(1.18 to 1.28)
329,164
(56 RCTs)
⊕⊕⊕○
moderate
There was substantial unexplained heterogeneity
between studies (I2= 93%; p < 0.00001)
Proportion of patients attending
screening – strategy specifically
targeting DRS
335 per 1000 439 per 1000
(402 to 479)
RR 1.31
(1.20 to 1.43)
118,938
(13 RCTs)
⊕⊕⊕○
moderate
There was substantial unexplained heterogeneity
between studies (I2= 95%; p < 0.00001)
Proportion of patients attending
screening – general strategy to
improve the quality of diabetes care
534 per 1000 662 per 1000
(625 to 700)
RR 1.24
(1.17 to 1.31)
210,226
(43 RCTs)
⊕⊕⊕○
moderate
There was substantial unexplained heterogeneity
between studies (I2= 92%; p < 0.00001)
Outcomes
Anticipated absolute effectsa (95% CI)
Relative effect
(95% CI)
Number of
participants
(studies)
Quality of
the evidence
(GRADE) Comments
Risk with
intervention
alone
Risk with stepped
QI intervention
compared with
intervention alone
Stepped QI intervention compared with intervention alone for DRS
Proportion of patients attending
screening
361 per 1000 405 per 1000
(372 to 437)
RR 1.12
(1.03 to 1.21)
23,715
(10 RCTs)
⊕⊕⊕○
moderate
There was substantial unexplained heterogeneity
between studies (I2= 56%; p = 0.02)
Proportion of patients attending
screening – strategy specifically
targeting DRS
355 per 1000 384 per 1000
(295 to 497)
RR 1.08
(0.83 to 1.40)
19,698
(3 RCTs)
⊕⊕○○
low
There was substantial unexplained heterogeneity
between studies (I2= 68%; p = 0.04). The
pooled estimate of effect includes both
appreciable benefit and harm
Proportion of patients attending
screening – general strategy to
improve the quality of diabetes care
394 per 1000 457 per 1000
(406 to 516)
RR 1.16
(1.03 to 1.31)
4017
(7 RCTs)
⊕⊕⊕○
moderate
There was moderate unexplained heterogeneity
between studies (I2= 46%; p = 0.08)
a The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate quality: we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low quality: our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.
Very low quality: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.
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Discussion
Summary of the main results
Impact of quality improvement interventions on diabetic retinopathy screening
A comprehensive search of the literature identified 66 RCTs/cluster RCTs that investigated the effectiveness
of interventions to improve attendance for DRS. Fifty-six studies (enrolling 446,078 patients) compared a
variety of QI interventions with usual care. A meta-analysis of 56 of these studies found that QI intervention
components that were aimed at patients, HCPs or the health-care system were associated with a 12%
absolute increase in DRS attendance. In 13 of these studies, the QI intervention specifically targeted DRS
and in 43 studies the intervention consisted of a general QI intervention to improve diabetes care. Although
the pooled effect estimate was larger for DRS-targeted interventions than for non-targeted interventions
(17% vs. 12% increase in DRS attendance), this difference was not statistically significant.
Ten studies (enrolling 51,736 patients) compared a less intensive intervention (‘active’ control) with a more
intensive intervention. Three of these studies specifically targeted DRS and seven were general QI interventions.
The aim of these studies was to determine whether stepping up the intensity of an intervention component, or
introducing further components, would increase DRS attendance. The pooled effect estimate for these studies
was smaller, with a 5% increase in DRS attendance in favour of the more intensive intervention, suggesting
that it is possible to further enhance the effect size by using more intense interventions.
The main comparison in this review (any QI intervention vs. usual care) was associated with substantial
heterogeneity. Heterogeneity was explored by subgroup analysis and meta-regression. There was some
evidence for larger effect sizes in populations with lower baseline levels of DRS attendance; however,
much of the observed heterogeneity was unexplained. Sufficient numbers of studies were available to
investigate the impact of particular QI components or BCTs to identify the active ingredients of the
interventions. All 12 QI components, as defined by the modified EPOC taxonomy, were used in at least
one study and interventions were generally multifaceted with two to three QI components per intervention
arm. QI components targeting patients, HCPs or the health-care system were all effective in subgroup
analysis. A meta-regression comparing studies using particular QI components with those not using them
showed no statistically significant difference between intervention components, although there was some
evidence of an association for ‘team changes’ and ‘promotion of self-management’.
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FIGURE 16 Funnel plot of comparison: any QI intervention compared with usual care. SE(RD), standard error
of the risk difference. Reproduced from Lawrenson et al.,127 with permission from John Wiley & Sons, Ltd.
Copyright © The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Behaviour change techniques that were particularly effective at improving DRS attendance when directed
at patients included ‘goal-setting (outcome)’, that is, agreeing a goal defined in terms of a positive
outcome resulting from the behaviour. There was a statistically significant improvement in DRS attendance
in studies including this technique compared with those without. There was also some evidence of an
association for ‘restructuring the social environment’ in interventions targeting HCPs. This technique
involves changing the social environment to facilitate performance of the wanted behaviour, for example
the assignment of multilingual link workers to work with specific intervention general practice surgeries
in the study by Bush et al.110 The technique ‘credible source’ was effective for both patients and HCPs.
This involved verbal or visual communication from a high-status professional or organisation in favour of
the behaviour.
We found no studies reporting our secondary outcome measure of ongoing adherence to DRS
following the initial screening appointment post intervention and no data on the relative effectiveness of
interventions in particular population subgroups, for example according to socioeconomic characteristics.
Health economic outcomes
Fourteen studies reporting economic outcomes were included in the review; however, only five of these
were full economic evaluations. Overall, we found that there is insufficient evidence to draw robust
conclusions about the relative cost-effectiveness of the interventions compared with each other or
with usual care. QI components aimed at patients directly appeared to be more resource intensive than
those aimed at HCPs, with the exception of establishing an electronic patient registry, although there
would be economies of scale in that there are high set-up costs but the ongoing running costs would be
comparatively low.
The effectiveness of interventions that included specific QI or BCT components was calculated for levels
of resource use as measured on an ordered ranking scale. The purpose was to explore whether or not
more resource-intense interventions were more likely to be effective. The results indicate that there is no
clear relationship between the two. Although it is possible that such a relationship may exist, there was no
a priori reason to suppose that a more expensive intervention will also be more effective. Variation in
resource use can usefully be categorised into variation in intensity of the same intervention and variation
in the type of intervention. As an example of the first category, it may be supposed that spending more
time face-to-face with a person with diabetes explaining the health consequences of behaviour may be
more effective. Alternatively, designing, printing and distributing a 50-page document explaining health
messages is likely be more expensive but possibly less effective than designing, printing and distributing a
leaflet. As an example of the second category, providing text message prompts and cues is a completely
different intervention from providing a leaflet on health consequences. The text messaging system is likely
to be more expensive, but we cannot be sure it will be more effective. Furthermore, information about
health consequences could also be delivered by telephone or in a leaflet. The telephone call is likely to be
more expensive than the leaflet, but we cannot be sure that it will be more effective.
Quality of the evidence
Overall, we judged the quality of the evidence to be moderate using the GRADE evidence rating system.57
The level of evidence was downgraded one step because of inconsistency of findings in studies comparing
QI interventions with usual care and one step for imprecision or inconsistency in studies comparing a less
intensive with a more intensive intervention. Using the Cochrane EPOC risk-of-bias tool,51 we found that
nearly half of the included studies were at high risk of bias in at least one domain. This was most often
because of incomplete outcome reporting. For many domains it was not possible to judge the risk of bias
because of poor reporting. For example, because many of the RCTs did not have a prospectively published
protocol, it was not possible to make a judgement whether or not outcomes were selectively reported.
A subgroup analysis found that, although studies that were at a high risk of bias had slightly higher effect
estimates than those at a low risk of bias, this difference was not statistically significant. The consensus of
the review team was not to downgrade the quality of the evidence for risk of bias.
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Of the 22 potential ‘economic’ studies identified by the review team, 14 studies were eligible for the
review as partial or full economic evaluations. We identified a publication bias in two of the eight excluded
studies.94,123 These studies failed to report the planned economic evaluations as no evidence of intervention
effectiveness was identified. Such an approach could be considered as selective outcome reporting, such
that potentially negative economic findings are not reported. This phenomenon of reporting bias has been
recognised previously,129 when studies with unfavourable effectiveness results are not published or are
published later in low-impact journals. Furthermore, analytically, such an approach is substandard as these
studies conflate absence of evidence with a finding of evidence of absence (of an effect).
Most of the economic evaluations had limitations in their reporting, with few providing a breakdown
of the costs associated with delivering the different components of the intervention. There was also
insufficient evidence to show whether or not part of the direct costs of the intervention and care may be
offset by reduced productivity costs. However, it is important to note that the expected findings of an
effective intervention would be gains in health and reductions in the costs of treating diabetes. The overall
methodological quality of the included economic studies was mixed. The partial economic evaluations
identified lack, by their nature, the methodological characteristics expected of an economic evaluation.
The methodological quality of the full economic evaluations was considered to be moderate.
Agreements and disagreements with other studies or reviews
Only one systematic review22 has previously investigated the effectiveness of interventions to increase
the uptake of DRS. Although this review included 48 studies, only 12 of these were RCTs (10 of which
were included in the current review). The authors similarly concluded that a variety of interventions can
be effective in improving screening uptake, including increasing patient and provider awareness of
diabetic retinopathy, introducing a computer-based registration/reminder programme and developing a
community-based health-care system.
Compared with the paucity of systematic reviews of the impact of interventions to improve DRS outcomes,
many reviews have evaluated the impact of general QI interventions to improve the overall quality of
diabetes care.28 A systematic review published by members of the current team29 included 48 cluster RCTs
and 94 patient RCTs and found improvements in many important quality outcomes for patients with
diabetes. A meta-analysis of a subset of 23 RCTs reporting the uptake of DRS found a similar pooled
relative effect size to that in the current review (RR 1.22, 95% CI 1.13 to 1.32; I2 = 80.4%).
Limitations of the review
Our systematic review has some limitations. Coding of intervention content was challenging given the
paucity of primary data sources, although in some cases this was offset by obtaining further information
from researchers on intervention content, who also provided the materials used to deliver the interventions.
We were not able to assess the impact of some QI intervention components because of too few trials being
available for our subgroup and meta-regression analyses. Furthermore, we could not control for all potential
confounding factors. Given the complexity of the interventions under investigation, which incorporate
multiple QI components, it is likely that other covariates may have interacted synergistically or antagonistically
with them. The short duration of the included RCTs (typically ≤ 12 months) also meant that we were unable
to assess the effect of the QI interventions on ongoing DRS attendance or their impact on the progression of
diabetic retinopathy.
Implications for practice
The results of this review provide evidence that QI interventions targeting patients, HCPs or the health-care
system are likely to be associated with meaningful improvements in DRS attendance compared with usual
care. There was no statistical difference between interventions specifically aimed at DRS and those that
were part of a general QI strategy for improving diabetes care. This is a significant finding because of the
additional benefits of general QI interventions in terms of improving glycaemic control, vascular risk
management and screening for other microvascular complications.28,29 It is likely that further (but smaller)
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improvements in DRS attendance can also be achieved by increasing the intensity of a particular QI
component or adding further components.
One of the main objectives of the review was to identify the ‘active’ components of successful
interventions by using validated taxonomies to describe the content of the interventions. All of the QI
components as defined by the modified EPOC taxonomy were associated with improvements in DRS
attendance. To better characterise intervention content we coded the interventions in terms of patient
and provider BCTs. For BCTs aimed at patients, higher effect estimates were found for interventions
incorporating goal-setting; for BCTs aimed at HCPs, higher effect estimates were found for interventions
involving environmental restructuring. However, only 42% of the 93 possible BCTs were reported in
the included interventions and, although not all BCTs in the taxonomy might be appropriate for DRS,
the findings of this review suggest that there may be opportunities to assess the potential of additional
BCTs in future trials of novel interventions to improve screening attendance.
Although only three of the studies were conducted in the UK, we believe that the results of the review are
applicable to a UK context. Two-thirds of the included studies were conducted in North America, where
guideline recommendations include a DFE by an ophthalmologist or optometrist at least once every 2 years
(or more frequently in high-risk individuals). Although the North American system for DRS is different from
the national screening programme that operates in the UK, the two care pathways are similar in that DRS
is generally conducted in a different health-care setting from that for other aspects of diabetes care.
Implications for research
The review highlighted a number of gaps within the evidence base. There was limited evidence on the
relative effectiveness of QI interventions in particular population subgroups according to demographic
characteristics that could have an impact on health equity, for example ethnicity, level of education or
socioeconomic status. There is also insufficient evidence on the cost-effectiveness of QI interventions to
improve DRS attendance.
Most of the included studies, whether targeting DRS or general QI, enrolled patients not achieving
diabetes-relevant quality indicators. For example, five studies specifically targeting DRS exclusively recruited
patients who were not meeting guideline recommendations for screening. It is not clear if the interventions
would be as effective in populations with a higher level of screening attendance (> 80%). There was some
evidence from our meta-regression analysis that the effectiveness of the interventions is negatively
correlated with baseline level of DRS.
Although we have been able to show that interventions containing particular BCTs have a greater likelihood of
success, given the multicomponent nature of interventions, it is likely that the presence of other BCTs or other
effect modifiers in the intervention arm may also have an impact on effectiveness. The analysis conducted as
part of this review did not attempt to isolate the impact of individual QI/BCT components, although exploratory
analysis was conducted using multivariate meta-regression methods to determine cost-effectiveness (reported
in Chapter 6). Further research is needed to identify which components of interventions or combinations of
components can optimally improve DRS attendance at an acceptable cost.
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Chapter 4 Barriers to and enablers of diabetic
retinopathy screening attendance: a systematic review
of published and grey literature
Background
In addition to identifying the ‘active components’ in complex interventions (reported in Chapter 3),
evidence is also needed on how QI interventions might work. Understanding the theoretical determinants
(e.g. barriers and enablers) of screening behaviour is an important step in intervention development and in
interpretation of the results of evaluations of interventions. In phase 2 of this study, identification of
barriers and enablers provides an evidence base to assess the extent to which existing QI interventions
address the theoretical determinants of attendance behaviour, to offer guidance as to why some
interventions might work better than others and to identify which theoretical determinants are likely to
mediate the effects of interventions.
There is some evidence that theory-based interventions may be more effective than those that are not
theory based.31,32 This suggests that interventions that target DRS behaviour are more likely to be effective
if they target the theoretical determinants of screening behaviour. However, the explanatory factors
(theoretical constructs) from different theories often overlap, making it challenging to identify the
key determinants.130
To address this, 128 explanatory constructs from 33 theories of behaviour change have been synthesised
into an integrated framework, the TDF, which consists of 14 overarching ‘theoretical domains’. These
domains are labelled (1) knowledge, (2) skills, (3) social/professional role and identity, (4) beliefs about
capabilities, (5) optimism, (6) beliefs about consequences, (7) reinforcement, (8) intentions, (9) goals,
(10) memory, attention and decision processes, (11) environmental context and resources, (12) social
influences, (13) emotions and (14) behavioural regulation.39 Appendix 7 presents the definitions of the TDF
domains. Each domain represents a set of related constructs that may mediate behaviour change. For
example, the ‘social influences’ domain includes constructs such as social support, group norms and social
comparison.130 The TDF thus provides an accessible, comprehensive, theory-driven basis for investigating
the potentially wide-ranging barriers to and enablers of behaviour change.
Barriers and enablers can operate at multiple levels in the health-care system. Ferlie and Shortell131
propose four distinct levels of change that should be considered to maximise the likely effectiveness
of QI interventions: individual, group or team, overall organisation and wider system or environment.
The TDF can be applied at the level of the individual, team and/or health-care organisation to investigate
barriers to and enablers of behaviour change.130 A related framework is the Consolidated Framework for
Implementation Research (CFIR). The CFIR draws on a different theoretical literature from the TDF, primarily
relating to organisational behaviour change. The CFIR provides an integrated framework of theory-based
constructs to guide the identification of potential barriers to and enablers of health-care innovation across
different organisational levels. It includes 39 constructs organised into five domains: (1) ‘intervention
characteristics’, (2) ‘inner setting’, (3) ‘outer setting’, (4) ‘characteristics of the individuals involved’ and
(5) the ‘process of implementation’. Appendix 8 presents the constructs and definitions for each of the
five CFIR domains. The CFIR can potentially be used concurrently with the TDF to offer an organisational
focus to investigating barriers/enablers, which might identify further insights.132
Both the TDF and the CFIR have been applied in numerous studies, primarily interview and survey studies,
to systematically identify and characterise barriers to and enablers of implementation across a wide range
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of clinical contexts. More recently, the TDF has been applied in systematic reviews of barriers and enablers,
as a coding framework for data synthesis.133–136 For example, Wilkinson et al.133 undertook a review to
identify barriers to and enablers of the translation of gestational diabetes guidelines into clinical practice.
They used data including routinely collected hospital data, staff survey data, clinic observations and team
discussions and evidence from relevant literature. Data representing barriers were then coded into the
TDF domains and mapped onto potential implementation strategies. Identifying barriers and enablers in
the literature, framing these in terms of theoretical domains and identifying their likely importance for
screening attendance are steps that might explain why some interventions are more effective than others.
This would enable intervention designers to optimise interventions by ensuring that they target the likely
determinants of screening attendance.
Aim
In the evidence synthesis reported in this chapter we set out to complement the evidence on the
effectiveness of QI interventions used in RCTs to improve attendance for DRS (see Chapter 3). We aimed
to clarify how QI interventions might work and gain an understanding of DRS attendance behaviour by
identifying the theoretical determinants of DRS attendance.
The specific objectives were to:
l identify the published and grey literature reporting perceived barriers and enablers associated with
DRS attendance
l extract reported barriers/enablers and categorise them according to TDF/CFIR domains
l identify key content themes within domains, regarding barriers to and enablers of DRS attendance
l apply prespecified criteria to identify the likely importance of TDF/CFIR domains in influencing
DRS attendance.
Methods
The protocol for this review was published in Systematic Reviews on 8 August 2016137
(PROSPERO CRD42016032990).
Study eligibility criteria
Types of study
Studies were included if they reported primary data relating to barriers and enablers that might hinder or
facilitate patient attendance at DRS. Such barriers or enablers included organisational, emotional, cognitive,
behavioural and social factors; however, they were required to be potentially modifiable (i.e. not demographic
or historical factors such as age, gender, ethnicity, socioeconomic status or duration of illness). By primary
data we mean any data relating to participant perceptions of barriers and/or enablers or data that document
specific modifiable factors associated with attendance.
Evaluations of QI interventions were excluded if they did not signal investigations of primary data relating
to barriers and/or enablers in the title. This decision was based on the results of a scoping exercise
performed on a subset of studies, returned by the search that reported evaluations of QI interventions.
From this subset we identified that no information relevant to this review would be lost if we eliminated
such studies based on screening at the abstract level. Reviews of studies reporting primary data were also
excluded to avoid duplication of findings.
We included studies reported in English, conducted within the time period from January 1990 to March 2016,
basing the lower date limiter on the publication of the St Vincent Declaration,138 which set a target to reduce
new cases of blindness in Europe by one-third or more, as this is arguably the catalyst for the development
of screening programmes for diabetic retinopathy worldwide.
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Participants
Those diagnosed with type 1 or type 2 diabetes and eligible for DRS were included in the review. There
were no restrictions on participant demographics or characteristics. HCPs responsible for diabetes care
were also included. In the context of this review a HCP was defined as anyone who provides information,
guidance, screening or treatment to people with diabetes to assist with the management of their diabetes.
Such professionals include, but are not limited to, general practitioners (GPs), diabetologists, diabetes
specialist nurses, optometrists, ophthalmologists and retinal screeners. Samples from any country
were included.
Context
There were no restrictions on population-based DRS programmes/models (e.g. fixed location screening
services, mobile screening services, optometry-based services and mixed service delivery models).
Search strategy
Identifying published studies
We searched MEDLINE, EMBASE, PsycINFO, Web of Science, CENTRAL (The Cochrane Library) and
ProQuest (from January 1990 to March 2016). The search strategy was adapted to suit each database.
The reference list of any study that met the inclusion criteria was screened for any additional studies not
identified in the database searches. The reference lists of any relevant reviews that were identified in the
database search were also screened for any additional studies. An example of the search strategy for
MEDLINE is provided in Appendix 9 and the full search strategy for each database is provided in Report
Supplementary Material 2 (see Search strategies for phase 2 systematic review).
We undertook a scoping search to develop an appropriate search strategy and terms were agreed by
the research team. Search terms addressed three distinct concepts: (1) diabetic retinopathy (e.g. diabetic
retinopathy, proliferative retinopathy, diabetic eye disease), (2) screening (e.g. screening, vision tests,
ophthalmoscopy, eye examination, fundus photography) and (3) potential barriers and enablers [e.g.
(non)compliance, (non)responsive], including terms relating to background characteristics of the population
for which there is evidence in the literature of disparities in health screening attendance (e.g. patient
acceptance of health care, health promotion, health-care disparities, socioeconomic factors, education
and ethnic groups).
In addition to the terms listed above, the search strategy included terms related to each of the TDF
domains, to ensure that the potential range of barriers and enablers was represented. These were agreed
by a consensus group exercise. Consensus group participants (seven research psychologists who were
familiar with the TDF) were presented with the TDF domain labels and component constructs and asked to
rank the constructs in terms of the extent to which they represent/summarise the domain. The highest
ranking (i.e. the top two) constructs within each domain were selected and added to the list of keywords
representing the TDF. For example, in the domain ‘emotions’ the top two constructs selected were
‘anxiety’ and ‘fear’.
Identifying grey literature
Established sources of grey literature were searched using two approaches. First, we used a modified
version of the search strategy described above to search grey literature databases, for example OpenGrey,
PsycEXTRA and the Healthcare Management Information Consortium (HMIC) database. Second, we carried
out an internet search using the search engine Google (Google Inc., Mountain View, CA, USA) using the
terms ‘diabetic retinopathy’ AND screening AND [barrier* OR ‘facilitate* OR enable]. We limited the Google
search to the first 15 pages. We also consulted with the project representative stakeholder group to identify
further sources of grey literature.
DOI: 10.3310/hta22290 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 29
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Lawrenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
Study selection process
Following deduplication, one member of the research team (EGR) screened the titles and abstracts of all
of the identified references against the inclusion/exclusion criteria to decide whether or not the full-text
manuscripts should be retrieved. Each study was judged as either (1) not meeting the eligibility criteria for
inclusion or (2) potentially meeting the eligibility criteria for inclusion. A second report author (FL) screened
the titles of approximately 10% of the titles and abstracts. Inter-rater reliability statistics were calculated.
The full-text screening was conducted using similar methods as used to screen titles and abstracts.
Data extraction and analysis materials/tools
We developed a data extraction form to extract study characteristics, including author/date, method of
identification (e.g. database search, Google search), country where study was conducted, research
objectives, topics of investigation (e.g. knowledge, attitudes, beliefs or perceptions of barriers/enablers),
methodological/theoretical approach, data collection methods, data analysis methods, participant
characteristics and sample size.
We prepared a codebook with the definitions of each of the 14 theoretical domains from the TDF and the
39 distinct constructs from the five domains of the CFIR, to facilitate coding consistency and reliability.
Two report authors (EGR and FL) collaboratively coded three included studies, making reference to the
codebook and amending it when appropriate.
Quality assessment
One review author (EGR) assessed the quality of the included studies using items selected from the
Critical Appraisal Skills Programme (CASP) qualitative checklist139 and the Mixed Methods Appraisal Tool
(MMAT).140 Studies that reported mixed methods were appraised using both the quantitative and the
qualitative appraisal tools. A quantitative survey that reported open-ended questions but which did not
analyse the responses qualitatively was defined as a quantitative study. Studies presented as abstracts only
were not subjected to quality appraisal. A second review author (JGL) assessed a random sample of studies
(20%) and differences of opinion regarding quality were resolved by discussion.
Analysis
To the extent that it was possible in a secondary analysis context, we followed analysis methods that have
been used in previous studies applying the TDF to interview transcripts from semistructured interviews.141–143
These methods typically follow a combined content and framework analysis approach and involved five steps:
(1) data extraction, (2) deductive analysis (TDF coding), (3) inductive analysis (thematic synthesis), (4) CFIR
coding and (5) identifying important domains. Figure 17 presents a flow diagram of the steps in the analysis.
Data extraction
Step 1: data extraction
One report author (EGR) identified and extracted data reporting participants’ (e.g. people with diabetes
and/or HCPs) perceptions of barriers to and enablers of DRS attendance that met our inclusion criteria,
presented in Types of studies. Extracted data included, for instance, participant quotations from qualitative
studies, quantitative findings from questionnaire and survey studies and authors’ interpretive descriptions
and summaries of results. Reported predictors of and associations with attendance/non-attendance
reported in quantitative studies were also extracted.
Deductive analysis
Step 2a: pilot coding exercise
To practise coding extracted data into TDF domains, three pilot transcripts were collaboratively coded using
the TDF as a coding framework. Emerging heuristics were documented (e.g. ‘knowledge’ may be clinically
correct or incorrect but must relate/link to attendance). Any discrepancies were discussed until agreement
was reached (see Appendix 7 for the TDF codebook).
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Step 2b: Theoretical Domains Framework coding
One review author (EGR) coded the data extracted from all remaining studies. Extracted data were coded
according to which TDF domain they were judged to represent, guided by the TDF codebook that was
developed as a result of step 2a. For example, if a person with diabetes was quoted as saying, ‘I believe
that having my eyes screened once a year will help preserve my vision’, this was coded into the domain
‘beliefs about consequences’. If a reported barrier/enabler was judged to concurrently represent more than
one domain, it was coded into multiple domains. For example, if a person with diabetes was quoted as
saying, ‘I am anxious about attending my screening appointment because I can’t drive home after
receiving eye drops’, this was coded into two domains, ‘emotions’ and ‘beliefs about capabilities’.
Inductive analysis
Step 3: thematic synthesis
In line with a framework analysis approach, step 3 focused on sifting and sorting the data within each
domain to thematically synthesise and identify key emerging content themes.144,145 One report author (EGR)
grouped together similar data relating to perceived barriers to/enablers of DRS attendance for each of the
14 domains. Theme labels and, when appropriate, subtheme labels were then generated for each cluster
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FIGURE 17 Flow diagram of steps in the analysis.
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of similar data to express these shared views. These initial grouping and theme labels were then reviewed
in a consensus group exercise. Two additional report authors (FL, JJF) reviewed the initial groupings
to assess (1) their agreement with the grouping of extracted data, (2) their agreement with the
assigned theme labels and (3) if the themes were appropriately allocated to the given domains.
Disagreements were discussed until consensus was reached. The theme groups/labels/allocation of
domains were revised accordingly, based on consensus.
Additionally, EGR assigned the data within the themes as representing either barriers to or enablers of DRS
attendance. The decision was made depending on the interpretation of the data from the study where the
data originally came from. This was usually clear as data either were reported in a table entitled ‘barriers to
DRS’ or ‘enablers to DRS’ attendance or were interpreted as one or the other by the study authors, who
were familiar with the raw data. A theme/subtheme was then classified as (1) a barrier theme if the data
points within it related to barriers only (e.g. receiving insufficient notice of appointments), (2) an enabler
theme if the data points within it related to enablers only (e.g. support from local community groups/
networks) and (3) both a barrier and an enabler theme if the data points related to both [e.g. (in)flexibility
of choice of times/dates of appointments].
Step 4: Consolidated Framework for Implementation Research coding
To further explore potential organisational factors that might influence DRS attendance we recoded the
themes identified in the inductive analysis (described above in step 3) into CFIR constructs. This exercise
was carried out on the themes identified within the four TDF domains that are arguably related to the
organisation: (1) ‘environmental context and resources’, (2) ‘social influences’, (3) ‘social/professional roles
and identity’ and (4) ‘behavioural regulation’.146
Identifying important domains
Step 5: applying importance criteria
Each domain identified in step 2 was reviewed against an established set of ‘importance criteria’146 to
determine which domains were likely to be important for influencing screening attendance. There were
three importance criteria: (1) frequency (the number of studies that identified each theme), (2) level of
elaboration (number of themes and subthemes) within each domain and (3) ‘expressed importance’ within
each domain (either a statement from the authors’ interpretation of the study findings articulating specific
beliefs as important influences or direct quotes from study participants expressing importance).
Results
Search results
Searches of MEDLINE, EMBASE, PsycINFO, Web of Science, CENTRAL and ProQuest generated 3251
records. Searches in OpenGrey, PsycEXTRA and the HMIC database generated a further 62 records. A
further 144 records were identified through the other sources, totalling 3457 records. After deduplication,
a total of 3010 records were screened based on title and abstract. In total, 2800 records were excluded,
leaving 210 studies for full-text screening. When the full text of a record was not available but the
abstract presented meaningful results, these were also screened against our inclusion/exclusion criteria.
We identified 65 studies24,147–210 that met our eligibility criteria. Figure 18 presents the PRISMA
flow diagram.
Characteristics of included studies
Report Supplementary Material 2 [see Characteristics of the 65 included studies (phase 2 review)] shows the
characteristics of the 65 included studies. Forty-one (63%)147,148,150,151,153,156,162–166,171,175–180,182,184–187,190,192,194–199,
201–210 used quantitative methods only (e.g. questionnaires, surveys), 18 (28%)149,152,154,155,157–160,168,169,172–174,181,
188,189,191,200 used qualitative (e.g. interviews/focus groups) methods only and six (9%)24,161,167,170,183,193 used
mixed methods. Forty-seven studies used quantitative methods in full or as part of a mixed-method design.
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Of these 47 studies, 37 (79%) used a cross-sectional survey design, nine (19%) used a follow-up design and
one (2%) was a report of a questionnaire development study. Twenty-four studies used qualitative methods
in full or as part of a mixed-method design. Of these 24 studies, 19 (79%) were descriptive studies that had
no specific analytical or theoretical approach, one (4%) was part of an evaluation of a QI intervention, one
(4%) used a theoretical framework (TDF), one (4%) used a grounded theory approach, one (4%) used a
case-base approach and one (4%) was a service evaluation.
Twenty-nine (45%) of the studies were carried out in the USA, 12 (18%) in the UK, four (6%) in Australia,
three (5%) in Canada, 10 (15%) in Asia, four (6%) in Africa, two (3%) in Europe and one (2%) in South
America. Forty-eight studies (74%) were published as full texts in peer-reviewed journals, five (8%) were
reported as unpublished full-text reports/dissertations and 12 (18%) were published in abstract/poster
form only.
Fifty studies (77%) reported barriers/enablers from the perspective of the people with diabetes only,
14 (21%) reported barriers/enablers from the perspective of both people with diabetes and HCPs and
one (2%) reported barriers/enablers from the perspective of HCPs who were diagnosed with diabetes.
Twenty-nine studies (45%) reported barriers/enablers from a subset of patient samples. These included
10 studies (15%) that reported barriers/enablers from the perspective of specific ethnic groups (e.g. African
Americans, American Indians, Aboriginal Canadians, people of South Asian or Hispanic origin), six studies
(9%) that reported from the perspective of people who were classified as either non- or late attenders,
four studies (6%) that reported from the perspective of older adults, two studies (3%) that reported from
the perspective of younger adults, two studies (3%) that reported from the perspective of women only,
two studies (3%) that reported from the perspective of people who had been diagnosed with diabetic
retinopathy, one study (2%) that reported from the perspective of people with diabetes receiving
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FIGURE 18 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.
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treatment, one study (2%) that reported from the perspective of people with diabetes who had
participated in a blindness prevention programme and one study (2%) that reported from the perspective
of a Medicare population. Report Supplementary Material 2 [see Excluded studies (phase 2 review)]
presents a description of articles that were assessed for inclusion at the full-text stage but which were
subsequently excluded.
Quality of included studies
The quality appraisals of the included studies (n = 5324,147–161,163–170,172–175,177–180,182,184,185,187,190–192,194,195,197,199,201–210)
are presented in Report Supplementary Material 2 [see Quality assessment (phase 2 review)]. Overall, studies
were judged to be at low, medium or unclear risk of bias. However, studies were often poorly reported,
which made the process of quality appraisal difficult. Limitations in the qualitative studies included (1) limited
reporting or rigour of the data analysis and (2) limited reporting or consideration of the relationship between
the authors and the participants. Generally, the strengths of these studies were (1) the research design
(although there was often a lack of information justifying the approach), (2) the recruitment strategy and
(3) the data collection procedures. Limitations in the quantitative studies related to (1) poor reporting of
questionnaire validity and (2) low response rates.
Deductive analysis
In total, 612 units of data were extracted, of which 378 were qualitative (126 quotations from study
participants and 252 from authors’ conclusions) and 234 were quantitative [e.g. percentages of
participants agreeing with a questionnaire item or odds ratios (ORs)].
Reported barriers were identified in all but one of the TDF domains (‘skills’). Enablers were identified in all
but two domains (‘beliefs about capabilities’ and ‘skills’). However, overall, there were almost three times
as many themes/subthemes identified as barriers only than themes/subthemes identified as enablers only
(60 vs. 22). Twenty-one themes/subthemes represented both barriers and enablers. Table 8 reports the
frequencies of barriers and enablers identified within each of the 15 TDF domains.
TABLE 8 Frequencies (numbers of themes/subthemes) of barriers and enablers reported within each of the
14 domains of the TDF
TDF domain Barriers only Enablers only Both barriers and enablers
Environmental context and resources 18 3 6
Social influences 6 4 5
Knowledge 3 2 6
Memory, attention and decision processes 9 3 –
Beliefs about consequences 8 3 –
Emotions 6 2 1
Social/professional role and identity 5 1 –
Goals 2 1 1
Beliefs about capabilities 2 – –
Behavioural regulation – 2 1
Intentions 1 1 –
Optimism 1 1 –
Reinforcement – – 1
Skills – – –
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Inductive analysis
Report Supplementary Material 2 (see Themes/subthemes within each of the 14 domains from the
Theoretical Domains Frameworks) presents all themes and subthemes identified within each domain,
alongside frequencies, relevant studies and sample quotations. A narrative description of the themes,
within domains, is presented later in this chapter, organised into two groups: (1) domains that were
identified as being ‘high’ in importance (see Thematic synthesis for domains identified as having high
importance) and (2) domains that were identified as being less important (see Domains identified as being
less important).
Consolidated Framework for Implementation Research: organisational analysis
Themes identified in the four TDF domains that arguably relate to the organisational level (as specified
in step 4 of the methods) were recoded into CFIR constructs. The full results are presented in
Report Supplementary Material 2 (see Coding of themes/subthemes into Consolidated Framework for
Implementation Research constructs). The studies included in this review predominantly reported barriers
and enablers for the person with diabetes, as reported by the patient, HCP or study author, rather than
for the organisation or HCP, as conceptualised by the CFIR. Therefore, the majority of the themes were
coded into the construct ‘needs and resources of those served by the organisation’ which, according to
the CFIR, is defined as ‘the extent to which the needs of those served by the organisation (e.g. patient),
as well as barriers and facilitators to meet those needs, are accurately known and prioritized by the
organisation’ [reproduced from the CFIR.211 This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/]. The focus of the CFIR on the HCP as the individual of
interest and not the person with diabetes means that, in this study, it did not offer any additional insights
over and above the TDF. As a consequence, no further analysis was conducted using the CFIR.
Importance of the Theoretical Domains Framework domains
This section reports the findings regarding the three importance criteria (frequency, elaboration and
expressed importance).
Domain frequency
Most of the data units extracted from included studies were coded into the domains (1) environmental
context and resources (50 studies24,147–151,153–170,172,174,175,177,179–191,194–196,199–202,206,207), (2) knowledge
(33 studies24,151,152,155–161,165–169,172,174–178,181,188,190–195,200,203,205,206), (3) social influences (32 studies24,148–150,152,154,
156–161,165–175,181,182,184,188,191,192,195,201,203), (4) memory, attention and decision processes (31 studies24,149,155–161,165,
166,168–170,172,175,177,179–184,187,189,190,194,195,199,201,203), (5) beliefs about consequences (25 studies24,155–159,161,165–168,170,
174,175,181–189,192,198) and (6) emotions (22 studies148,154,157–161,165,167,170,174,175,181,183,185,188–193,204). These six domains
were identified by at least one-third of the included studies (Table 9).
Level of elaboration
Approximately 83% of themes/subthemes relating to barriers and 80% relating to enablers were captured
in the same six TDF domains. Table 9 (columns 3 and 4) lists the numbers of themes and subthemes
identified within each domain.
Rank order of domain importance
In Table 9, the fourteen TDF domains are presented in rank order. In general, there was good convergence
between frequency (number of studies in which the domain was evident) and elaboration (number of
themes and subthemes based on the inductive analysis). All three columns in Table 9 identify environmental
context and resources as the most important domain and, with one exception, the same six domains as
more important than the remaining eight domains. One more subtheme was identified in the domain of
social/professional role and identity than in the domain of emotions. However, the overall signal for
importance was stronger for emotions, which was therefore ranked sixth for importance.
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Expressed importance
Study authors’ interpretations of the study findings (e.g. in discussion sections) articulating specific beliefs
as important influences were also considered to be evidence of the importance of barriers and enablers.
Quotations expressing importance are presented in Report Supplementary Material 2 (see Expressed
importance) alongside the TDF domain that they were judged to represent. For example, the quotation
‘Getting to and from screening appointment was important pragmatically for many patients, who had to
overcome a range of issues’158 represents expressed importance for the domain ‘environmental context and
resources’ and the quotation ‘The main reason for refusal was the retinal photos taken might worsen
sight’ represents expressed importance for the domain ‘beliefs about consequences’.186 After all quotations
regarding expressed importance had been coded into the corresponding themes, the number of studies
that identified each domain through expressed importance was counted, with the higher the count, the
higher the expressed importance.
On the basis of expressed importance, domains judged to be important in the included studies were
‘environmental context and resources’ (19 studies148,152,154,155,158,160,161,166,170,179,185–187,189,191,194,199,201,207),
‘knowledge’ (19 studies152,158–161,165,167–169,173–175,181,190,191,193,195,200,205), ‘memory, attention and decision
processes’ (11 studies156,166,170,179–182,187,189,193,201), ‘social influences’ (nine studies148,154,165,167,168,170,172,174,191),
‘beliefs about consequences’ (six studies158,165,183,186,189,204) and ‘emotions’ (four studies167,191,193,204). This list
corresponds well with the list of six domains of high importance identified by the importance criteria
frequency and elaboration. However, the domain ‘knowledge’ came out more strongly in expressed
importance than it did in frequency or elaboration. No other domains were identified through
expressed importance.
In summary, there was good convergence between all three criteria for identifying the importance of
six theoretical domains, suggesting that these domains are likely to be key mediators of screening
attendance behaviour.
TABLE 9 Frequency and elaboration within each of the 14 TDF domains, presented in rank order from most
important to least important
TDF domain
Frequency Level of elaboration
Number of studies
identified Number of themes
Number of
subthemes
1. Environmental context and resources 50 10 23
2. Social influences 33 10 8
3. Knowledge 33 5 9
4. Memory, attention and decision processes 31 6 9
5. Beliefs about consequences 25 7 8
6. Emotions 22 6 4
7. Social/professional role and identity 10 3 5
8. Goals 11 2 3
9. Beliefs about capabilities 9 1 2
10. Intentions 7 2 0
11. Behavioural regulation 7 2 0
12. Optimism 3 2 0
13. Reinforcement 1 1 0
14. Skills 0 0 0
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Thematic synthesis for domains identified as having high importance
The content themes in the domains that were identified as being potentially important factors influencing
screening attendance are described in further detail in the sections below.
Environmental context and resources
Theme: accessibility to the screening clinic
This was a theme identified in many studies in this review by both people with diabetes and HCPs.
‘Accessibility’ included issues with both transportation (e.g. lack/cost/poor quality) and distance to the DRS
clinic. In one correlational study the author noted that those living ≥ 8 miles from the screening facility
were significantly less likely to attend for screening than those living within an 8-mile radius.147 However,
in another study the authors reported that half of the participants lived very close to the DRS clinic yet
86% still cited distance as a barrier.148 In several studies, the participants felt that having access to DRS
services close to home was favourable and would improve attendance.159,161,169
Theme: time (competing demands)
People with diabetes often cited time constraints as a barrier to attendance. Competing demands on their
time from work commitments, family responsibilities (e.g. childcare) and clashes with other immoveable life
events such as holidays and religious/cultural activities were all cited. For example, one HCP commented
that ‘People go away . . . to the Caribbean, Africa, Asia, Pakistan, India . . . You find out in retrospect
where they’ve been, and because they’re away they’re not going to get their screening done’.149
Theme: financial concerns
Financial concerns, such as the cost of the eye examination/care and the cost or lack of insurance were
prevalent, especially among those with diabetes participating in the US studies. Having private insurance
was reported to be associated with higher attendance rates in two studies.150,151 However, in some cases
people with diabetes were not aware that they were exempted from payment and this lack of awareness
or ‘knowledge of benefits’ resulted in lower attendance rates.152,153 Self-employed people with diabetes
had additional hidden financial costs as they lost income when they took time off work to attend their
screening appointments.154,155
Theme: scheduling appointment issues
Issues with scheduling appointments, including a long wait to receive an appointment and an inability to
get an appointment, were understandably perceived to be barriers to attendance. Three studies, all from
the UK, mentioned that people with diabetes had not received an invitation for screening or had been
given insufficient notice, making it impossible to attend.155–157 In several studies people with diabetes
expressed a preference for appointment flexibility and wanted to be able to choose a time that suited
them. However, in one study older people with diabetes expressed a preference for fixed appointments.24
Centrally allocated appointments were perceived by some HCPs as a barrier as they counteracted their
own attempts to bring patients to the clinic, especially if administrative systems were thought to be
inflexible.158,159 However, when there was no alternative the centralised systems were viewed as beneficial.149
Theme: time (service issues)
Long waiting times on the day of the appointment and lengthy appointments were identified as barriers to
attendance by both people with diabetes and HCPs. Multiple appointments scheduled back to back could
result in people with diabetes ‘waiting around’ all day.160 In one study this was identified as being
especially problematic for people with diabetes, because of lengthy food abstinence.158
Theme: referral issues
Issues with referrals were identified as a substantial problem for some. In one UK study the authors
described how a person with diabetes who normally attends her screening appointments had attempted to
access screening through her general practice but was refused as she was in temporary accommodation
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waiting to be rehoused.158 In some countries there was a lack of referral because of an absence of eye
doctors where patients were registered.161
Theme: specialist diabetes services and staff
The integration of specialist diabetes services or the use of ‘one-stop shops’ was viewed as beneficial in a
number of studies; in one study a person with diabetes reasoned that ‘if the eye appointment was on the
same day as the DM [diabetes mellitus] appointment I would definitely attend’.161 Inflexible or incompatible
administration systems were perceived to cause problems. Furthermore, a practice employing a specialist
nurse was associated with increased attendance in two studies.162,163
Theme: availability of dedicated screening resources
Diabetic retinopathy screening clinics with dedicated resources, such as non-mydriatic cameras, were
reported to improve attendance in one study.164 However, in another study such clinics were reported to
be problematic when the practices did not have appropriate space for the equipment without causing staff
overcrowding and communication problems between the screeners and practice staff.149 Integrating
screening and routine care was perceived by HCPs in one study as being too resource intensive.149
Social influences
Theme: doctor–patient communication
Doctor–patient communication was discussed in many of the studies included in this review. For example,
a recommendation by a HCP to attend screening was voiced as an enabler to attend in some studies165,166
and the absence of a recommendation from a HCP was viewed as a barrier in others.161,167 HCPs in one
study suggested that the best time to advise a person with diabetes to attend screening is at the time of
their diagnosis.152 However, elsewhere it was noted that when a person with diabetes is first diagnosed
they are likely to have other more pressing diabetes-related complications that the HCP needs to address
and providing recommendations or prompts to attend screening can often go unnoticed.168 Some people
with diabetes reported a general lack of information provision, especially at the point of diagnosis.169
Another barrier identified within the theme of doctor–patient communication was language and/or
communication style, in particular for people with diabetes whose first language was not the same as that
of the HCP. In some studies people with diabetes reported language difficulties as the primary reason for
not attending at screening appointments (e.g. Sachdeva et al.156). In one study a person with diabetes
complained that she ‘didn’t understand her physician and was too intimidated to ask him to slow down
when conversing’ and therefore was unaware of the recommendation to change her behaviour.154
Although language difficulties were viewed as a barrier by both people with diabetes and HCPs there was
no consensus as to their significance.159 In some studies, participants felt that systems were in place to
overcome this barrier, such as accompanying family members and the provision of interpreters.149,159,169
However, in other studies HCPs pointed out that in multicultural societies many different languages are
spoken within any given practice area149 and that accompanying relatives might not have the language
skills needed to interpret correctly.159
Theme: trust in doctors
Advice and recommendations from doctors were perceived to be an enabler in several studies.150,161,165–167,
169,170,188 Conversely, in one study it was reported that a small number of people with diabetes did not trust
doctors170 and in another study it was found that low confidence in doctors was more common among
non-attenders than attenders.167 At the system level, perceived discrimination in the health-care system
was associated with longer time periods between screening visits.171 Conversely, one study reported that a
culturally sensitive community-based clinic overcame such barriers in a small sample of Aboriginal people
with diabetes in Canada.154
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Theme: presence or absence of support from family members
Family support, both on a practical level (e.g. providing transport to the clinic) and on an emotional
level (e.g. providing encouragement and offering gentle reminders), was viewed as an enabler of
attendance.149,168–170,188 Furthermore, an absence of such support was perceived to be a barrier.157 Family
support appeared to be especially important to people with diabetes from communities that traditionally rely
on their family members to look after them169 or when the person with diabetes had a physical disability.168
Theme: encouragement/support from local community groups/networks plus media
attention and coverage
Encouragingly, community-based programmes were seen to foster trust and support among attendees
in one study.154 Not having to rely exclusively on doctors to encourage, support and remind people
with diabetes to attend screening was seen as an enabler when local community groups and support
networks were also available sources of support and information.169,172 Furthermore, local media
(television, newspapers, radio channels) were highlighted as potential forums to raise awareness and
promote attendance at screening169,172 and it was suggested by one HCP that such a lack of media
attention could be a contributing factor to low attendance rates.158
Theme: stigma
Some people with diabetes spoke of social stigma being attached to a diabetes diagnosis169,188 and in one
study women talked about feeling ashamed and not wanting people to know about their health issues.169
HCPs also spoke about the difficulties of being confronted by a patient’s perceptions of stigma.173
Knowledge
Theme: (lack of) awareness of illness
Several studies reasoned that a patient’s lack of knowledge about diabetes, diabetic retinopathy and the
link between the two was a barrier to attendance. People with diabetes reported that an understanding of
how diabetes can affect vision was an essential and motivating factor associated with attendance:
If I had realised the possibility that it would suddenly go [sight], that I wouldn’t realise that it was
coming on, I think I would have taken more care. It’s all great in hindsight but if I knew then what I
know now, then this problem wouldn’t have happened.174
In several studies HCPs argued that people with diabetes do not always have a clear idea about the link
between diabetes and diabetic retinopathy. However, there was also some suggestion that HCPs were not
always happy to make the link clear and were careful not to alarm their patients: ‘I would never say to
someone that there is a possibility that you could go blind from diabetes’.174
Theme: (lack of) awareness of screening and confusion between screening and routine
eye tests
Similarly, but unsurprisingly, a lack of awareness of the need to screen (including the recommended
frequency and an understanding of the importance of attendance) was seen as a barrier to attendance
and awareness was seen as an enabler. Furthermore, several study authors asserted that some people with
diabetes were not aware of the difference between DRS and routine eye examinations, resulting in some
patients believing that they had attended screening when they had not.155–159,169,175
Theme: education and training
This theme highlighted the association between attendance at education or training classes and
attendance at screening. Some studies suggested that receiving diabetes self-management or blindness
prevention classes significantly increased the likelihood of attendance at screening,151,176,177 whereas people
with diabetes who had not received such an education were screened significantly less often.178
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Memory, attention and decision processes
Theme: symptoms
The absence of symptoms often resulted in patients making the decision not to attend for screening.
This barrier was evident across different countries and screening contexts (e.g. UK, USA, Africa, Asia and
Australia). In one study > 50% of people with diabetes who had never had a dilated eye examination
indicated that it was because they did not have problems with their eyes179 and in another study this
barrier appeared to be especially relevant for men.161 It was reported by both people with diabetes and
HCPs that a small number of people were not motivated to attend screening until they had experienced
symptoms.149,155,159,168 However, even when symptoms were experienced some people with diabetes did
not always link these to diabetic retinopathy but rather to an inevitable consequence of getting older.168
Theme: competing health problems
Many people with diabetes experience competing health problems that at times can overshadow any
concern that they might have about their eyes. For some people with diabetes, missing a screening
appointment might simply be the result of a temporary illness or health problem156–158 but for others it
might be as a consequence of comorbidities24,147,169,175,180 or because of the burden of diabetes and
its treatments.160,181
Theme: forgetting
For some people with diabetes, the failure to attend screening was attributed to forgetting. This theme
included forgetting to make an appointment,24 forgetting to attend157,159,160,180,183,190 and forgetting whether
or not they had previously attended for screening.159 Several studies alluded to HCPs’ attempts to prompt
or remind people with diabetes in advance of their upcoming appointment149,159 and some reported that
reminders prompted patients to maintain regular attendance.172
Theme: patients’ perception that they have been checked elsewhere
Three studies stressed that people with diabetes did not always attend their screening appointments
as they believed that they had been or were going to be checked elsewhere. In one study people
with diabetes indicated that they had not received a dilated eye examination because they had been
transferring their eye care to another specialist;180 in two other studies some of the people with diabetes
indicated that they had not had their eyes examined by the ophthalmologist or optometrist in the previous
year as their eyes had been examined by a family physician or optician.158,182
Beliefs about consequences
Theme: short-term effects of screening
Some people with diabetes reported that screening has negative short-term effects that can be off-putting
and in some cases a barrier to attendance. For example, some studies reported that people with diabetes
dislike mydriatic eye drops (given to temporarily dilate the pupils) so much that they do not attend.165,170,182–184
These drops were often described as uncomfortable or in some cases painful.158,168,185 In one case it was
reported that a woman had developed a phobia of these eye drops.157
Mydriatic drops were perceived as being negative not only because of the discomfort they cause but also
because of the inconvenience of not being able to see well enough because of the temporary effects that
they have on vision. This effect was described as inconvenient not only because people with diabetes were
prohibited from driving until the effects of the drops had worn off but also because the effects on vision
can make it difficult to navigate public transport.158,165 Furthermore, it was evident that some people with
diabetes believed that the screening procedure could have long-term negative effects on vision, as a
consequence of either the drops or the retinal photographs.156,158,169,186
BARRIERS TO AND ENABLERS OF SCREENING ATTENDANCE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
Theme: perceived necessity of screening
People with diabetes do not always perceive screening to be necessary. In many studies both patients and
HCPs reported that people with diabetes do not attend for screening as they believe that there is ‘no need’
or that it is ‘unnecessary’.158,166,175,187,192 Specific reasons given for holding such a belief included ‘I was told
that my eyes are fine at my last screening’,24,159,170 ‘my diabetes is under control’161,168,181 and ‘screening is
not useful at my age’.167 However, other people with diabetes reported that screening was necessary as it
provided important information on the health status of their eyes. Some people reported that believing
that screening will identify problems early was a motivating factor for them158,170,183,185,188 and others
reported that they were motivated to attend as screening can provide reassurance that all is well.155,170,189
In two studies people with diabetes explained that they attended screening as family members had
experienced problems with diabetes or retinopathy in the past and this salience was a motivating factor
to attend.158,183
Emotions
Theme: fear or anxiety
For some people with diabetes, the fear of losing their vision acted as a strong incentive to attend screening
(e.g. Applebee,159 Hartnett et al.160 and Dervan et al.165). However, fear of a diabetic retinopathy diagnosis
was perceived as a barrier to attendance for others (e.g. Lewis et al.,174 Pasagian-Macaulay et al.185 and
Njambi190). People with diabetes also expressed fear or anxiety about the screening procedure157,188,204 and
some feared a medical intervention if they were confronted with a diagnosis.148,191 Interestingly, one study
reported that non-adherent people expressed less concern about losing their vision than adherent people.192
Theme: defensive responses
In a small number of studies defensive responses were noted. In one study the authors explained that,
despite the fact that the young adults who participated in their study wanted to attend screening, they
actively engaged in strategies that prevented them from doing so.189 In other studies people with diabetes
would offer no explanation for their refusal to attend.157,161,181 One HCP reported that ‘[the patient] is
refusing to even discuss his condition, so all you can do is keep sending invites’.157
Theme: emotional burden of diabetes
There was a sense that for some people with diabetes there was an emotional burden from having
diabetes. Attending screening appointments sometimes reminded patients that they had not been able to
control their diabetes. This could sometimes exacerbate negative emotions including a sense of failure,
guilt, fear and anger.159,160,174
Domains identified as being less important
The content themes in the domains that were not identified as being factors of high importance in
influencing screening attendance are described in further detail in the sections below.
Social/professional role and identity
Theme: illness identity
Some people with diabetes communicated that they did not identify with having diabetes. Both people
with diabetes and HCPs reasoned that some patients might be in denial and had not yet accepted that
they have been diagnosed with diabetes.157,158,180,193 Other people with diabetes felt uncomfortable with
identifying as a person with diabetes. One young person expressed how they found it difficult to attend
diabetes-related groups as the other patients were so much older than they were and they did not feel
that they fitted in.188 In another study a person explained that they just wanted to be treated as normal:
‘I can’t help it. I don’t like being diabetic . . . I am as normal as anybody else; I can do what anybody else
can do’.174
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Beliefs about capabilities
Theme: physical capability to attend
Both people with diabetes and HCPs suggested that some people did not have the physical capability to
attend screening because of a physical disability.167,194,195 Some had limited personal mobility because of
poor overall health or were housebound.157,180 Additionally, if a person required physical assistance to
attend but none was available this was also noted as being a barrier.147,148,161,196 In one study it was
reported that requiring an accompanying person was more likely for non-attenders than for attenders.167
Goals
Theme: goal priorities
Some regular attenders prioritised the health of their eyes and it was this prioritisation that motivated
them to attend screening.158,183,190 One person explained: ‘I want my vision because I want to see my
grandchildren’.170 Others attended screening from a desire to stay in control of their health.170 However,
for others eye health was not always a priority.166,192,194 This lack of priority was linked to the burden of
having diabetes and the expectation of attending multiple appointments.159,169 One HCP was quoted as
saying, ‘Having diabetes is very hard work and the patient has to have a lot of incentives to actively comply
with everything that is expected of them’.159
Intentions
Themes: do not want to go or nothing would stop me
In a number of studies people with diabetes declared that the reason that they did not attend screening
was because they just did not want to go or had no interest in attending.167,183–185 Often there was no
explanation for why they did not want to attend. However, in one case a patient was quoted as saying,
‘one endocrinologist I went to just said “do this, do that” and I did not want to. I did not understand why
I needed to’.181 For others, little would prevent them from attending: ‘I would go no matter what, except if
insurance doesn’t cover it, but the Lord would provide a way’.170
Behavioural regulation
Theme: (lack of) engagement with self-management
In one study the authors reported that for every 10-point increase in self-rated diabetes management the
odds of receiving an eye examination increased by 16%.197 Both people with diabetes and HCPs noted
that some people might not attend screening as they were disengaged with their diabetes care.157
One HCP argued that attendance relied on people with diabetes being proactive as appointment times
were not always convenient and patients might need to call up the screening service and change their
appointment.158 People setting their own prompts was seen by HCPs as a positive behaviour.159,172
Optimism, reinforcement and skills
The domains ‘optimism’ and ‘reinforcement’ were sparsely populated in terms of thematic content. See
Report Supplementary Material 2 (Themes/subthemes within each of the 14 domains from the Theoretical
Domains Frameworks) for themes, frequencies and accompanying quotes. None of the data extracted from
the studies were coded into the domain ‘skills’ at step 2.
UK studies
Twelve24,149,155–159,162,169,174,183,189 of the 65 studies (18%) were carried out in the UK, three162,183,189 of which
were reported in abstract form only. Most of the key issues (themes) identified from studies in other
countries were also identified in at least one study carried out in the UK. Table 10 lists the themes/
subthemes that were identified in (1) UK studies only, (2) UK studies and studies from other countries and
(3) non-UK studies only.
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TABLE 10 Themes/subthemes identified in UK studies or in studies other than the UK
Themes or subthemes
identified in UK studies only
Themes or subthemes identified in UK
and other country studies
Themes or subthemes not identified in
UK studies
Environmental context and resources
l Receiving insufficient
notice
l Centralised systems
l Seriousness (perception
of hospital)
l Inaccurate register
l Transportation
l Distance to clinic
l Improving accessibility
l Work (career)
l Generally busy (competing demands)
l Family (e.g. childcare)
l Clashes with specific occasions
l Cost of eye care/examinations
l Loss of earnings (self-employed)
l Long waiting time to receive
an appointment
l (In)flexibility/choice of times/dates
l Length of waiting time (e.g. delays)
l Lengthy appointments
l Lack of referral (including no access
to doctor)
l Integration of services
l Specialist staff
l Availability of dedicated resources
l Screening is perceived as too resource
intensive
l Lack of insurance/cost of insurance
l Consequences of private insurance
l Inability to get an appointment
l Feeling (un)comfortable (in hospital)
Social influences
l Communication within
or between services
l Lack of media attention
l Absence or presence of a HCP
recommendation to attend screening
l Language
l General lack of information provision
l Instrumental/pragmatic support
(from family)
l Social/emotional support (from family)
l Stigma
l Support from local community groups
l Using media to promote attendance
l Unable to contact patients
(doctor–patient communication)
l Trust in doctors
l Cultural/social compatibility –
patient/HCP
l Obligation to attend
l Having a screening team leader
Memory, attention and decision processes
l Feeling unwell
(competing health issues)
l Forgetting to make a
screening appointment
l Lack of attention given
to screening
l Absence of symptoms
l Presence of symptoms
l Comorbidities
l Forgetting to attend a screening
appointment
l HCP prompts and cues for patients
l Have been checked elsewhere
l Knowing it is a routine test
l Burden of disease and its treatment
l Symptoms attributed to old age
Knowledge
l Biofeedback as an
educational resource
l (Lack of) awareness of diabetic
retinopathy
l (Lack of) awareness of the link
between diabetes and retinopathy
l (Lack of) awareness of importance
of screening
l General lack of awareness
l General lack of awareness
(of screening)
l Confusion between screening and
routine eye tests
l Misunderstanding of treatment
options for diabetic retinopathy
l (Lack of) awareness/knowledge
of diabetes
l (Lack of) awareness of recommended
frequency of screening
l General self-management education/
training
l (Lack of) education on importance
of screening
continued
DOI: 10.3310/hta22290 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 29
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Lawrenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
The themes and domains most frequently identified within the UK studies were (1) scheduling
appointment issues (environmental context and resources), identified in eight24,149,155–159,169 of the 12 UK
studies (67%), (2) accessibility of the screening clinic (environmental context and resources), identified in
eight149,156–159,162,169,183 of the 12 UK studies (67%), (3) time – competing demands (environmental context
and resources), identified in eight149,155–158,174,183,189 of the UK studies (67%), (4) confusion between
screening and routine eye tests (knowledge), identified in six155–159,169 UK studies (50%), (5) symptoms
(memory, attention and decision processes), identified in six149,155,158,159,169,189 UK studies (50%),
(6) competing health problems (memory, attention and decision processes), identified in six24,149,156–158,169
UK studies (50%), (7) awareness of illness (knowledge), identified in five155,158,159,169,174 UK studies (42%),
(8) doctor–patient communication (social influence), identified in five24,149,156,159,169 UK studies (42%),
(9) fear and anxiety (emotions), identified in five157–159,174,183 UK studies (42%) and (10) forgetting
(memory, attention and decision processes), identified in five24,149,157,159,183 UK studies (42%).
Patient and health-care professional perspectives
All studies included in this review either reported findings from the patient’s perspective or tested a
hypothesis based on patient data. Only 14 studies (22%) reported barriers and enablers from the perspective
of the HCP. Most of these studies did not distinguish between the two perspectives and integrated the
findings from people with diabetes and HCPs. Only four studies noted any clear differences between the
two perspectives.152,160,169,174 In one study the authors reported that HCPs had cited inadequate patient
education as the major barrier, yet claimed that participating patients largely reported that diabetes
education was adequate and instead felt that financial concerns were their biggest barrier.160 In another
study the author reported that, for the most part, patients’ and HCPs’ perspectives mirrored each other.169
However, they did note that views on whether or not language was a barrier differed. Although people with
diabetes reported to some degree that language was a barrier, most reported that there were systems in
place to overcome these issues. In contrast, HCPs (in this case screeners) reported that language was an
issue that they faced in everyday practice. In a third study, people with diabetes and HCPs agreed that
regular attendance could be inconvenient but suggested that HCPs underestimated the difficulties that
people could face when taking time off work.174 In the fourth study the author explained that HCPs and
TABLE 10 Themes/subthemes identified in UK studies or in studies other than the UK (continued )
Themes or subthemes
identified in UK studies only
Themes or subthemes identified in UK
and other country studies
Themes or subthemes not identified in
UK studies
Beliefs about consequences
l Perception that screening is not
necessary if previous results
were clear
l General perception that screening is
not necessary
l Concerns about harmful effects of
screening procedure
l Discomfort
l Early detection
l Reassurance
l Salience of the consequences
l Inconvenience
l Perception screening not necessary if
diabetes is under control
l Perception screening not necessary in
certain patient groups
l Lack of understanding of the benefits
of DRS
l General doubt about the ability of
conventional health care to change
health status
Emotions
l Fear/anxiety about vision loss
l Fear/anxiety about DRS procedure
l Defensive responses
l Emotional burden of diabetes
in general
l Absence of fear/worry about
vision loss
l Fear/anxiety about treatment
implications
l The need for HCPs to express
compassion
l Depression
l Screening is enjoyable
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people with diabetes face different barriers to annual screening. For the person with diabetes the biggest
barrier was a lack of understanding of the importance of screening and a lack of awareness of insurance
coverage. The HCPs, on the other hand, identified the need for patient education on eye examinations and
suggested that greater assistance was needed with tracking the patient through the system.152
Discussion
The aim of this review was to investigate how QI interventions might work by identifying the theoretical
determinants of DRS attendance. This was achieved by identifying studies reporting primary data on
barriers to and enablers of DRS attendance from the perspective of people with diabetes and associated
HCPs and framing them in terms of theoretical domains from the TDF and CFIR.
Summary of findings
The combined content and framework analysis identified six TDF domains [(1) ‘environmental context
and resources’, (2) ‘social influences’, (3) ‘knowledge’, (4) ‘memory, attention and decision processes’,
(5) ‘beliefs about consequences’ and (6) ‘emotions’] as representing the most important factors potentially
influencing screening attendance. Hence, the hypothesis arising from this review is that interventions
that target these domains are more likely to be effective at increasing screening attendance. This process
also identified three TDF domains that potentially have the least influence on screening: (1) ‘optimism’,
(2) ‘reinforcement’ and (3) ‘skills’. Hence, we propose that interventions targeting these three domains are
less likely to be effective at increasing screening attendance (see Tables 8 and 9).
Inductive analysis within domains generated specific content themes that may help to identify potential
targets for future QI interventions. The content themes were identified at multiple levels, including the
person with diabetes (e.g. confusion between screening and routine eye tests), the HCP (e.g. absence or
presence of a HCP recommendation), the health-care system (e.g. inaccurate register) and the wider
community (e.g. lack of media coverage) (see Table 10). Recoding the themes from the TDF domains into
CFIR constructs did not offer any further insights and, as a consequence, we did not apply the importance
criteria to the CFIR constructs. The large majority of barriers and enablers were identified in the UK and
also in the context of health systems in other countries (see Table 10).
Strengths, limitations and challenges
The combination of deductive coding (informed by theoretical frameworks to guide barrier identification)
and inductive analysis (to allow more granular content themes, unanticipated findings and patient insights
to emerge) is a strength of this review. Furthermore, this relatively novel approach of applying multilevel
theoretical frameworks within the systematic review context acknowledges the potential influence of
organisational and contextual factors on screening attendance. We were able to code all extracted data
from the 65 studies into the TDF domains, thus demonstrating that the TDF framework provided a
comprehensive coverage of barriers and enablers.
Another strength of this review is its inclusiveness. We included published and grey literature, qualitative
and quantitative methodologies, patients’ and HCPs’ perspectives and any context and/or screening model.
We reasoned that limiting the search to UK studies only or to one methodological perspective would risk
overlooking potentially important and relevant findings. Although not all barriers and enablers will be
relevant to all settings, this review gives a comprehensive overview of potential factors that may influence
screening attendance.
The studies in this review predominantly identified barriers and enablers from the perspective of the person
with diabetes rather than from the perspective of the organisation or HCP. Even the data that we had from
the HCPs mostly focused on their views regarding patient barriers. Therefore, the CFIR did not offer additional
insights over and above those obtained from the TDF. The CFIR could potentially contribute an interesting
perspective but this would involve a slight reconceptualisation of the components of the framework.
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For example, it is plausible that, by conceptualising the patient as part of the ‘system’ (rather than the ‘outer
context’) and describing DRS in terms of ‘innovation characteristics’ (see Appendix 7), the CFIR could offer
additional insights over and above those obtained from the TDF. This kind of reconceptualisation would need
further investigation and methodological work, which is outside the scope of this study.
Although there were no major methodological concerns that we believe would have biased the outcomes
of the included studies, it was unfortunate that a number of the studies were poorly or thinly described.
This was problematic as it hampered our ability to differentiate between HCPs’ and patients’ perspectives
or to distinguish between different patient subgroups. Furthermore, the data extracted and analysed in
the present review were the data that were reported, analysed and interpreted by the study authors. It is
possible that our data set may have been biased in that authors may have selectively reported findings on
perceived barriers/enablers that were more prevalent or interesting or that had a better fit with the stated
research question. There may have been additional views on barriers/enablers in the full, original data set
that were not represented in the present findings. A final limitation of this review worth noting is that the
theoretical frameworks used are limited in that they do not specify relationships between domains and
hence the strength of the direct impact of barriers on behaviour is not known.
Implications for research
The findings of this review have important implications for the design of effective interventions to promote
DRS attendance as they can be used to assess the extent to which the active components (BCTs) identified
in existing QI interventions are actually targeting the theoretical domains that are important in determining
attendance. This can be achieved by mapping the BCTs identified in the review reported in Chapter 3
against the theoretical domains identified in the current review using established mapping tools. The
results of the mapping study are reported in Chapter 5.
Implications for practice
The findings from this review can help to inform a set of recommendations on which theoretical domains
to target in interventions (i.e. ‘environmental context and resources’, ‘social influences’, ‘knowledge’,
‘memory, attention and decision processes’, ‘beliefs about consequences’ and ‘emotions’) and which
to avoid (i.e. ‘optimism’, ‘reinforcement’ and ‘skills’), thus enhancing the likely effectiveness of DRS
programmes. Furthermore, within the TDF domains judged to be of high importance, the findings from
the inductive analysis provide more detailed insight into which specific barriers and enablers may be
associated with attendance behaviour. Findings from this level of analysis suggest potential targets for
future QI interventions. Four key recommendations based on the findings from the thematic synthesis are
presented in the following sections.
Reduce inconvenience to people with diabetes
Many of the barriers and enablers identified within the domains of ‘environmental context and resources’
and ‘memory, attention and decision processes’ relate to perceptions of convenience. Difficulties with
transportation, distance to the screening clinic, competing health and time demands, lack of instrumental/
pragmatic support and scheduling appointment issues were all reported to be important factors that may
hinder attendance, whereas attempts to reduce inconvenience by improving accessibility, having flexible
appointments and integrating services were reported to facilitate attendance. Therefore, providing local
screening facilities and ‘one-stop shops’ (integrating screening with other diabetes appointments), offering
flexible appointment systems and childcare facilities and providing transportation may be advantageous.
Increase awareness of the importance of screening
Within the ‘knowledge’ domain both people with diabetes and HCPs reported that a lack of awareness
or understanding of diabetes and diabetic retinopathy and the link between the two was a barrier to
attendance. Similarly, a lack of awareness of the importance of screening and the recommended screening
frequency and a lack of targeted patient education were also reported to be patient barriers, whereas
providing blindness prevention programmes and general diabetes self-management education was reported
to be an enabler. Within the ‘social influences’ domain the perceived absence of a HCP recommendation to
attend screening and/or a lack of information provision from the HCP were also perceived to be patient
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barriers. Using local media and local community networks to improve awareness and promote attendance
was reported as a potential but often untapped strategy.
Increase patients’ sense of comfort and support
Within the ‘emotions’, ‘social influences’ and ‘beliefs about consequences’ domains, some people with
diabetes reported barriers relating to difficulties with communicating with HCPs, a lack of trust in doctors,
a lack of emotional support and negative emotions (e.g. fear, worry). Although there were limited reports
of potential enablers to overcome such barriers, there was some mention that community-based clinics,
social/cultural compatibility between the person with diabetes and the HCP and compassion from the HCP
were enablers that might encourage patients’ feelings of comfort, support and trust.
Improve message content
Within the ‘memory, attention and decision processes’ domain we found that the absence of symptoms
was a common barrier to attendance. Furthermore, within the ‘beliefs about consequences’ domain we
found that some people with diabetes perceived that DRS was not necessary, especially if they felt that
their diabetes was under control, they were not old or their previous test result was clear. Therefore, it
would seem desirable to provide messages that highlight the asymptomatic nature of diabetic retinopathy
and make salient the potential consequences if left unchecked. Likewise, providing messages that highlight
the benefits of early detection, the safety of the procedure and the reassurance that a positive result can
provide would all be desirable as they were identified within the ‘beliefs about consequences’ domain. In
addition, a barrier identified within the ‘knowledge’ domain related to the confusion between DRS and
routine eye tests. Messages that highlight the difference between the two and emphasise the importance
of continuing to attend for DRS despite attendance at other eyes tests could be helpful. Furthermore,
messages emphasising that DRS is a routine part of diabetes care could also be helpful as this belief was
identified as an enabler within the ‘memory, attention and decision processes’ domain. The offer of a
reminder to attend for DRS was also regarded as an enabler addressing this domain.
Recommendations for future research
In this review only 12 studies were conducted in the UK. Additional high-quality studies are therefore
needed from the UK, from the perspective of both HCPs and people with diabetes. Ideally, such additional
research would focus on sampling the subgroups that are potentially at the highest risk of blindness or
that are least likely to attend for screening, as the pattern of important domains may differ between these
subgroups depending on specific patient characteristics (e.g. location, age or socioeconomic status).
Future research could endeavour to identify which theoretical domains are most important for the subgroups
that have been identified as being most at risk and/or least likely to attend for screening. For example, only
two studies identified in this review explored factors that affect young adults.188,189 This patient group is not
only under-researched but also at high risk of vision loss/blindness from diabetic retinopathy.
It is possible that the less frequently identified domains (e.g. ‘skills’, ‘intentions’, ‘optimism’) may simply not
be as commonly assessed in quantitative work or are less likely to be spontaneously mentioned in response
to open questions in interviews. Although such an occurrence may itself be an indication of low importance,
it may be interesting to carry out a comparison of the results of this study against the results of more
comprehensive assessments that identify not only omissions of these factors but provide evidence which shows
that they have been assessed empirically and have been found to have no association with DRS attendance.
Concluding remarks
This review employed a systematic, theory-informed and replicable approach to identify barriers and
enablers associated with DRS attendance. Six TDF domains were identified as having high importance
and therefore are the theoretical domains most likely to be key mediators of DRS attendance behaviour.
Thematic synthesis identified key content themes that offer further insights into which specific issues need
to be addressed. Future research is needed to identify which domains are most important for subgroups of
people with diabetes who have been identified as being most at risk.
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Chapter 5 Do intervention components target
theoretical determinants of diabetic retinopathy
screening attendance? Mapping behaviour change
techniques to barriers and enablers
Background
The benefits of designing interventions based on theory are widely recognised.212 Theory provides an
explanatory, integrated summary of the proposed determinants of behaviour and the mechanisms involved
in behaviour change.213 A wide range of BCTs can be applied to change the various theoretical determinants
of behaviours.214 However, different BCTs are likely to be more, or less, effective at addressing different
types of determinants. For example, the technique ‘behavioural rehearsal/practice’ is likely to be effective
when the barrier is a lack of skill to perform the behaviour. This represents high theoretical coherence
(i.e. match) between the intervention component and the theoretical determinant it targets. However,
the same technique is unlikely to be effective where the determinant is a lack of motivation to perform the
behaviour,214 due to low theoretical coherence (i.e. mismatch) between the intervention component and
the determinant it targets. It has been argued that interventions are more likely to be effective if they include
components that specifically target the important theoretical determinants of behaviour and behaviour
change.214,215 The research reported in this chapter addresses the question, ‘Do existing interventions to
improve DRS attendance address the known barriers to attendance?’
The components of the existing interventions to increase DRS attendance that were included in the first
systematic review (see Chapter 3) were identified and characterised using a validated taxonomy: the
BCTTv1.36 The subgroup analyses reported in Chapter 3 identified BCTs that were associated with higher
screening attendance. The theoretical determinants (e.g. barriers/enablers) of DRS attendance were
identified in the second systematic review, reported in Chapter 4. The TDF of behaviour37,39 was used to
classify reported barriers to and enablers of screening attendance from the perspectives of people with
diabetes and HCPs. Important barriers to and enablers of screening attendance were identified (e.g.
‘emotions’ and ‘beliefs about consequences’ of screening) (see Chapter 4). In this chapter we explore the
level of theoretical coherence between techniques in DRS interventions and theoretical domains in the
barriers literature. We use the term ‘theoretical coherence’ to denote the extent to which a BCT included
in existing DRS interventions targets an important theoretical domain. For example, high coherence would
be demonstrated if the BCT ‘provide information on health consequences of the behaviour’ was identified
as an intervention component in interventions included in the first systematic review and ‘knowledge’ was
identified as an important domain in the second review. In this instance, interventions including this BCT
would address the relevant theoretical determinant of the target behaviour. Conversely, low coherence
would be displayed if the first systematic review identified the BCT ‘material reward’ as an intervention
component, yet the second systematic review identified the theoretical domain ‘reinforcement’ to be of
low importance to screening attendance.
This study therefore aimed to integrate the findings from the two reviews (see Chapters 3 and 4) to
identify the extent to which frequently used BCTs address important barriers to screening attendance. To
explore this in a systematic way, we used a structured tool to map BCTs against domains from the TDF.
This tool was developed by integrating two published instruments that map BCTs against domains in the
TDF, on the basis of expert consensus data,214,216 and is presented in Report Supplementary Material 3
(see Behaviour change techniques theoretically coherent with important domains). Both matrices propose
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numerous theoretically coherent BCT and domain pairings, which achieved expert agreement that the
BCTs are likely to be effective at addressing a given domain [e.g. the BCT ‘social support (practical)’ is
theoretically coherent with the domain ‘social influences’].
This kind of tool is frequently used to design interventions by identifying BCTs to target important barriers
to health-related behaviour change. For instance, Cadogan et al.217 conducted semistructured interviews
based on the TDF with community pharmacists and GPs to examine barriers to/enablers of prescribing and
dispensing of appropriate polypharmacy to older patients. Eight important domains were identified and the
mapping tool216 was used to select four BCTs for inclusion in an intervention for GPs or pharmacists (e.g.
the use of the technique ‘prompts and cues’ to address the important barrier domain ‘memory, attention,
decision processes’).
However, although BCT taxonomies and the TDF have both been recently applied in secondary analyses
as part of systematic reviews,134,218 to our knowledge no systematic review has reported the use of a
mapping tool to identify the theoretical coherence in the manner described above. Evidence of coherence
can facilitate interpretation of observed intervention effectiveness (or ineffectiveness). For example, if a
BCT–domain pair has high coherence and coherence is associated with effectiveness, this can help to
explain how interventions work to achieve target outcomes and why some interventions are more effective
than others. Similarly, if coherence is associated with effectiveness, then BCT–domain pairs with low
coherence would arguably be best avoided when designing DRS attendance interventions. Furthermore,
such mapping between BCT and barriers or enablers may highlight potential ‘missed opportunities’ for
intervention design, in the form of BCTs that are likely to be effective in targeting a given barrier or
enabler, but which are not currently used in existing interventions. However, if coherence is not associated
with effectiveness, this would suggest that there are limitations in the validity of the mapping tool
approach. The objective of this research was thus to explain the findings from review 1 (see Chapter 3)
and to propose possible enhancements to DRS attendance interventions.
Aims
This study aimed to integrate the findings from Chapters 3 and 4 by applying a mapping tool to assess the
theoretical coherence of existing DRS interventions, that is, the extent to which BCTs used in interventions
(see Chapter 3) target the identified important theoretical determinants of screening attendance (see
Chapter 4).
The specific research questions were:
1. What is the level of theoretical coherence of the intervention literature relating to DRS, that is, to what
extent do BCTs frequently used in existing interventions to increase DRS attendance target the
important barriers to attendance?
2. To what extent is observed theoretical coherence associated with intervention effectiveness, that is,
higher screening attendance?
3. Are there any potential ‘missed opportunities’ for intervention design in terms of BCTs that are not
frequently used in existing interventions but which are theoretically coherent with important barriers?
Methods
Sample
Data from the first systematic review (see Chapter 3) relevant to the work presented in this chapter included
(1) the frequency with which each BCT was identified as present in intervention arms targeting people with
diabetes and/or HCPs and, for those BCTs that were frequently identified (i.e. in ≥ 10 intervention arms),
(2) the observed association between the BCT and intervention effectiveness (i.e. higher DRS rates in terms
of RD, 95% CI). Findings from the review of perceived barriers to and enablers of screening attendance
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(see Chapter 4) relevant to the work presented in this chapter included the domains identified as important
to screening attendance. Important domains (ranked in the top six) were ‘environmental context and
resources’, ‘social influences’, ‘knowledge’, ‘memory, attention, and decision processes’, ‘beliefs about
consequences’ and ‘emotions’ (see Table 9).
Materials: mapping tool
A mapping tool was developed by integrating two previously published tools214,216 (see Report
Supplementary Material 3). The integrated tool was used to identify the BCTs that are theoretically
coherent with important domains (i.e. the domains that, arguably, should be used; presented in Report
Supplementary Material 3, Behaviour change techniques theoretically coherent with important domains).
The tool was also applied to the DRS literature to identify the domains that have been targeted by
frequently used BCTs (i.e. the barriers that have been targeted in interventions; presented in Report
Supplementary Material 3, Domains targeted by frequently used behaviour change techniques).
Procedure and analysis
Exploration of theoretical coherence between BCTs identified in the first review (see Chapter 3) and TDF
domains identified in the second review (see Chapter 4) was conducted through two, bidirectional
mapping processes, structured around the three research questions.
Research question 1: theoretical coherence of published diabetic retinopathy
screening interventions
Frequently used BCTs were defined as those identified in a minimum of 10 patient and/or HCP intervention
arms (as in Chapter 3). The integrated tool was then used to identify which domains, according to expert
consensus, the frequently used BCT would be potentially relevant to and effective at addressing. A BCT
could be paired with more than one domain. Each pairing was classified as having high or low theoretical
coherence. A pair was deemed to have high coherence if the frequently used BCT targeted an important
domain (from Chapter 4). BCTs paired with more than one domain in the integrated mapping tool were
classified as having high coherence if at least one domain was important, regardless of the importance
classification of the remaining paired domains. Conversely, a BCT was deemed to have low coherence if it
targeted only (i.e. was paired with only) domains of lower importance.
Research question 2: association between theoretical coherence and
intervention effectiveness
Effect estimates for frequently used BCTs were obtained from the subgroup analyses reported in Chapter 3
(see Figures 12 and 13). The relationship between BCT effectiveness and coherence was explored by
comparing the numbers of reliably effective and ineffective BCTs that had high or low theoretical coherence.
Research question 3: ‘missed opportunities’ for intervention design
For the second mapping process, the integrated mapping tool was used to identify the BCTs paired with
the six most important domains. ‘Missed opportunity’ was noted if the recommended BCT paired with the
important domain was infrequently identified in published interventions (i.e. ≤ 10 patient and/or HCP
intervention arms). Conversely, ‘opportunity seized’ was noted if the recommended BCT was frequently
identified (i.e. ≥ 10 patient and/or HCP intervention arms).
Results
Interventions included a median of four BCTs targeting people with diabetes (range 0–16) and three
targeting HCPs (range 0–14) (see Figures 6 and 7). Ten BCTs were frequently identified in at least
10 interventions targeting people with diabetes and seven were frequently identified in at least
10 interventions targeting HCPs (Table 11 and see Figures 12 and 13).
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TABLE 11 Theoretical coherence of frequently used BCTs in existing interventions and important theoretical
domains according to expert consensus
BCT
Intervention
arms, n RD (95% CI) I2
Linked TDF domains
according to integrated
tool (maximum n= 14)
Domain
importance
rankinga
Coherence
between
BCT and
domain
BCTs targeting people with diabetes
Goal-setting
(outcome)
14 0.26
(0.16 to 0.36)
93 Goals 8
Skills 14 Low
Behavioural regulation 11
Feedback on
outcomes of
behaviour
(including
biofeedback)
15 0.22
(0.15 to 0.29)
94 Beliefs about capabilities 9
Beliefs about consequencesb 5 High
Knowledgeb 3
Credible source 10 0.22
(0.06 to 0.38)
95 Beliefs about consequencesb 5
Social influencesb 2 High
Prompts and cues 25 0.11
(0.07 to 0.14)
92 Memory, attention, decision
makingb
4 High
Behavioural regulation 11
Environmental context and
resourcesb
1
Social support
(unspecified)
14 0.19
(0.09 to 0.28)
93 Social influencesb 2
Social professional role/
identity
7 High
Beliefs about capabilities 9
Goals 8
Problem-solving 10 0.17
(0.08 to 0.27)
89 Skills 14
Beliefs about capabilities 9 Low
Goals 8
Restructuring the
social environment
17 0.17
(0.10 to 0.24)
85 Environmental context and
resourcesb
1
Social influencesb 2 High
Instruction on how
to perform the
behaviour
35 0.13
(0.11 to 0.15)
94 Knowledgeb 3
Skills 14 High
Social support
(practical)
20 0.14
(0.09 to 0.20)
90 Social influencesb 2 High
Social/professional role and
identity
7
Beliefs about capabilities 9
Goals 8
Information
about health
consequences
19 0.12
(0.07 to 0.16)
92 Knowledgeb 3 High
Beliefs about consequencesb 5
Goals 9
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Research question 1: theoretical coherence of existing diabetic retinopathy
screening interventions
Overall, high levels of theoretical coherence between frequently used BCTs in existing interventions and
important theoretical domains were observed. The majority (80%) of frequently used BCTs in interventions
targeting people with diabetes and all (100%) frequently used BCTs in HCP interventions were paired with
at least one important domain (from Chapter 4). Only two BCTs in interventions targeting people with
diabetes were paired exclusively with domains of lesser importance and were thus deemed to have low
theoretical coherence: ‘goal-setting (outcome)’ and ‘problem-solving’ (see Table 11).
Research question 2: association between theoretical coherence and
intervention effectiveness
The subgroup analyses reported in Chapter 3 (see Figures 12 and 13) identified that all BCTs frequently
used in patient and/or HCP interventions were associated with higher DRS attendance (see Table 11).
Higher effect estimates were observed for the BCTs ‘goal-setting (outcome)’ and ‘credible source’ in
interventions targeting people with diabetes and for the BCTs ‘restructuring the social environment’ and
TABLE 11 Theoretical coherence of frequently used BCTs in existing interventions and important theoretical
domains according to expert consensus (continued )
BCT
Intervention
arms, n RD (95% CI) I2
Linked TDF domains
according to integrated
tool (maximum n= 14)
Domain
importance
rankinga
Coherence
between
BCT and
domain
BCTs targeting HCPs
Restructuring the
social environment
23 0.19
(0.12 to 0.26)
91 Environmental context and
resourcesb
1
Social influencesb 2 High
Credible source 13 0.16
(0.08 to 0.24)
95 Beliefs about consequencesb 5
Social influencesb 2 High
Adding objects to
the environment
15 0.14
(0.07 to 0.20)
88 Environmental context and
resourcesb
1 High
Social support
(practical)
10 0.13
(0.03 to 0.22)
87 Social influencesb 2 High
Social/professional role and
identity
7
Beliefs about capabilities 9
Goals 8
Instruction on how
to perform the
behaviour
30 0.13
(0.08 to 0.17)
93 Knowledgeb 3
Skills 14 High
Prompts and cues 15 0.12
(0.06 to 0.17)
85 Memory, attention, decision
makingb
4 High
Behavioural regulation 11
Environmental context and
resourcesb
1
Feedback on
outcomes of
behaviour
(including
biofeedback)
17 0.11
(0.07 to 0.16)
81 Beliefs about capabilities 9 High
Beliefs about consequencesb 5
Knowledgeb 3
a Domain importance ranking based on domain frequency and elaboration (see Chapter 4).
b TDF domains classified as having high importance (see Table 9).
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‘credible source’ in interventions targeting HCPs (see Figures 12 and 13). However, with the exception of
‘goal-setting (outcome)’ (p = 0.001), differences in effect estimates between BCTs were not statistically
significant (see Table 5). All frequently used BCTs were associated with effectiveness, regardless of whether
they had high or low theoretical coherence. However, the majority (n = 15/17) of statistically significant
BCTs had high theoretical coherence according to the integrated mapping tool.
Research question 3: ‘missed opportunities’ for intervention design
Table 12 presents the frequency with which BCTs paired with important TDF domains were identified in
existing DRS interventions. Overall, the BCTs that paired with the six most important domains have not
been used frequently in existing interventions targeting DRS attendance. This finding indicates numerous
missed opportunities for intervention design. Opportunity seized was highest for the domains ‘memory,
attention and decision processes’ (50% of the theoretically coherent BCTs were frequently used in
interventions) and ‘knowledge’ (43% of the theoretically coherent BCTs were frequently used). The most
missed opportunities were for the domain ‘emotions’ (no BCTs paired with this domain were frequently
used in existing DRS interventions (range 0–3 intervention arms) (see Table 11).
TABLE 12 Opportunities for intervention design: the frequency with which BCTs that are theoretically coherent
with important theoretical domains are used in existing DRS interventions
BCTs paired with domain as per the merged tool
BCT frequency,
n studies
Mapping opportunity missed vs.
opportunity seized for intervention design
Environmental context and resources
Restructuring the physical environment 4 Missed
Discriminative (learned) cue 0 Missed
Prompts/cues 48 Seized
Restructuring the social environment 47 Seized
Avoidance/changing exposure to cues for the
behaviour
0 Missed
Social influences
Social comparison 11 Seized
Social support (unspecified) 20 Seized
Social support (emotional) 3 Missed
Social support (practical) 34 Seized
Information about others’ approval 1 Missed
Vicarious reinforcement 0 Missed
Restructuring the social environment 47 Seized
Identification of self as a role model 0 Missed
Social reward 1 Missed
Demonstration of the behaviour 6 Missed
Knowledge
Information on health consequences 25 Seized
Biofeedback 36 Seized
Information about antecedents 0 Missed
Feedback on behaviour 20 Seized
Information on social/environmental consequences 4 Missed
Information on emotional consequences 1 Missed
Salience of consequences 4 Missed
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Discussion
This study applied a systematic approach to examine the extent to which components of interventions to
increase DRS attendance target the important theoretical determinants of DRS attendance. This was
achieved by integrating the findings on BCTs identified in existing interventions from the first systematic
review (see Chapter 3) with the important theoretical domains identified from the studies of perceived
barriers to/enablers of DRS attendance from the second review (see Chapter 4). An integrated tool merging
two published BCT and domain mapping tools was applied to explore the level of theoretical coherence
between currently used BCTs and important TDF domains. ‘High coherence’ was defined as the frequent
use of BCTs that target important TDF domains. ‘Low coherence’ was defined as the frequent use of BCTs
that target less important TDF domains. Missed opportunities for intervention design were noted as
infrequent use of BCTs that are paired with, and which are potentially relevant to targeting, important
domains. Findings on levels of coherence were used to address three research questions.
TABLE 12 Opportunities for intervention design: the frequency with which BCTs that are theoretically coherent
with important theoretical domains are used in existing DRS interventions (continued )
BCTs paired with domain as per the merged tool
BCT frequency,
n studies
Mapping opportunity missed vs.
opportunity seized for intervention design
Memory, attention and decision processes
Self-monitoring of behaviour 4 Missed
Self-monitoring of outcome of behaviour 8 Missed
Action-planning 12 Seized
Prompts and cues 35 Seized
Beliefs about consequences
Information about emotional consequences 1 Missed
Salience of consequences 4 Missed
Covert sensitisation 0 Missed
Anticipated regret 0 Missed
Information about social/environmental
consequences
4 Missed
Pros and cons 0 Missed
Vicarious reinforcement 0 Missed
Threat 0 Missed
Comparative imagining of future outcomes 0 Missed
Self-monitoring of behaviour 4 Missed
Self-monitoring of outcome of behaviour 8 Missed
Information on health consequences 25 Seized
Feedback on behaviour 20 Seized
Feedback on outcomes of behaviour 36 Seized
Credible source 30 Seized
Emotions
Reduce negative emotions 0 Missed
Information about emotional consequences 1 Missed
Self-assessment of affective consequences 0 Missed
Social support (emotional) 3 Missed
Conserving mental resources 0 Missed
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Research question 1: theoretical coherence of existing diabetic retinopathy
screening interventions
Overall, there is a high degree of theoretical coherence between the components of existing DRS attendance
interventions and the important theoretical determinants of screening attendance. Nearly all component
BCTs frequently included in existing interventions were paired with at least one of the six most important
theoretical domains representing the key barriers to or enablers of DRS attendance. This suggests that existing
interventions may work as they are targeting important factors influencing whether or not people with
diabetes attend DRS.
Research question 2: association between theoretical coherence and
intervention effectiveness
It was not possible to formally evaluate the association between theoretical coherence and effectiveness as
all frequently used BCTs were associated with improved screening attendance. This suggests that all BCTs
are effective regardless of whether they have high or low theoretical coherence. However, the majority
(88%) of frequently used BCTs with significant effect estimates were classified as having high theoretical
coherence. It is possible that intervention designers more frequently select BCTs with high coherence
because they are aware of theory and/or evidence or because they intuitively select BCTs that are more
likely to address relevant barriers to and enablers of screening attendance.
Implications of mapping frequently used behaviour change techniques against
theoretical domains
Complex interventions to change health-related behaviours often consist of multiple, interacting intervention
components that are poorly specified.219 These interventions are also often developed without an explicit
theoretical rationale for the selection of a particular intervention strategy or intervention component.220 This in
turn renders it difficult to interpret intervention outcomes, identify the specific ‘active ingredients’ contributing
to effectiveness or identify the pathways through which these active ingredients might have their effect.
Identifying areas of high theoretical coherence for BCTs with demonstrated effectiveness can thus shed light
on the mechanisms through which existing interventions might improve DRS attendance. Furthermore, the
present findings may facilitate replication and inform the design of future interventions to increase DRS
attendance or the enhancement of existing interventions. To maximise likely effectiveness, interventions may
benefit from the inclusion of BCTs that are presently identified as being highly coherent with the important
theoretical determinants of screening attendance.
The present findings may also inform intervention design in terms of how BCTs are operationalised and
delivered. According to the integrated tool, the majority of BCTs with high theoretical coherence were
paired with multiple domains, of which only one was typically classified as important. These BCTs were
effective, despite also targeting theoretical domains that were less important to DRS attendance. It may be
that these BCTs were effective because their specific content targeted the more important domain, rather
than the less important domains. For example, the BCT ‘feedback on outcomes of behaviour’ maps onto
both the domain ‘beliefs about consequences’ and the domain ‘beliefs about capabilities’. The BCT may
have been associated with higher screening attendance because it contained information related to the
consequences of screening attendance (domain ‘beliefs about consequences’) rather than providing
motivational feedback aiming to boost self-efficacy (domain ‘beliefs about capabilities’), that is, the BCT
may have targeted the important domain, ‘beliefs about consequences’. Indeed, examples of instances in
which this BCT was coded in the first review suggest that this may have been the case: ‘immediately after
receiving the dilated eye exam, the patient was told the results by the examining ophthalmologist’ (patient
feedback)108 and ‘the reviewers entered their findings into electronic forms within the telemedicine system,
and the system automatically sent the evaluation reports to the clinics via email or fax’ (HCP feedback).116
Such findings may thus point to potential means of designing the delivery of specific BCTs to increase
theoretical coherence and thus potential effectiveness.
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Behaviour change techniques with low theoretical coherence
Two BCTs had low theoretical coherence for patient interventions: ‘problem-solving’ and ‘goal-setting
(outcome)’. We had proposed that the inclusion of BCTs that target the less important domains of screening
attendance may be less effective and dilute the impact of BCTs that do coherently map onto important
theoretical determinants of DRS attendance. However, we found that the BCT ‘goal-setting (outcome)’ was
significantly associated with the greatest effect estimates and also had low theoretical coherence. The
observed low coherence may result from differences between how this BCT was operationalised in existing
interventions included in the first review and how it was investigated in the second review. Goal-setting in
existing interventions was typically related to general diabetes self-management or lifestyle behaviour change,
for example ‘Participants developed a self-management action plan . . . They next selected a behaviour change
goal in the area of smoking, diet, or exercise’ (patient goal-setting)73 and ‘all practices were instructed to target
the same values [glycated haemoglobin, systolic blood pressure, low-density lipoprotein]’ (HCP goal-setting).58
In contrast, the second review focused on understanding the role of the domain ‘goals’ specifically in the
context of DRS attendance. Thus, the difference in focus and content of goal-setting between the data sets
from both reviews may undermine the validity of the mapping process for this technique.
Despite low coherence, it is possible that ‘goal-setting (outcome)’ was effective when directed at people
with diabetes for a number of other reasons. For example, attendance for DRS is only one of numerous,
inter-related behaviours involved in general diabetes self-management. Thus, goal-setting around general
diabetes self-management may have still been highly effective at increasing DRS attendance, despite not
directly targeting it, because of spillover effects resulting from the setting of general self-management
goals for other related behaviours. In addition, our method investigates BCTs in isolation rather than in
combination. Interventions typically contain multiple BCTs. It is possible that goal-setting could interact or
work synergistically with other BCTs, which could enhance its potency.
Research question 3: ‘missed opportunities’ for intervention design
Our second mapping process investigated the extent to which theoretically coherent BCT–domain pairs
have been used in existing interventions to increase DRS attendance. We identified that the inclusion of
BCTs that are potentially relevant to the important domains is limited and variable in existing interventions.
All six important domains had at least one theoretically coherent BCT that was not frequently used in
existing interventions. Such BCTs thus represent potential ‘missed opportunities’ for intervention design.
Addressing these missed opportunities may thus increase intervention effects.
Specifically, all BCTs paired with the domain ‘emotions’ were used not at all, or only very infrequently, in
existing interventions. There is thus a specific priority for the inclusion in future interventions and research
of BCTs that target the emotional determinants of screening attendance. For instance, an important theme
within the ‘emotions’ domain was fear/anxiety about vision loss. For some people with diabetes, the fear
of losing their vision acted as a strong incentive to attend screening (e.g. Applebee,159 Hartnett et al.160
and Dervan et al.165). However, for others, fear of a diabetic retinopathy diagnosis and of the screening
procedure were perceived barriers to attendance.174,185,190 This barrier to screening attendance could
be addressed through the delivery of the BCTs ‘reduce negative emotions’, ‘information on health
consequences of behaviour’ and ‘anticipated regret’, by providing information on treatment options for
diabetic retinopathy. Such information could focus on providing reassurance by emphasising that effective
treatments are available following early detection. The ‘missed opportunities’ identified through this
second mapping process therefore represent a theoretically informed means of identifying BCTs that may
be of greater relevance and effectiveness.
Strengths
The strengths of the current study include the transparent approach to systematically assessing the extent to
which intervention components target theoretical determinants of behaviour. The use of available BCT × TDF
domain mapping tools in a systematic review context represents a methodologically innovative aspect of this
work and provides an example of how these recently developed tools may be further applied in secondary
analyses of existing interventions. This systematic approach also demonstrates how these frameworks may be
applied to identify limitations of, and missed opportunities in, the design of existing interventions,221 and
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thus offers clear implications for future intervention refinement, design and research. In turn, this systematic
approach has clear implications for future intervention design, refinement and research.
Additionally, to our knowledge, this is the first study to provide empirical findings that can be used to
evaluate the validity of the proposed BCT and domain pairings in the mapping tools, which are based on
expert opinion and consensus. Although based on a limited sample size, the frequently used BCTs that
were effective and that map onto key TDF domains provide empirical support for the agreed BCT and
domain pairings. Conversely, frequently used BCTs that were effective but that do not map onto key TDF
domains with high coherence potentially refute the recommendations in the mapping tools. Given the
high proportion of effective BCTs achieving high theoretical coherence, there is a trend towards a
supportive pattern of findings for the proposed pairings in the available tools.
Limitations
An important caveat when interpreting these findings and a limitation to this methodological approach
concerns the validity and applicability of the mapping tools. There are discrepancies across, and limitations
of, the published tools132,216 on which we based the integrated mapping tool. Hence, low observed
coherence may not reflect the ‘true’ level of theoretical coherence and instead may be a product of
limitations regarding the validity of the materials used to identify coherence. For instance, one may query
if the BCT ‘goals’ is conceptually applicable to the domain ‘skills’ or if the BCT ‘feedback on outcomes of
the behaviour’ is conceptually applicable to the domains ‘beliefs about consequences’ and ‘beliefs about
capabilities’ (see Report Supplementary Material 3, Behaviour change techniques theoretically coherent with
important domains). It is also surprising that the BCTs involving ‘feedback’ are not paired with the domain
‘behavioural regulation’, given that feedback is regarded as the archetypal self-regulation strategy.218,222,223
Further research is thus needed to empirically evaluate and refine these mapping tools.
Furthermore, current BCT–domain mapping tools do not distinguish between different contexts,
populations and types of behaviour, whereas theoretical coherence may depend on the nature of the
behaviour and the population being investigated.
Conclusions
The first aim of this study was to assess the theoretical coherence of existing DRS interventions, that is,
the extent to which BCTs used in interventions (see Chapter 3) target the identified important theoretical
determinants of screening attendance (see Chapter 4). We identified high levels of theoretical coherence
between frequently used BCTs in interventions to increase DRS attendance and important barriers to and
enablers of screening attendance. The second aim was to identify whether high theoretical coherence was
associated with intervention effectiveness (i.e. higher screening attendance). Although the large majority
(88%) of frequently used BCTs with significant effect estimates had high theoretical coherence, it was not
possible to formally evaluate the association between theoretical coherence and effectiveness, as all
frequently used BCTs were associated with improved screening attendance. The third aim was to identify
potential ‘missed opportunities’ for intervention design, in terms of infrequently used BCTs that are
theoretically coherent with important barriers. A number of additional BCTs may be relevant to addressing
important theoretical determinants of screening attendance that are not included in existing interventions.
There are particular gaps around the inclusion of intervention components to address the emotional
barriers to and enablers of screening attendance. Inclusion of such components in the design of future
interventions, or the enhancement of existing interventions, may help to further improve DRS attendance
and in turn ensure the timely referral and treatment of patients who test positive for diabetic retinopathy.
There is also a need for further empirical research to evaluate the validity of mapping tools to facilitate the
selection of coherent BCTs for future research and intervention design.
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Chapter 6 Economic model
Introduction
The first objective of the economic analysis was to identify which QI and BCT components of interventions
used to encourage attendance for DRS are most likely to be cost-effective and therefore which BCT or QI
components should be prioritised for further research into interventions that encourage DRS attendance.
The QI and BCT taxonomies used to code intervention components are described in Appendices 4 and 5
respectively.
A further objective was to estimate the cost threshold below which an intervention designed to increase
DRS attendance would be cost-effective at different levels of effectiveness. The systematic review reported
in Chapter 3 identified which BCT and QI components were included in the main interventions in the
RCTs. The QI components were included in one economic analysis and the BCT components were included
in another economic analysis.
To address these objectives in a timely manner an existing economic model was used as the basis of the model
reported here. This model was used to estimate the cost–utility of BCT and QI components of interventions
that aimed to increase DRS attendance. Single BCT and QI components were compared in the model in
terms of their cost-effectiveness. BCT or QI combinations were not evaluated. Although this is unrealistic in
terms of an intervention, because of the way that the effectiveness of these components has been derived
(as described in Intervention effect estimates), it does serve to illustrate the relative economic merits of each
component and indicate which components could be prioritised in future research to develop interventions to
increase DRS uptake and provide a benchmark against which local services could be judged with regard to
whether or not they represent value for money. The BCTs and QI components evaluated were those that met
the inclusion criteria for the meta-analyses reported in Chapter 3; thus, only BCT and QI components that
were recorded as intervention components in at least 10 studies were included in the economic analysis.
The model included a front end, which modelled the probability of DRS based on the intervention used
to encourage uptake, and a back end, which modelled the long-term outcomes of DRS attendance and
non-attendance. The long-term outcomes were based on data identified from a published economic model
adapted for this analysis.224
A literature search identified the published economic evaluations that could potentially provide the costs and
benefits associated with DRS. The cost-effectiveness of DRS has been assessed in numerous studies.61,225–227
A published economic model of screening intervals for diabetic retinopathy, recently developed for the English
and Welsh setting, with detailed published data to enable the reproduction of the model for the purpose
of this analysis, was selected. This was a NIHR HTA report on the optimisation of DRS intervals by Scanlon
et al.224 This study did not report cost and utility estimates for DRS strategies across a range of baseline
probabilities of DRS attendance, but it provided sufficient information to model the long-term outcomes of
DRS attendance and non-attendance and this enabled the cost-effectiveness of BCT and QI components to
be estimated at different baseline probabilities of DRS attendance. A simplified model was produced from
the data reported by Scanlon et al.224 and the probabilities of DRS attendance and the cost of BCT and QI
components were modelled using the results of the effectiveness and cost analyses described in this chapter.
A full description of the economic methods is provided in Report Supplementary Material 4 (see Economic
model). This includes a full description of the model structure of the screening programmes and the
progression of diabetic retinopathy disease, the costs and utilities associated with the model states and the
effectiveness and cost estimates of the interventions. A summary of the key elements of the methods is
reported here.
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The economic model
It was not necessary to perfectly reproduce the analysis reported in Scanlon et al.224 as our objective was to
evaluate the cost-effectiveness of interventions to improve DRS attendance. However, the essential features
of the models are the same, as are the key assumptions, and the interested reader is referred back to the
report by Scanlon et al.224 for a detailed description of these. For the same reason we have not reviewed
all of the assumptions that underpin the Scanlon et al.224 model. We rely on sensitivity analyses to explore
the significance of substantial changes to the model. The model compares the different BCT and QI
components and used evidence from meta-analyses (and associated estimates of imprecision) to estimate
their relative effectiveness and costs. The Scanlon et al.224 model modelled a cohort of people with diabetes
based on a Gloucestershire Diabetic Eye Screening Service cohort of patients. The cohort represented all
people within the screening programme. For simplicity, this analysis modelled a cohort of patients with the
median values of the cohort modelled in the Scanlon et al.224 model (median age was 64 years). Although it
is acknowledged that a lot of people will be eligible for a DRS programme at a much earlier age, a simple
approach was required given the objectives and scope of this study, which was to identify the QI components
and BCTs that are most likely to be cost-effective. As this age was not reflective of people offered DRS, it was
varied in sensitivity analysis. Diabetic retinopathy is considered to consist of different stages affecting one or
both eyes and people with diabetic retinopathy may progress or regress between them.
A pictorial representation of the front end of the model is provided in Figure 19. If an individual attends
DRS there will be an opportunity to receive treatment, which will result in different costs and quality
of life from those for an individual who did not attend DRS but who would have required treatment.
An intervention to increase DRS attendance increases the probability that an individual will attend for
screening and hence changes the health service costs and quality of life. Within the model the health
outcomes of attending DRS were measured in QALYs, as this is the standard metric for informing the
allocation of resources in the NHS in the UK.
Diabetic retinopathy screening occurs at regular intervals; currently in the UK, annual screening is
recommended. The results of the Scanlon et al.224 cost–utility analysis identified DRS every 3 years as the
most cost-effective frequency for patients with diabetes and no preproliferative diabetic retinopathy or
proliferative diabetic retinopathy or diabetic maculopathy. However, the UK National Screening Committee228
has recommended that the screening interval for diabetic retinopathy should change from 1 year to 2 years
for those at low risk (based on two screening episodes with no detected diabetic retinopathy). One-year
intervals are recommended for those having any diabetic retinopathy in either of two previous screening
episodes. The base-case model in our analysis assumed annual DRS screening, with 2-yearly and 3-yearly
DRS used in sensitivity analyses. A positive screening episode was classified as screening positive for
preproliferative diabetic retinopathy, proliferative diabetic retinopathy or diabetic maculopathy.
The outcomes of attending DRS and non-attendance are presented in Figure 20. Once an individual
attends DRS he or she receives a positive or a negative test result. Individuals receiving a negative result
from the initial screen or those not attending any of their appointments in a given screening period are
invited for DRS a year later. Individuals with a positive result are referred to Hospital Eye Services (HES),
Attended
screening
Non-attendance
Intervention to
increase
screening uptake
Costs
(Scanlon model)
Quality of life
Costs
(Scanlon model)
Quality of life
FIGURE 19 Pictorial representation of the initial stages of the economic model.
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where appropriate ophthalmic assessment takes place. The HES tests are assumed to have perfect
sensitivity and specificity in the model. Once referred to HES, patients might or might not attend.
Following diagnosis, if an individual attends the HES and is diagnosed with preproliferative diabetic
retinopathy, proliferative diabetic retinopathy or diabetic maculopathy, they may or may not be offered
treatment. An individual who is offered treatment then re-enters the DRS programme and has the
opportunity to be screened at the next screening interval. An individual who does not receive treatment is
either monitored every 6 months in the HES or re-enters the DRS programme and has the opportunity to
be screened at the next screening interval. The costs and utilities for the model states were derived from
econometric analyses of the data set obtained from the Gloucestershire Diabetic Eye Screening Service and
other sources, as described in Report Supplementary Material 4.
Intervention effect estimates
The effectiveness results reported in the included clinical studies are the effect estimates for the complex
interventions studied. This economic analysis investigated the cost-effectiveness of individual components
of these complex interventions and therefore effect estimates for individual QI components and BCTs
were estimated by adjusting for other components. This is in contrast to the analysis in Chapter 3, which
sought to estimate mean effects for interventions that included a specific component (compared with
interventions that did not include it).
A meta-regression analysis with multiple explanatory variables representing the different QI components
was conducted for the effects of the QI components on the log OR of screening attendance. A separate
analysis was conducted for the BCTs. Both the patient- and HCP-targeted techniques were included in
the same regression analyses for both the resource use and the effect analyses. Although this is a large
number of explanatory variables, there is a predefined set of competing interventions and there is no
reason to exclude one over the other. In addition, no statistical tests were conducted as part of this
analysis. These results in terms of the effect of QI and BCT components should be interpreted as additive,
whereas the results in Chapter 3 are not additive.
The studies varied in their populations and other characteristics. Most studies were conducted outside
the UK. Furthermore, there were insufficient data to model interaction effects between the BCTs and
between the QI components. Consequently, the effect estimates are not precise estimates for a specific UK
population. The purpose was to provide the parameter estimates for the cost-effectiveness model, which
evaluates the probability that each QI/BCT is cost-effective accounting for each QI/BCT simultaneously.
This can help prioritise further research by identifying the most promising intervention components and
developing interventions utilising them.
Invited to
screening
Attended
screening
Non-attendance
Positive result:
referral to HES
Attended
HES
Non-attender
Screening
programme
Negative result
FIGURE 20 Screening pathway for diabetic patients offered DRS. HES, Hospital Eye Services. Reproduced from
Figure 15 of Scanlon et al.224 Contains information licensed under the Non-Commercial Government Licence v1.0.
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Behaviour change techniques or QI components were excluded from the analysis if there were insufficient
data to estimate a coefficient, if there was collinearity (overlap of studies between indicator variables)
or if there were perfect predictions. As with the meta-analyses reported in Chapter 3, only BCTs and QI
components that occurred in at least 10 studies were included in the economic model and only these results
are reported here. These were considered to be less prone to a spurious result. It is likely that there is variation
between interventions that are coded as a particular QI or BCT. It is also likely that different approaches to
implementing a QI or BCT intervention are present when QI components and BCTs are coded in different
studies. Random-effects meta-regressions were performed in Stata® 15 (StataCorp LP, College Station,
TX, USA). The dependent variable was the log OR. Fifty-six studies58–63,65–72,74–78,80–89,92–105,108–112,115–118,120–123 with
a usual care comparator were included in the analyses.
The full set of regression results is presented in Report Supplementary Material 4. The results transformed
into RRs with 95% CIs for the QI components that occur in at least 10 studies and the BCTs that occur in
at least 10 studies are reported in Tables 13 and 14 respectively. The ordered resource ranking analysis
that appears in Tables 13 and 14 is explained in Resource use and cost estimates.
In the model, the baseline probability of DRS attendance was based on a minimum standard set by the
UK National Screening Committee,229 not on the probabilities in the usual care arms in the RCTs. The
probability of DRS attendance varied in a sensitivity analysis. Details of how the effect estimates were
utilised within the economic model are provided in Report Supplementary Material 4.
Resource use and cost estimates
The level of the cost of resource use in each included study was of interest for two purposes in this study.
First, in the economic analysis, we were interested in estimating the cost of the individual components
of the complex interventions included in each study rather than the cost of the complex interventions.
This requires a form of multivariable regression with the QI and BCT components as explanatory variables,
as used in the intervention effectiveness analysis. Second, in Chapter 3 the association between resource
use and intervention effectiveness was investigated. In Chapter 3 the average effectiveness was calculated
at different levels of resource use and resource use intensity was added as a covariate in a meta-regression.
A measure of resource use intensity was needed for each study. As there were 56 studies with a usual care
comparator, an efficient method was required to derive this measure. The approach taken was to design a
data abstraction method for recording predefined key categories of resource use and the levels of each category.
TABLE 13 The QI component resource use (ordered logit) and effectiveness (meta-regression) results obtained from
analyses including all of the QI components as explanatory variables
QI components
Ordered resource ranking:
proportional RR (95% CI)
Effect meta-regression:
RR (95% CI)
Audit and feedback 1.22 (0.79 to 1.38) 0.99 (0.78 to 1.16)
Case management 1.40 (1.28 to 1.42) 0.87 (0.67 to 1.05)
Team changes 1.26 (0.97 to 1.38) 1.14 (1.00 to 1.24)
Electronic patient registry 0.69 (0.17 to 1.23) 1.01 (0.74 to 1.21)
Clinician education 0.89 (0.42 to 1.24) 1.06 (0.89 to 1.19)
Clinician reminders 1.26 (0.73 to 1.40) 1.08 (0.83 to 1.25)
Patient education 0.80 (0.38 to 1.18) 1.09 (0.92 to 1.22)
Promotion of self-management 1.28 (0.85 to 1.40) 1.12 (0.93 to 1.26)
Patient reminders 0.64 (0.24 to 1.09) 1.02 (0.84 to 1.16)
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The details are provided in Report Supplementary Material 4. The process of determining the resource
categories and levels involved agreement between reviewers on an ordered ranking of resource use for
each study. The cost of each level of each resource category was then estimated through random sampling
of at least three studies with each category and level of resource use, costing the resource use associated
with the intervention description using national cost estimates and calculating the average. The total cost
of a complex intervention in each study is the product of the resource categories and estimated costs for
each category. The cost variable was therefore categorical and the applicable regression method to
estimate the incremental cost of each QI/BCT component was an ordinal logistic regression, with the
ordered resource use ranking as the dependent variable.
The costs of the interventions from the 56 included studies were distributed across a total of 16 ordered
ranks, which were utilised in the economic model. In Chapter 3 these 16 ranks were put into five groups
to facilitate the analysis of an association between resource use and intervention effectiveness. The
grouping was as follows: ranks 1–3 became rank 1; ranks 4–6 became rank 2; ranks 7–9 became rank 3;
ranks 10–12 became rank 4; and ranks 13–16 became rank 5.
The cost analysis for the economic model differs from the work conducted in the review of economic
outcomes reported in Chapter 3 in that the economic model utilises unit cost estimates for England and
Wales to value the described interventions rather than converting the costs reported in the studies from
one currency to another. Arguably, such data would be more transferable as the resources required to
provide an intervention may not vary between settings.
TABLE 14 The BCT component resource use (ordered logit) and effectiveness (meta-regression) results obtained
from analyses including all of the BCTs as explanatory variables
BCT components
Likert resource ranking:
proportional RR (95% CI)
Effect meta-regression:
RR (95% CI)
Patient-targeted BCTs
Problem-solving 1.37 (1.03 to 1.42) 0.95 (0.73 to 1.13)
Goal-setting (outcome) 1.27 (0.57 to 1.41) 1.24 (1.10 to 1.32)
Feedback on outcomes of behaviour/biofeedback 0.59 (0.13 to 1.19) 1.17 (1.02 to 1.27)
Social support (unspecified) 0.15 (0.01 to 0.81) 1.07 (0.87 to 1.22)
Social support (practical) 1.29 (0.75 to 1.41) 0.95 (0.76 to 1.11)
Instruction on how to perform the behaviour 1.38 (1.09 to 1.42) 0.89 (0.70 to 1.06)
Information about health consequences 0.17 (0.02 to 0.76) 1.15 (1.00 to 1.25)
Prompts/cues 0.17 (0.02 to 0.81) 0.91 (0.73 to 1.07)
Credible source 0.38 (0.01 to 1.33) 0.85 (0.56 to 1.10)
Restructuring the social environment 0.80 (0.05 to 1.40) 0.82 (0.58 to 1.03)
HCP-targeted BCTs
Feedback on outcomes of behaviour/biofeedback 0.51 (0.12 to 1.11) 0.85 (0.68 to 1.01)
Social support (practical) 1.42 (1.30 to 1.43) 1.27 (1.10 to 1.35)
Instruction on how to perform the behaviour 0.90 (0.28 to 1.32) 0.81 (0.61 to 0.99)
Prompts/cues 1.34 (0.67 to 1.42) 0.96 (0.67 to 1.18)
Credible source 0.89 (0.22 to 1.34) 0.95 (0.73 to 1.13)
Restructuring the social environment 1.42 (1.33 to 1.43) 1.13 (0.94 to 1.25)
Adding objects to the environment 0.19 (0.02 to 0.93) 0.98 (0.76 to 1.15)
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It was assumed that all people with diabetes would be eligible for DRS and that BCT/QI interventions
would target all eligible people. It is noted that some of the evidence on the effectiveness of BCT/QI
interventions came from studies targeting those most likely not to attend DRS. It was not possible to
control for this factor in the meta-regression data and we have assumed a constant effect. However, we
have explored the impact of different baseline uptake rates of DRS to illustrate the relative impact of
BCTs/QI components when the baseline uptake is lower (see Base-case and sensitivity analyses).
Resource use may be incurred at different organisational levels. It may differ between individuals or at the
GP or practice level or even be determined at the level of the NHS. It was assumed that all software
development and the design of educational pamphlets would be financed at a higher organisational level
than, for example, a general practice, for simplicity taken as the national level. This assumes that a country
takes advantage of economies of scale. The total numbers of people with diabetes (n = 2,913,538),230
general practices (n = 8151) and GPs (n = 40,265)231 in England were used to derive a cost per patient for
each intervention. The price year was 2016.
Details of how the ordered resource use and cost estimates were incorporated in the model are provided
in Report Supplementary Material 4 (see Economic model).
Analyses and interpretation
Point estimates of incremental cost-effectiveness
To identify the interventions that are most likely to be cost-effective at a specific cost-effectiveness threshold,
£20,000 per QALY in the main analyses, the estimated costs and effectiveness of each intervention were
incorporated into the model and the total costs (including the long-term cost of health service use) and
benefits (measured in QALYs) were calculated for intervention and no intervention. The results at a threshold
of £30,000 per QALY were also calculated and are reported in Appendix 10. Interventions with an ICER of
< £20,000 per QALY are commonly considered to be cost-effective according to National Institute for Health
and Care Excellence guidelines.232 A cost of £30,000 per QALY is quoted as the upper value for the plausible
range of willingness-to-pay thresholds.
Probabilistic analysis
The cost-effectiveness results depend on all of the model parameters listed in Resource use and cost
estimates. As explained above, only uncertainty in the effect and cost parameters of the BCTs and QI
components was included in the model. The imprecision in estimates of the effect and cost of the BCTs
and QI components was accounted for by conducting probabilistic sensitivity analyses. This involved
simultaneously sampling from probability distributions assigned to each model parameter. For example,
the normal distribution for the log OR effect of each intervention was derived from the point estimate
and standard error of the relative effectiveness and constant reported in the meta-regression analyses.
Uncertainty associated with regression model specification could not be accounted for. For example, there
were insufficient data to model interactions between BCTs and QI components in the multiple ordered logit
regression for resource use and the multivariable meta-regression for effectiveness.
Although the Scanlon et al.224 model accounted for uncertainty in all of the model parameters, in this
model no uncertainty was accounted for in the parameters related to the outcomes of being screened or
not being screened.
Two sets of results were produced from the probabilistic sensitivity analyses. The first is the probability that
each intervention is cost-effective compared with no intervention at a specific cost-effectiveness threshold
of £20,000 per QALY. The results at a threshold of £30,000 per QALY were also calculated and are
reported in Appendix 10.
The model estimates a long-term benefit Bi for intervention i and a long-term benefit Bni for no
intervention ni. The model also estimates a total cost Ci for intervention, which includes the long-term cost
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of health service use and the cost of intervention. The total cost of long-term health service use for no
intervention was Cni.
For a specific cost-effectiveness threshold γ (£20,000 per QALY in the main analyses), the incremental net
benefit of the intervention compared with no intervention was calculated:
Incremental net benefit = (Bi −Bni) × γ− (Ci −Cni). (1)
Given that the purpose of this analysis was to identify the BCT and QI components that are most likely to
be cost-effective and therefore most worthy of further consideration when developing an intervention, the
absolute costs, benefits and net benefits are not reported in the results section. What is of most interest
is the probability that each BCT/QI is cost-effective at a specific cost-effectiveness threshold given the
available evidence.
The probability that the incremental net benefit is positive was derived from the probabilistic sensitivity
analysis. For example, consider the comparison of an intervention and no intervention. A probability of
0.5 indicates that the intervention and no intervention are equally likely to be considered cost-effective.
A probability of 0.95 indicates that the intervention is highly likely to be the cost-effective option. A
probability of 0.05 indicates that the no-intervention option is highly likely to be the cost-effective option.
The second set of results is the probability x that each intervention is the most cost-effective, accounting
for all of the interventions and no intervention simultaneously. First, the net benefit is calculated for each
intervention, as described in the following equation:
Net benefit = Bi × γ−Ci. (2)
Second, the proportion of times that the net benefit of intervention X has the highest net benefit is the
probability that intervention X is cost-effective relative to the other interventions. The probability x is a
measure of certainty and the complement (1 – x) is the error probability. The highest probability does not
necessarily indicate that the corresponding intervention is expected to be the most cost-effective; it means
that it is the most likely to be the most cost-effective of all of the interventions compared.
It should also be noted that the more comparators there are, the lower the probabilities are likely to be for
any given intervention. For example, if 10 interventions are each equally likely to be cost-effective then for
each intervention the probability of being cost-effective would be 0.1. As the objective of this analysis is
to identify which of the BCT/QI components is the ‘best bet’ in economic terms, to consider further when
developing an intervention, it is the relative size of the probabilities that is important.
Threshold analysis
This analysis identified the maximum cost that an intervention must have for any given level of
effectiveness of DRS such that society’s maximum willingness to pay for a QALY is not exceeded. Thus,
this provides us with a maximum amount that we should devote to increasing the uptake of DRS for any
expected uptake rate of DRS that we would expect to achieve.
A hypothetical intervention was assumed to have a hypothetical clinical effectiveness φ, which was associated
with a long-term benefit Bi. The long-term benefit of a no-intervention alternative was Bni. The hypothetical
intervention was assumed to have a hypothetical intervention cost ω, which was associated with a total cost
Ci, which includes the long-term cost of health service use. The total cost of long-term health service use of
no intervention was Cni. For a specific cost-effectiveness threshold γ, £20,000 per QALY in the main analyses,
the incremental net benefit of the intervention compared with no intervention was calculated:
Incremental net benefit = (Bi −Bni) × γ− (Ci −Cni). (3)
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For each level of assumed intervention effectiveness φ, the value of the intervention cost ω was varied in a
threshold analysis. The highest value of ω was identified that resulted in a positive incremental net benefit
for each value of φ. The highest cost for each level of effectiveness then creates a maximum cost curve.
The maximum cost curve was then utilised to obtain the maximum cost associated with the mean estimate
of effect for each BCT/QI and with the lower and upper limits of the 95% CI. The results of this analysis
are reported in Appendix 11.
Base-case and sensitivity analyses
The base-case model assumed that:
l screening would be conducted annually
l the baseline probability of screening uptake would be 0.7
l a cohort of 64-year-olds is modelled
l the probability of a patient being monitored is 0.78 following HES referral and a positive diagnosis
l there are no social care cost implications.
Sensitivity analyses to evaluate the impact of different scenarios on the results were conducted for the
probabilistic analyses.
Annual DRS is currently the most common screening frequency in the UK. The results of the Scanlon
et al.224 cost–utility analysis identified DRS every 3 years as the most cost-effective screening frequency for
patients with diabetes and no preproliferative diabetic retinopathy or proliferative diabetic retinopathy or
diabetic maculopathy. However, the UK National Screening Committee228 has recommended that the
screening interval for diabetic retinopathy should change from 1 year to 2 years for those at low risk (based
on two screening episodes with no detected diabetic retinopathy). One-year intervals are recommended for
those having any diabetic retinopathy in either of two previous screening episodes. Consequently, sensitivity
analyses were conducted assuming that screening was carried out every 2 years and every 3 years, with the
latter analysis conducted to help benchmark the results with those from Scanlon et al.224
The diabetic eye screening (DRS) uptake rate was 83.1% in England in 2015 based on data from the
81.9% of diabetic eye screening programmes that reported data against the new DRS pathway for
2015.233 The minimum standard set by the UK National Screening Committee234 is at least 70%, with an
achievable objective of at least 80%. The base-case analysis used a baseline uptake rate of 70% based on
the minimum standard. Sensitivity analyses were conducted assuming screening uptake rates of 50%,
60%, 80% and 90%. These rates were chosen to represent rates that may apply to the UK and specific
subgroups eligible for screening in the UK. For example, and as noted earlier, the lower rates may be more
applicable to subgroups less likely to engage with the DRS service. The economic model used in this
analysis was a simplified version of the Scanlon et al.224 model, which utilised the data reported in the HTA
report. An interquartile range was reported for the baseline age of the screening cohort in the Scanlon
et al.224 model. This indicates that a heterogeneous population may have been modelled. For simplicity, in
this base-case analysis a cohort of 64-year-olds enters the model at the start of the analysis (64 years was
the median age in the baseline population in the Scanlon et al.224 model). To understand the effect on the
results of modelling baseline populations with different ages, sensitivity analyses were conducted with
cohorts of 56-year-olds and 70-year-olds.
In the Scanlon et al.224 model, in the base-case analysis it was assumed that, of the people who are not
treated following a positive diagnosis of preproliferative diabetic retinopathy, proliferative diabetic
retinopathy or diabetic maculopathy, the probability that a patient would be monitored was 0.78. This
assumption was also made in this base-case analysis. In sensitivity analysis the probability was reduced
to 0.4.
As described earlier, the cost of social care was excluded in the base-case model. In sensitivity analysis it was
assumed that 10% of people with diabetic maculopathy in both eyes lived in nursing/residential homes.
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Sensitivity analyses for the threshold analysis to derive the maximum cost curve were informed by the
sensitivity analyses conducted for the probabilistic analyses.
Results
Quality improvement results
The base-case analysis includes a baseline probability of DRS attendance of 0.7. The probability that each
QI component is more cost-effective than no QI intervention at improving attendance at DRS is presented
in Table 15. All of these results are based on effectiveness and cost analyses that adjust for the other
QI components. They provide an indication of which QI components are worth prioritising over which
others when designing a DRS attendance intervention, which is likely to consist of a combination of QI
components. The results of the sensitivity analyses including baseline DRS attendance probabilities of 0.5,
0.6, 0.8 and 0.9 are also reported in Table 15. These results assume a societal willingness-to-pay threshold
for a QALY of £20,000. The results assuming a threshold of £30,000 per QALY are reported in Appendix 10.
The results are presented as the probability that a QI component is cost-effective at a specific willingness-
to-pay threshold. See Analyses and interpretation for an explanation of these results.
Table 15 shows that there is considerable uncertainty in the results when considering which interventions
are cost-effective compared with no intervention. In pairwise comparisons, a probability of > 0.95 could be
considered highly likely to be cost-effective and a probability of > 0.7 could be considered to show some
evidence of cost-effectiveness, but with significant uncertainty. There are areas of uncertainty that are
not captured in these results but the results indicate which QI components are worth prioritising when
developing interventions from a cost-effectiveness perspective. In the base case, with a baseline probability
of DRS attendance of 0.7, there are no QI components with a probability of cost-effectiveness of > 0.9.
Patient education has the highest probability of being cost-effective (0.64).
The greater scope for increasing DRS attendance with a lower baseline probability of screening attendance
is reflected in the higher probabilities of cost-effectiveness for each QI component compared with no QI
intervention at lower baseline probabilities of screening attendance. Even at a baseline probability of DRS
attendance of 0.5, only ‘team changes’ and ‘patient education’ have a probability of being cost-effective
of > 0.7. As the baseline probability of DRS attendance reduces from 0.7 to 0.5, the probability of being
TABLE 15 Probability that an intervention is cost-effective (compared with no intervention) for QI interventions at
a £20,000 per QALY threshold
Intervention
Baseline probability of screening uptake
0.5 0.6 0.7 0.8 0.9
Audit and feedback 0.329 0.229 0.109 0.031 0.001
Case management 0.012 0.005 0.000 0.000 0.000
Team changes 0.764 0.625 0.360 0.041 0.001
Electronic patient registry 0.536 0.479 0.418 0.319 0.084
Clinician education 0.652 0.587 0.491 0.307 0.038
Clinician reminders 0.530 0.421 0.246 0.069 0.010
Patient education 0.769 0.714 0.644 0.473 0.084
Promotion of self management 0.653 0.530 0.299 0.051 0.004
Patient reminders 0.573 0.531 0.463 0.344 0.065
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cost-effective increases more for ‘team changes’ than for ‘patient education’. This is because resource use
is estimated to be much less for ‘patient education’ than for ‘team changes’ (see proportional RRs of
resource use ranking in Table 13).
The probability of each QI intervention being cost-effective when all QI factors are compared simultaneously
is reported in Table 16. The QI components with the highest probabilities of cost-effectiveness in Table 15
also have the highest probabilities of cost-effectiveness in Table 16. What Table 16 shows is that, among the
QI components with the highest probabilities of being cost-effective, there is no single QI component that
stands out as being far more likely to be cost-effective. Patient education has the highest probability of being
cost-effective and this is only 0.31 in the base case.
Sensitivity analyses for scenarios including different probabilities of monitoring following HES referral
attendance, different DRS frequencies and different ages of the baseline cohort and including and
excluding social care costs are presented in Table 17.
Monitoring may occur if treatment is not provided after a positive diagnosis following HES referral
attendance. In the base-case analysis it was assumed that 78% of people who are not treated following a
positive diagnosis of preproliferative diabetic retinopathy, proliferative diabetic retinopathy or diabetic
maculopathy are monitored. If this proportion is reduced to 40% then the probability of a given QI component
being cost-effective compared with no QI intervention increases when DRS is scheduled every year.
The probability of an intervention being cost-effective is higher when DRS is carried out every 3 years than
when it is carried out every 2 years, which in turn is higher than when DRS is carried out every year.
This is consistent with the results of the Scanlon et al.224 cost–utility analysis, which identified screening
every 3 years as being the most cost-effective frequency of screening.
In the base-case analysis it was assumed that the age of the cohort being screened was 64 years. If either a
younger (age 56 years) or older (age 70 years) cohort is considered then the probability of an intervention
being cost-effective compared with no intervention decreases. The cost-effectiveness of the intervention
decreases at age 70 years because the potential cumulative benefit associated with the intervention decreases.
Specifically, the likelihood of attending a referral to the HES decreases, the utility of an individual decreases
with age and mortality increases. The quality of life benefits and potential cost savings increase with age.
TABLE 16 Probability that an intervention is cost-effective (including all interventions) for QI interventions at a
£20,000 per QALY threshold
Intervention
Baseline probability of screening uptake
0.5 0.6 0.7 0.8 0.9
No intervention 0.034 0.063 0.121 0.270 0.783
Audit and feedback 0.015 0.009 0.008 0.005 0.000
Case management 0.000 0.000 0.000 0.000 0.000
Team changes 0.133 0.092 0.042 0.011 0.001
Electronic patient registry 0.129 0.149 0.159 0.167 0.071
Clinician education 0.122 0.131 0.140 0.115 0.026
Clinician reminders 0.086 0.075 0.048 0.023 0.008
Patient education 0.280 0.293 0.314 0.261 0.062
Promotion of self management 0.119 0.097 0.048 0.018 0.003
Patient reminders 0.082 0.090 0.120 0.128 0.047
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TABLE 17 Sensitivity analyses for the probability that an intervention is cost-effective (compared with no intervention) for QI interventions assuming different screening,
monitoring, age at start of screening and care home cost scenarios, at a £20,000 per QALY threshold
Intervention
Screening
every year,
Pm= 0.78,
cohort age
64 years,
no care costs
Screening
every year,
Pm= 0.4,
cohort age
64 years,
no care costs
Screening
every 2 years,
Pm= 0.78,
cohort age
64 years,
no care costs
Screening
every 3 years,
Pm= 0.78,
cohort age
64 years,
no care costs
Screening
every 3 years,
Pm= 0.4,
cohort age
64 years,
no care costs
Screening
every year,
Pm= 0.78,
cohort age
70 years,
no care costs
Screening
every year,
Pm= 0.78,
cohort age
56 years,
no care costs
Screening
every year,
Pm= 0.78,
cohort age
64 years,
care costs
Audit and feedback 0.109 0.126 0.374 0.453 0.422 0.079 0.066 0.181
Case management 0.000 0.001 0.027 0.075 0.048 0.000 0.000 0.001
Team changes 0.360 0.434 0.809 0.883 0.872 0.271 0.196 0.555
Electronic patient registry 0.418 0.439 0.549 0.570 0.555 0.415 0.393 0.468
Clinician education 0.491 0.517 0.693 0.729 0.705 0.442 0.415 0.562
Clinician reminders 0.246 0.294 0.590 0.664 0.660 0.194 0.163 0.374
Patient education 0.644 0.667 0.800 0.814 0.805 0.611 0.597 0.706
Promotion of self management 0.299 0.371 0.708 0.784 0.783 0.232 0.178 0.471
Patient reminders 0.463 0.488 0.596 0.616 0.618 0.434 0.405 0.505
Pm, probability of being monitored following a HES referral and a positive diagnosis.
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Starting DRS at an earlier age increases the duration that a benefit may be realised for an individual, but the
greatest benefits occur a longer time after the start of DRS and these are discounted more heavily.
For other scenarios considered, the results described in Table 17 indicate that there remains considerable
uncertainty. However, for a cohort of people aged 64 years, increasing the screening interval to 2 or
3 years means that the probability that ‘team changes’ and ‘patient education’ would be considered
cost-effective would be > 0.8 compared with no intervention. Similarly, increasing the screening interval
to 3 years for the same cohort would mean that the probability that ‘promotion of self-management’ and
‘clinician education’ are cost-effective compared with no intervention would increase to > 0.7.
Behaviour change technique results
The base-case analysis includes a baseline probability of DRS attendance of 0.7. The probability that each
BCT component would be more cost-effective than no BCT intervention in terms of improving attendance
at DRS is presented in Table 18. The BCT components are listed as being either patient targeted or HCP
targeted. All of these results are based on effectiveness and cost analyses that adjust for the other BCT
components. They provide an indication of which BCT components are worth prioritising over which
others when designing a DRS attendance intervention, which is likely to consist of a combination of BCTs.
The results of the sensitivity analyses including baseline DRS attendance probabilities of 0.5, 0.6, 0.8 and
0.9 are also reported in Table 18. These results assume a societal willingness-to-pay threshold for a QALY
of £20,000. The results assuming a threshold of £30,000 per QALY are reported in Appendix 10.
TABLE 18 Probability that an intervention is cost-effective (compared with no intervention) for BCT interventions
at a £20,000 per QALY threshold
Intervention
Baseline probability of screening uptake
0.5 0.6 0.7 0.8 0.9
Patient-targeted BCTs
Problem-solving 0.677 0.556 0.264 0.023 0.001
Goal-setting (outcome) 0.999 0.992 0.964 0.558 0.151
Feedback on outcomes of behaviour/biofeedback 1.000 0.999 0.997 0.961 0.672
Social support (unspecified) 0.988 0.985 0.980 0.964 0.793
Social support (practical) 0.784 0.688 0.416 0.100 0.006
Instruction on how to perform the behaviour 0.514 0.335 0.117 0.012 0.000
Information about health consequences 1.000 1.000 0.999 0.994 0.936
Prompts/cues 0.877 0.873 0.841 0.748 0.400
Credible source 0.658 0.638 0.563 0.465 0.191
Restructuring the social environment 0.562 0.501 0.386 0.250 0.055
HCP-targeted BCTs
Feedback on outcomes of behaviour/biofeedback 0.728 0.705 0.613 0.476 0.088
Social support (practical) 0.982 0.786 0.388 0.049 0.001
Instruction on how to perform the behaviour 0.534 0.477 0.350 0.191 0.014
Prompts/cues 0.676 0.599 0.362 0.089 0.009
Credible source 0.863 0.818 0.714 0.479 0.094
Restructuring the social environment 0.758 0.321 0.178 0.006 0.000
Adding objects to the environment 0.939 0.929 0.916 0.860 0.550
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Similar interpretations of the probabilities presented for the cost-effectiveness of BCT components can be
made as for the QI components. For the patient-targeted BCTs, at a probability of screening uptake of 0.7,
‘goal setting (outcome)’, ‘feedback on outcomes of behaviour’, ‘social support (unspecified)’ and ‘information
about health consequences’ have extremely high probabilities of being cost-effective compared with no BCT
intervention. To put this into context, this is crudely analogous to saying that a comparison is statistically
significant in a one-sided test at conventional (5% levels) of statistical significance. The BCT ‘prompts/cues’ is
also associated with a high probability of 0.84 of being cost-effective compared with no intervention.
For the HCP-targeted BCTs, only ‘adding objects to the environment’ has a probability of being
cost-effective of > 0.9, with ‘credible source’ having a probability of being cost-effective of > 0.7.
When the baseline probability of DRS is decreased, then each BCT component has a higher probability
of being considered cost-effective compared with no BCT intervention. At a baseline probability of DRS
attendance of 0.5, ‘social support (practical)’ and ‘credible source’ are the only BCTs that have a
probability of being cost-effective that rises above 0.8 compared with scenarios with a higher baseline
probability of DRS attendance. When the baseline probability of DRS attendance is 0.9, however, all BCTs
are less likely to be cost-effective and only the patient-targeted ‘information about health consequences’
has a probability of being cost-effective of > 0.9.
The probability of each BCT component being cost-effective when all BCT components are compared
simultaneously is reported in Table 19. The BCT components with the highest probabilities of being
TABLE 19 Probability that an intervention is cost-effective (including all interventions) for BCT interventions at a
£20,000 per QALY threshold
Intervention
Baseline probability of screening uptake
0.5 0.6 0.7 0.8 0.9
No intervention 0.00 0.00 0.00 0.00 0.01
Patient-targeted BCTs
Problem-solving 0.000 0.000 0.000 0.000 0.000
Goal-setting (outcome) 0.172 0.119 0.071 0.037 0.012
Feedback on outcomes of behaviour/biofeedback 0.311 0.305 0.278 0.197 0.092
Social support (unspecified) 0.105 0.127 0.151 0.199 0.256
Social support (practical) 0.000 0.000 0.000 0.000 0.000
Instruction on how to perform the behaviour 0.000 0.000 0.000 0.000 0.000
Information about health consequences 0.371 0.419 0.465 0.520 0.521
Prompts/cues 0.001 0.002 0.004 0.007 0.021
Credible source 0.003 0.003 0.002 0.004 0.014
Restructuring the social environment 0.000 0.000 0.000 0.000 0.001
HCP-targeted BCTs
Feedback on outcomes of behaviour/biofeedback 0.000 0.000 0.000 0.000 0.000
Social support (practical) 0.021 0.004 0.001 0.000 0.000
Instruction on how to perform the behaviour 0.000 0.000 0.000 0.000 0.000
Prompts/cues 0.001 0.002 0.001 0.001 0.000
Credible source 0.000 0.000 0.002 0.001 0.001
Restructuring the social environment 0.000 0.000 0.000 0.000 0.000
Adding objects to the environment 0.013 0.017 0.026 0.034 0.067
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cost-effective in Table 18 also have the highest probabilities of being cost-effective in Table 19.
What Table 19 shows is that, among the BCT components with the highest probabilities of being
cost-effective, there is no single BCT component that stands out as being far more likely to be
cost-effective. Patient-targeted ‘information about health consequences’ has the highest probability of
being cost-effective and this is only 0.47 in the base case. Patient-targeted ‘goal-setting (outcome)’,
‘feedback on outcomes of behaviour’, ‘social support (unspecified)’ and ‘information about health
consequences’ all have a significant probability of being the most cost-effective isolated BCT component.
Sensitivity analyses for scenarios including different probabilities of monitoring following HES referral
attendance, different screening frequencies and different ages of the baseline cohort and including and
excluding social care costs are presented in Table 20.
Monitoring may occur if treatment is not provided after a positive diagnosis following HES referral
attendance. As in the QI analysis, in the base-case analysis it was assumed that 78% of people who are
not treated following a positive diagnosis of preproliferative diabetic retinopathy, proliferative diabetic
retinopathy or diabetic maculopathy are monitored. If this proportion is reduced to 40% then the
probability of a given BCT component being cost-effective compared with no BCT intervention increases
when DRS is scheduled every year.
As the frequency of DRS is reduced, the probability of a BCT component being considered cost-effective
compared with no BCT intervention increases. When the screening interval is extended to 3 years, all BCTs
have a probability of being cost-effective of > 0.8 except for ‘Instruction on how to perform the behaviour’
targeted at both the patient and the HCP, ‘credible source’ targeted at the patient, ‘restructuring the social
environment’ targeted at the patient, ‘instruction on how to improve behaviour’ targeted at HCPs and
‘feedback on outcomes of behaviour’ targeted at HCPs. This is consistent with the results of the Scanlon
et al.224 cost–utility analysis, which identified screening every 3 years as the most cost-effective screening
frequency. However, when the age of the cohort is reduced from 64 years (the base case) to 56 years then
the BCT components all become less cost-effective compared with no BCT intervention, although for some
BCTs, such as ‘information about health consequences’ targeted at the patient, the change is very small
(the probability that this BCT is cost-effective remains at 0.998, which is extremely high). When the age
of the cohort is increased to 70 years then the probability that a BCT is cost-effective compared with
no intervention also decreases. The quality-of-life benefits and potential cost savings increase with age.
Starting DRS at an earlier age increases the duration that a benefit may be realised for an individual,
but the greatest benefits occur a longer time after the start of DRS and these are discounted more heavily.
The results do not change greatly in the other sensitivity analyses.
Threshold cost curve
The threshold intervention cost per patient was derived for a range of hypothetical RD effect estimates,
using the base-case model and assuming a societal willingness-to-pay threshold for a QALY of £20,000
(Figure 21). The base-case analysis excludes the social care cost implications but the results of a model
including the social care cost implications are also presented in Figure 21.
Similar results but with effectiveness reported as ORs are provided in Figure 22. As with Figure 21,
the results for scenarios excluding and including social care cost implications are presented.
The cost thresholds for a range of RDs and RRs are presented in Table 21. The cost thresholds are
presented using three different units: per patient, per general practice and for England as a whole.
This table represents a lookup table indicating a plausible cost range over which an intervention with a
specific level of effect may be cost-effective at a societal willingness-to-pay threshold for a QALY of £20,000.
The maximum costs for the mean RD estimates for the QI and BCT components are presented in
Appendix 11.
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TABLE 20 Sensitivity analyses for the probability that an intervention is cost-effective (compared with no intervention) for BCT interventions assuming different screening,
monitoring, age at start of screening and care home cost scenarios, at a £20,000 per QALY threshold
Intervention
Screening
every year,
Pm= 0.78,
cohort age
64 years,
no care costs
Screening
every year,
Pm= 0.4,
cohort age
64 years,
no care costs
Screening
every 2 years,
Pm= 0.78,
cohort age
64 years,
no care costs
Screening
every 3 years,
Pm= 0.78,
cohort age
64 years,
no care costs
Screening
every 3 years,
Pm= 0.4,
cohort age
64 years,
no care costs
Screening
every year,
Pm= 0.78,
cohort age
70 years,
no care costs
Screening
every year,
Pm= 0.78,
cohort age
56 years,
no care costs
Screening
every year,
Pm= 0.78,
cohort age
64 years,
care costs
Patient-targeted BCTs
Problem-solving 0.264 0.346 0.791 0.849 0.830 0.186 0.130 0.478
Goal-setting (outcome) 0.964 0.976 1.000 1.000 1.000 0.955 0.918 0.984
Feedback on outcomes of behaviour/
biofeedback
0.997 0.998 1.000 1.000 1.000 0.997 0.993 0.999
Social support (unspecified) 0.980 0.978 0.989 0.991 0.991 0.980 0.979 0.986
Social support (practical) 0.416 0.499 0.856 0.904 0.878 0.334 0.284 0.623
Instruction on how to perform the behaviour 0.117 0.174 0.631 0.740 0.708 0.071 0.044 0.275
Information about health consequences 0.999 0.999 0.999 1.000 1.000 0.999 0.998 1.000
Prompts/cues 0.841 0.846 0.891 0.896 0.902 0.819 0.810 0.867
Credible source 0.563 0.583 0.677 0.723 0.699 0.545 0.520 0.634
Restructuring the social environment 0.386 0.427 0.612 0.646 0.649 0.362 0.337 0.470
HCP-targeted BCTs
Feedback on outcomes of behaviour/
biofeedback
0.658 0.667 0.765 0.793 0.787 0.603 0.601 0.690
Social support (practical) 0.396 0.401 0.997 1.000 1.000 0.380 0.362 0.645
Instruction on how to perform the behaviour 0.377 0.401 0.573 0.617 0.625 0.325 0.316 0.455
Prompts/cues 0.398 0.469 0.766 0.829 0.824 0.320 0.286 0.545
Credible source 0.729 0.758 0.893 0.920 0.904 0.672 0.666 0.802
Restructuring the social environment 0.209 0.223 0.929 0.982 0.976 0.149 0.115 0.279
Adding objects to the environment 0.920 0.924 0.955 0.960 0.951 0.903 0.908 0.932
Pm, probability of being monitored following a HES referral and a positive diagnosis.
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FIGURE 22 The maximum cost per-patient-screened threshold below which a hypothetical DRS uptake intervention
remains cost-effective compared with no intervention for a range of OR effect estimates for the intervention
compared with no intervention.
TABLE 21 Cost per patient screened thresholds excluding and including care costs for different clinical effect sizes
per patient, per general practice and for England as a whole
RD RR
Cost threshold per patient (£)
No care costs Care costs
Per patient
Per general
practice
England
(000s) Per patient
Per general
practice
England
(000s)
0.3 1.43 73 5282 212,688 87 6295 253,478
0.28 1.40 68 4920 198,121 82 5933 238,910
0.26 1.37 63 4559 183,553 77 5572 224,342
0.24 1.34 58 4197 168,985 72 5210 209,775
0.22 1.31 53 3835 154,418 67 4848 195,207
0.2 1.29 48 3473 139,850 63 4559 183,553
0.18 1.26 45 3256 131,109 57 4124 166,072
0.16 1.23 40 2894 116,542 52 3763 151,504
0.14 1.20 36 2605 104,887 46 3329 134,023
0.12 1.17 31 2243 90,320 40 2894 116,542
0.1 1.14 26 1881 75,752 34 2460 99,060
0.08 1.11 21 1520 61,184 27 1954 78,666
0.06 1.09 16 1158 46,617 21 1520 61,184
0.04 1.06 11 796 32,049 14 1013 40,790
0.02 1.03 5 362 14,568 7 507 20,395
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FIGURE 21 The maximum cost per-patient-screened threshold below which a hypothetical DRS uptake intervention
remains cost-effective compared with no intervention for a range of RD effect estimates for the intervention
compared with no intervention.
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Discussion
The first objective of the economic analysis was to identify the BCT and QI components that are most
likely to be cost-effective at established cost-effectiveness thresholds and are therefore worth prioritising in
further research. A second objective was to estimate the maximum cost per person with diabetes eligible
for screening that an intervention could have for a level of clinical effectiveness and still be considered
cost-effective.
Summary of findings
In the base case there was considerable uncertainty in the cost-effectiveness of the QI components.
The QI component most likely to be cost-effective at a societal willingness-to-pay threshold of £20,000
per QALY was patient education, which is perhaps the closest QI component to the most cost-effective
BCT components. The probabilities of being cost-effective at a societal willingness-to-pay threshold of £20,000
per QALY were higher for BCTs than for QI components. Patient-targeted ‘goal-setting (outcome)’, ‘feedback
on outcomes of behaviour’, ‘social support (unspecified)’ and ‘information about health consequences’
had extremely high probabilities of being cost-effective compared with interventions not containing this BCT.
For the HCP-targeted BCTs, ‘adding objects to the environment’ had a probability of being cost-effective of
> 0.9. The BCT components with the highest probabilities of being cost-effective were patient targeted. The
sensitivity analyses that had a significant effect on the results were varying the baseline probability of screening
uptake and reducing the frequency of screening. The change in the results was much more pronounced for
the BCT components than for the QI components. A lower baseline probability of DRS attendance increased
the probability of an intervention being cost-effective, whereas a higher baseline probability of DRS attendance
reduced the probability of an intervention being cost-effective. Reducing the frequency of screening also
increased the probability of an intervention being cost-effective.
The second objective was to estimate the cost threshold below which an intervention might be
cost-effective over a range of effectiveness estimates. For a RD of 0.2, the cost threshold was £63 per
patient or £4559 per general practice when including social care costs in the analysis.
Strengths, limitations and challenges
This economic analysis was concerned with estimating the cost-effectiveness of interventions designed to
increase DRS attendance. Long-term cost and health outcomes (valued using QALYs) were incorporated
using a published model to derive more useful estimates of the likelihood that QI and BCT components
are cost-effective and of the cost threshold below which an intervention may be cost-effective. A number
of assumptions were adopted within the Scanlon et al.224 model that we have not been able to review.
In addition, the model used in our work was not a perfect reproduction of the Scanlon et al.224 model as
simplifications were made. We relied on sensitivity analyses to test particularly significant changes to
the model. It is possible that there are uncertainties that have not been evaluated, such as uncertainty
associated with the outcomes of DRS attendance for different combinations of screening frequencies and
interventions to encourage DRS attendance.
Although the objectives of the economic analysis were to evaluate the likelihood that individual QI
components and BCTs are cost-effective, the interventions to increase DRS attendance that were studied
are complex interventions consisting of multiple QI components and BCTs. The evidence on the effectiveness
of the complex interventions was identified through a systematic review of the literature. The individual
treatment effects and marginal costs of each QI component and BCT were estimated using multivariable
meta-regressions. Although this is an appropriate method to estimate the individual effects, there is a
possibility of confounding and spurious results when conducting meta-regression. Furthermore, there was
heterogeneity in the study characteristics and most studies were not conducted in the UK, making firm
conclusions around the cost-effectiveness of specific combinations of BCTs and QI components in specific UK
populations difficult. Consequently, the economic analysis was limited to providing evidence on the likelihood
that individual QI components and BCTs could be cost-effective. The focus of this was solely to help prioritise
future research by focusing on QI components and BCTs that are most likely to be cost-effective when
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designing and studying interventions. It is possible that a complex intervention designed to incorporate a BCT
or QI component with a high probability of being cost-effective may need to include a BCT or QI component
that is less likely to be cost-effective.
Future research
This analysis suggests that future research should focus on designing and studying interventions consisting
of one or more of the following patient-targeted BCTs: ‘goal-setting (outcome)’, ‘feedback on outcomes of
behaviour’, ‘social support (unspecified)’ and ‘information about health consequences’. The HCP-targeted
BCT, ‘adding objects to the environment’, should also be considered. The interventions studied may also
include other BCTs.
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Chapter 7 Discussion and conclusions
Discussion
The preceding chapters report a synthesis of the available evidence on the effectiveness and cost-effectiveness
of interventions aiming to increase attendance for DRS. We have taken a global view of the evidence base and
provide a summary of the intervention components that are most likely to be effective and cost-effective for
improving DRS attendance. These interventions can be tailored and potentially applied to service models
worldwide. We highlight uncertainties and provide evidence for the design of future studies in terms of the
‘best bet’ for behavioural components of interventions that could be tested in future research and in which
patient groups.
To apply our findings to the UK NHS, we held a knowledge exchange event with key UK stakeholders
(see Appendix 2). The integrated findings are reported later in this chapter.
Based on evidence from randomised controlled trials, how effective are quality
improvement interventions for increasing diabetic retinopathy screening attendance?
(see Chapter 3)
We conducted a systematic review of the evidence from RCTs that investigated any QI intervention to improve
attendance for DRS. Interventions could be directed at patients with diabetes, HCPs, the health-care system or
any combination thereof. The primary outcome was attendance for one or more visits for DRS within a 2-year
period following randomisation. We included data from 66 studies (analysing data for 352,879 participants).
Fifty of the included studies (76%) were RCTs of general QI interventions that sought to improve a number
of diabetes quality indicators and 16 studies (24%) tested interventions that specifically targeted DRS.
The majority of studies were conducted in North America, with only three studies conducted in the UK.
The interventions were usually multifaceted, consisting of multiple QI components (e.g. ‘patient education’,
‘team changes’ and ‘audit and feedback’). We used two validated taxonomies to describe the content of the
interventions: a modified version of the taxonomy29 originally developed by the Cochrane EPOC Group43 to
provide a general description of the intervention and the BCTTv136 to describe the specific QI components
present in each intervention. Interventions were further described in terms of their component BCTs, which
provides a level of granularity that is better suited to describing the active ingredients of the interventions.
BCTs were coded using the BCTTv136 in terms of whether they targeted the patient, the HCP, or both.
Although our meta-analysis for the main comparison identified that the pooled effect estimate for studies
that specifically targeted DRS was larger (17% absolute increase in DRS attendance) than that in studies of
general QI interventions (12% increase), the difference between these subgroups was not statistically
significant. This is an important finding given the previously demonstrated effectiveness of general QI
interventions for the overall quality of diabetes care. For example, a systematic review of the effectiveness
of such interventions by members of the current review team (NMI, JMG),29 which incorporated 26 of the
trials included in the current review, found improvements in glycated haemoglobin (HbA1c), diastolic and
systolic blood pressure, low-density lipoprotein cholesterol and medication use and increased monitoring
for other diabetes complications, for example foot screening.
The pooled effect estimates for studies comparing a more intensive (stepped) intervention with a less
intensive intervention were smaller (5% increase in DRS attendance) than the pooled effect estimates for
the comparisons with non-specified usual care. In terms of health economic outcomes, there was too
much methodological variability in studies reporting comparative cost-effectiveness outcome measures to
make a judgement on the relative cost-effectiveness of QI interventions compared with each other or
with usual care. The effectiveness of interventions that included specific QI components or BCTs was also
calculated for level of resource use, as measured on an ordered ranking scale, to explore whether or not
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more resource-intense interventions were more likely to be effective. The results indicate that there is no
evidence of a clear relationship between effectiveness and intensity of resource use.
Sufficient studies were available to investigate the effectiveness of nine out of 12 QI components and
17 BCTs by subgroup analysis and meta-regression. All QI components analysed were associated with
significantly higher DRS attendance. Larger pooled effect estimates were found for interventions directed
at patients (promotion of self-management and patient education) or the organisation of the health
system [team changes (e.g. use of multidisciplinary teams or expansion of professional roles) and
introducing an electronic diabetes register]. All frequently used BCTs identified in at least 10 patient and/or
HCP intervention arms were similarly associated with higher DRS attendance. Higher effect estimates were
observed for the BCTs of ‘goal-setting (outcome)’ and ‘credible source’ (information on the importance of
the behaviour from individuals/organisations with expertise in the field) in interventions targeting patients
and for the BCTs of ‘restructuring the social environment’ (e.g. introducing diabetes link workers to
facilitate the behaviour) and ‘credible source’ (e.g. persuasive argument from a respected colleague) in
interventions targeting HCPs. Using univariate meta-regression we found evidence for larger effects in
studies with poorer baseline DRS attendance.
The review highlighted a number of gaps within the evidence base. No data were available to assess the
effectiveness of QI interventions to improve ongoing adherence to screening and limited data were
available to assess the relative effectiveness of interventions in particular population subgroups, for
example type 1 compared with type 2 diabetes and those of different ethnicities or socioeconomic status.
Although we were able to show that interventions containing particular BCTs have a greater likelihood of
success, given the multicomponent nature of interventions, it is likely that there is interaction with other
BCTs or that other effect modifiers in the intervention arms may also be having an impact on effectiveness.
The analysis conducted as part of this review did not attempt to evaluate the impact of individual BCTs in
isolation; however, this was evaluated as part of the exploratory analysis (reported in Chapter 6) to
determine the likely cost-effectiveness of interventions in which multivariate meta-regression was used.
This approach allows for more flexible modelling of arm-level covariates.
What are the theoretical determinants (e.g. barriers/enablers) of diabetic retinopathy
screening attendance? (see Chapter 4)
We aimed to clarify how QI interventions might work and gain an understanding of factors influencing
DRS attendance behaviour. This was achieved by identifying studies reporting primary data on barriers to
and enablers of DRS attendance from the perspectives of people with diabetes and HCPs and framing
these in terms of theoretical domains from the TDF (an integrated framework of behaviour change
theories) and the CFIR (a comprehensive listing of constructs thought to influence implementation).
We hypothesised that interventions that target these theoretical domains are more likely to be effective
at increasing screening attendance.
From the analysis we identified the TDF domains ‘environmental context and resources’, ‘social influences’,
‘knowledge’, ‘memory, attention and decision processes’, ‘beliefs about consequences’ and ‘emotions’ as
representing the most important factors potentially influencing screening attendance. We also identified
that the other eight TDF domains – ‘social/professional role and identity’, ‘beliefs about capabilities’,
‘goals’, ‘intentions’, ‘behavioural regulation’, ‘optimism’, ‘reinforcement’ and ‘skills’ – may have less
influence on screening behaviour.
These findings have two important implications for the design of effective interventions to promote DRS
attendance: (1) they identify which theoretical domains to target in future QI interventions and which
to avoid and (2) they can be used to assess the extent to which the active components (BCTs) identified
in existing QI interventions are actually targeting the theoretical domains that are important in
determining attendance.
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The studies in this review predominantly identified barriers and enablers from the perspective of patients
rather than the perspective of organisations or HCPs. Even the data from HCPs were mostly focused on
patient barriers. Therefore, the CFIR did not offer additional insights over and above those gained from
the TDF. Thematic synthesis within the TDF domains identified as being of high importance resulted
in the identification of specific content themes that may help to identify potential targets for future QI
interventions. There are four key recommendations based on these findings:
1. Reduce inconvenience to patients. Many of the barriers and enablers identified within the TDF domain
‘environmental context and resources’ relate to perceptions of convenience. Providing local screening
facilities, ‘one-stop shops’, flexible appointment systems, childcare facilities and transportation might all
be advantageous.
2. Increase awareness of the importance of DRS. HCP recommendations and information provision was
reported to be an enabler within the TDF domain ‘knowledge’. Furthermore, within the TDF domain
‘social influences’, use of local media and local community networks was identified as another potential
way to raise awareness.
3. Increase patients’ sense of comfort and support. A number of barriers were identified within the TDF
domains ‘emotions’, ‘social influences’ and ‘beliefs about consequences’ that highlight the need to
increase support for patients who struggle with issues such as communicating with HCPs, negative
emotions (e.g. fear), a lack of social support and a lack of trust in the HCP or system. These barriers
may be overcome by providing community-based clinics, ensuring that there is some social/cultural
compatibility between the patient and the HCP and the HCP showing compassion to the patient.
4. Improve message content. Within the TDF domains ‘memory, attention and decision processes’,
‘beliefs about consequences’ and ‘knowledge’ we found a number of barriers that relate to health
misconceptions. Many of the issues identified in this review, including those captured within
recommendations 2 and 3, can perhaps be addressed through improved message content. Messages
that highlight the asymptomatic nature of diabetic retinopathy, the safety of the screening procedure,
the benefits of early detection (e.g. providing piece of mind) and the potential negative consequences
if diabetic retinopathy is left unchecked are all potentially beneficial. Furthermore, messages that clarify
the differences between routine eye tests and DRS, that offer reminders to attend for screening and
which emphasise that DRS is a routine part of diabetes care could also be helpful.
The combination of deductive coding (informed by theoretical frameworks to guide barrier identification)
and inductive analysis (to allow more granular content themes, unanticipated findings and patient insights
to emerge) is a strength of this review. However, it is worth noting that the theoretical frameworks used in
this review are limited in as much as they do not specify relationships between domains and hence the
strength of the direct impact of barriers on behaviour is not known.
The majority of the studies included in this review were from North America. Additional UK studies are
needed from the perspective of both patients and HCPs. Ideally, such additional research would focus on
sampling the subgroups least likely to attend for screening.
Do the components of existing quality improvement interventions target the important
theoretical determinants of diabetic retinopathy screening attendance? (see Chapter 5)
We hypothesised that QI interventions to increase DRS attendance would be more effective if they
targeted the key barriers to/enablers of DRS attendance. To investigate this we integrated BCT components
identified in existing QI interventions (see Chapter 3) with the identified important theoretical determinants
of DRS attendance (see Chapter 4). Certain BCTs may be of greater or lesser relevance to addressing
barriers/enablers within a given theoretical domain (i.e. may be of higher or lower theoretical coherence).
We therefore examined the extent to which component BCTs in existing QI interventions are theoretically
coherent with domains representing key barriers to/enablers of DRS attendance. This was achieved by
applying published mapping tools that pair BCTs from taxonomies with domains from the TDF that experts
agree represent theoretically coherent pairings.
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We examined the extent of theoretical coherence for frequently used BCTs, identified in at least 10
intervention arms of existing QI interventions that target patients and/or HCPs (see Chapter 3). BCTs were
classified as having high theoretical coherence if at least one domain with which they were paired in
available mapping tools was classified as being important in the second review (see Chapter 4). Eight of
the ten frequently used BCTs targeting patients had high theoretical coherence: (1) ‘feedback on outcomes
(i.e. consequences) of behaviour (including biofeedback)’, (2) ‘credible source’ (i.e. persuasive argument
presented by a respected person), (3) ‘prompts and cues’, (4) ‘social support (unspecified)’, (5) ‘restructuring
the social environment’ (e.g. introducing a diabetes link worker), (6) ‘instruction on how to perform the
behaviour’ (i.e. provide further details about how to make, accept or attend a DRS appointment), (7) ‘social
support (practical)’ (e.g. assist with transport) and (8) ‘information about health consequences’ (e.g. provide
an information leaflet on how DRS assists with the early detection and treatment of retinopathy). All seven
frequently used BCTs targeting HCPs had high theoretical coherence: (1) ‘restructuring the social environment’,
(2) ‘credible source’, (3) ‘adding objects to the environment’ (e.g. reminder systems), (4) ‘social support
(practical)’, (5) ‘instruction on how to perform the behaviour’, (6) ‘prompts and cues’ and (7) ‘feedback on
outcomes of behaviour’ (including biofeedback).
Our findings thus suggest that the majority of components that are frequently used in existing QI
interventions do target the important determinants of DRS attendance. Although it was not possible to
formally examine the association between theoretical coherence and effectiveness, the observation that
nearly all frequently used BCTs associated with higher DRS attendance also had high theoretical coherence
supports the notion that interventions are more likely to be effective if they target the key determinants of
behaviour and behaviour change. Therefore, the design of future QI interventions, or the refinement of
existing QI interventions, may benefit from the inclusion of the aforementioned BCTs with demonstrated
effectiveness and high theoretical coherence.
However, existing QI interventions in this review were found to use a limited number of BCTs (median 4). Our
mapping investigation revealed that there are numerous ‘missed opportunities’ for intervention design, in the
form of BCTs that the mapping tools suggest are theoretically applicable to addressing the important domains
representing identified barriers to/enablers of DRS attendance, but which are not frequently used in existing QI
interventions. Missed opportunities for intervention design were identified for all six important TDF domains
identified in Chapter 4. These findings point to theoretically informed candidate BCTs that could be included
in future QI interventions to increase the targeting of the important domains to DRS attendance. This could
in turn increase intervention effectiveness and patient benefits. This is particularly true for the important
theoretical domain ‘emotions’. None of the five BCTs that are agreed to be theoretically coherent with this
domain was frequently identified in existing QI interventions (range 0–3 intervention arms). This suggests that
there is a critical need for future QI interventions to include components that target the emotional influences
on DRS attendance, such as the BCTs ‘reduce negative emotions’ (e.g. reassure the patient that any identified
retinal pathology will be treated without delay), ‘information on emotional consequences’ (e.g. mention that a
negative test will provide reassurance about eye health), ‘self-assessment of affective consequences’ (e.g. ask
the person with diabetes to record their feelings after the DRS examination), ‘social support (emotional)’
(e.g. ask a friend to comfort the person with diabetes) and ‘conserving mental resources’ (e.g. arrange a DRS
appointment at a time when the person with diabetes is less likely to be busy).
However, an important caveat to interpreting these findings concerns the applicability and validity of the
methods and mapping tools used to pair BCTs with theoretically coherent TDF domains. Although this
study is one of the first to provide an empirical test of the validity of available mapping tools, a number of
limitations and discrepancies were identified in the tools, suggesting a need for further research to refine
and expand these tools to enhance their validity and usability. The validity of any BCT and domain pairing
recommended in each mapping tool depends on the nature of the behaviour being investigated and what
intervention components are likely to be feasible, appropriate and acceptable to deliver in the context of
DRS attendance. Lastly, our methods and available data did not enable investigation of which component
BCTs may be more or less theoretically coherent for addressing barriers and enablers for different
subgroups of patients attending DRS. As future evidence emerges concerning which barriers/enablers are
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of greater importance to different subgroups, there is the potential to apply the present mapping methods
to develop more tailored interventions that include component BCTs that are theoretically coherent with
the determinants of DRS attendance for specific patient subgroups.
Which quality improvement interventions designed to increase diabetic retinopathy
screening attendance are most likely to be cost-effective and what are the potential
cost consequences? (see Chapter 6)
At a baseline probability of DRS attendance of 0.7 and when the maximum that society is willing to pay
for a QALY is £20,000, no QI components (coded using the modified EPOC Group taxonomy29) are likely
to be cost-effective (judged on a probability of > 0.7) compared with no QI intervention. When the
baseline probability of DRS attendance is decreased to 0.5, ‘team changes’ and ‘patient education’ have a
probability of being cost-effective of > 0.7.
The probabilities of being cost-effective at a societal willingness-to-pay threshold of £20,000 per QALY
were higher for BCTs (patient targeted or HCP targeted) than for QI components. Of the patient-targeted
BCTs, ‘goal-setting (outcome)’, ‘feedback on outcomes of behaviour’, ‘social support’ and ‘information
about health consequences’ had extremely high probabilities of being cost-effective compared with no
BCT intervention. Of the HCP-targeted BCTs, ‘adding objects to the environment’ (e.g. decision support or
monitoring tools such as diabetes passports) had a probability of being cost-effective of > 0.9. Nevertheless,
the BCT components with the highest probabilities of being cost-effective were patient targeted. Likewise,
the QI component with the highest probability of being cost-effective was ‘patient education’.
In sensitivity analyses, as the frequency of DRS was reduced, the cost-effectiveness of a BCT component
compared with no BCT intervention increased. When the screening interval was increased to 3 years,
all BCTs had a probability of cost-effectiveness of > 0.8 except for ‘instruction on how to perform the
behaviour’ targeted at both patients and HCPs, ‘credible source’ and ‘restructuring the social environment’
targeted at patients, and ‘instruction on how to perform the behaviour’ and ‘feedback on outcomes of
behaviour’ targeted at HCPs.
When the age of the cohort was reduced from 64 years (the base case) to 56 years then the BCT
components all became less cost-effective compared with no BCT intervention. However, for some BCTs,
such as ‘information about health consequences’ targeted at the patient, the change was very small
(the probability that this BCT is cost-effective remained at 0.998, which is extremely high).
The economic analysis utilised the best available effectiveness and resource use data to evaluate the
likelihood that individual QI and BCT components are cost-effective compared with no intervention and
with each other at willingness-to-pay thresholds for a QALY normally considered to be acceptable. Resource
use associated with the main intervention in each included study was recorded and valued so that both the
effects of the QI and BCT components on DRS attendance and resource use could be estimated. Data from
a recently published cost–utility model of screening frequency, conducted as part of a previous NIHR HTA
study,224 were used to model the long-term outcomes of screening attendance and non-attendance.
Interventions were assumed to target all people eligible for screening, that is, all people with diabetes.
It may be possible to target a subset of the eligible population who would benefit from encouragement
to attend screening. Included studies may have targeted different groups. This would require a baseline
probability of screening uptake specific to that population, an intervention effect estimate specific to that
population and cost estimates that account for a smaller targeted population. These data were not
available from this study.224
The economic analysis explores which individual BCTs and QI components are the most likely to be
cost-effective given the available evidence; it does not consider the cost-effectiveness of multicomponent
interventions. In reality, the interventions designed to encourage screening uptake are likely to be complex,
incorporating several BCTs or QI components. The results of the economic analysis are therefore less useful
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in informing which interventions to adopt but provide an indication of which QI and BCT components are
worth considering as a starting point in the design of a DRS attendance intervention.
The effectiveness evidence used in the economic model was derived from a multivariate meta-regression
with all of the QI components and BCTs included as explanatory variables. These analyses are essentially
based on observational data. The potential for the existence of uncontrolled confounding factors may
affect the power of the statistical model to predict outcomes in other studies and settings. Furthermore,
an additive model is assumed and the interaction effects between QI components and BCTs are unknown
and are not captured in the model. This statistical approach is different from the analysis conducted as
part of the phase 1 systematic review. The two approaches have different interpretations. The univariate
meta-regression analysis conducted as part of the phase 1 intervention review compared studies that
used multifaceted interventions that incorporate a particular QI/BCT component with studies using other
multifaceted interventions that do not contain that component. This analysis estimates the average effect
across a range of complex interventions. The additive (multivariate) model used in the economic analysis
estimates the effects of individual QI components by adjusting for the other components in the intervention.
There is far greater variation in the univariate model than in the multivariate model and some effects are
significantly different. For example, using a RD outcome variable, the patient-targeted BCT ‘restructuring the
social environment’ is ranked six out of 17 in the univariate analysis of BCTs with a coefficient of 0.051,
whereas it is ranked 17 out of 17 in the multivariate model with a coefficient of –0.19.
There is considerable heterogeneity in the data and most of the studies were not conducted in the UK;
therefore, it is difficult to make specific conclusions regarding people with diabetes in the UK. Consequently,
the economic analysis was limited to providing evidence on the likelihood that individual QI components
and BCTs are cost-effective to help prioritise future research by designing and studying interventions
based around the QI components and BCTs most likely to be cost-effective. It is possible that a complex
intervention designed to incorporate a BCT or QI component with a high probability of being cost-effective
may need to include a BCT or QI component that is less likely to be cost-effective. It may be possible to
develop an intervention based around a specific QI component or BCT that is more cost-effective than
indicated here; the cost thresholds below which an intervention may be cost-effective may be a guide to the
cost per patient of an intervention.
The evidence on the resources used to provide the QI/BCT components of interventions was based on an
ordered logistic regression with all of the QI components and BCTs included as explanatory variables.
A similar model was used to estimate the effectiveness of QI/BCT components and the same limitations
apply. With respect to resource use, the weights used were developed in an explicit fashion and care was
taken to check the scorings provided by the original raters. However, the resource use ordered rankings
were derived using a small sample of cost estimates based on the intervention descriptions. Uncertainty
associated with these cost estimates was not included in the analysis and further work could usefully be
undertaken to provide a wider sample of cost estimates to place a value on the resource use rankings.
Overall, the economic evaluation does have a number of limitations (described in more detail in Chapter 6),
primarily linked to the limitations of the evidence base. However, the economic analysis identified the
most promising BCT/QI components to take forward to enable further development of the evidence and
theory-based interventions to increase attendance for DRS.
Conclusions
The results of this study suggest that a number of interventions are likely to improve attendance for DRS.
We found that QI interventions targeted at those with diabetes, HCPs or the health-care system improve
attendance by 12% on average compared with usual care. Compared with usual care, QI interventions
aimed at improving the quality of diabetes care were as effective at improving attendance at DRS as those
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specifically targeting DRS attendance. There was some evidence to indicate that a larger effect size could
be anticipated in poor attenders.
Recommendations for practice and applicability to the UK setting
The findings suggest that, among interventions that target the patient, promotion of self-management
(provision of equipment or resources to promote self-management) and patient education (interventions
designed to promote greater understanding of diabetic retinopathy) are more likely to be effective at
increasing levels of DRS attendance. For interventions at a system or organisational level, team changes
(changes to the structure or organisation of the primary health-care team, e.g. adding a team member
or shared care, use of multidisciplinary teams or expansion or revision of professional roles) and the
establishment of an electronic diabetes registry (e.g. general electronic medical record system or electronic
tracking system for patients with diabetes) are associated with higher levels of DRS attendance.
Including behavioural interventions to support the uptake of DRS services could improve the uptake of DRS.
Such interventions include providing feedback on the consequences of attendance or non-attendance;
encouraging social (interpersonal) support to attend; providing more information on diabetic eye disease,
including information about the health consequences, and on the process of screening; introducing
reminder systems; and ensuring that patient information is provided by a credible source, such as respected
national clinical guidelines. These interventions can be delivered at a patient level and at the level of the
health system, including at the level of HCPs. We identified that these interventions are effective and are
also likely to target the important factors associated with attendance at DRS.
Considering cost-effectiveness and theoretical coherence (see Chapter 5), we have identified BCTs that could
be worthwhile for services with lower attendance levels. These are ‘feedback’ and ‘information about health
consequences’, for example providing information on diabetic retinopathy and the consequences and
benefits of DRS, explaining the difference between DRS and attendance for regular eye tests (e.g. enhanced
patient information sheets), introducing processes to facilitate social support to attend and improving the
screening environment [introducing processes to improve convenience for patients, e.g. online management/
booking systems or monitoring tools (e.g. diabetes passports)].
Interventions should be judged by their cost-effectiveness, but it is also useful to know the relative resource
implications that are likely to be associated with QI components and individual BCTs. The QI component
with the highest probability of being cost-effective was ‘patient education’, but in general QI components
were unlikely to be considered cost-effective. In terms of BCTs, among patient-targeted techniques,
‘problem-solving’, ‘goal-setting (outcome)’, ‘social support (practical)’ and ‘instruction on how to perform
the behaviour’ were associated with relatively high resource use; ‘feedback on outcomes of behaviour/
biofeedback’ and ‘restructuring the social environment’ were associated with moderately high resource
use; and ‘social support (unspecified)’, ‘information about health consequences’, ‘prompts/cues’ and
‘credible source’ were associated with relatively low resource use. Among the HCP-targeted BCTs, ‘social
support (practical)’, ‘prompts/cues’ and ‘restructuring the social environment’ were associated with
relatively high resource use; ‘instruction on how to perform the behaviour’ and ‘credible source’ were
associated with moderately high resource use; and ‘feedback on outcomes of behaviour/biofeedback’ and
‘adding objects to the environment’ were associated with relatively low resource use.
Implications for the UK NHS
In the UK, on average, 20% of those offered a DRS appointment fail to attend, with wide geographical
variations in screening uptake.20,23,24 Living in areas of high social deprivation, a younger age and having a
longer duration of diabetes are associated with lower attendance rates. Ethnicity is also an important
determinant of DRS attendance, with black, Asian and minority ethnic groups less likely to attend for
screening. How can attendance be improved for the missing 20%?
Integrating our findings to the specific context of the UK National Diabetic Eye Screening Programme,
during a knowledge exchange event (see Appendix 2), we agreed that interventions to increase the uptake
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of DRS should focus on low or non-attenders, especially those with multiple missed appointments, rather
than attempting to achieve 100% for all. Special consideration is needed of working people, people with
mental health issues, vulnerable groups including those on low incomes or those with special needs and
people with multiple conditions and thus competing demands on their time. It was noted that there is
great diversity across the UK and that initiatives should be tailored to local needs. The feasibility and ethical
issues around focusing on low attenders and vulnerable groups need to be explored in future research.
Based on the study findings on key determinants of attendance, potentially effective and likely cost-effective
interventions and the views of stakeholders, the following strategies could improve attendance at DRS.
l Patient-focused interventions: improve patient information regarding DRS to improve patients’
knowledge about the condition and the screening process, in particular the differences between a
regular eye test and a DRS appointment; work with other health professionals to use every potential
health-care visit to provide information about eye health; work closely with diabetes teams and patient
groups to review and update existing diabetes education programmes for both type 1 [Dose
Adjustment for Normal Eating (DAFNE)235] and type 2 (X-PERT Health236 and DESMOND237) diabetes
patients so that they include relevant content on eye health and visual loss and its relation to general
diabetes care; design and deliver media campaigns to ensure that the message is targeted and relevant
to people with diabetes; strategies could include components that target the emotional influences on
DRS attendance, which we identified as being under-represented in current interventions.
l Team changes: expand the role of retinal screeners so that they provide patients with information about
the findings at the time of screening and feed back to patients how the impact of these on vision can be
lessened; involve pharmacists to provide information, including a point of contact, to patients when they
attend a pharmacy for any diabetes-related medications or supplies; reassess and realise the importance
of the GP in terms of information provision and encouraging patients to attend for screening [GPs (and
general practice staff) are among the most trusted professions involved in patient care].
l Environment: restructure the screening setting, for example the use of ‘one-stop shops’, so that all
appointments related to diabetes occur in one place and during one patient visit; flexible timing of
appointments, including appointments outside normal working hours; provide reminders; enable
patients to self-book appointments, including the ability to cancel and reschedule; manage and update
existing electronic registers in terms of completeness both by fostering better relationships with other
health-care providers and through the use of health system intelligence such as electronic care records.
l There were no data on the effectiveness of financial incentives to encourage DRS attendance. The UK
stakeholder group proposed this as a possible intervention to improve uptake for those with a history
of poor attendance, especially in areas where socioeconomic deprivation is high and for those for
whom loss of income while attending appointments is a barrier. An abstract238 for a UK-based RCT
investigating the use of financial incentives to improve DRS attendance was identified, which did not
meet our inclusion criteria. This study has now reported in full.239
Recommendations for future research
The evidence synthesis identified interventions that could improve the uptake of DRS in different health
systems including in the context of a national DRS programme as in the UK. We have identified a number
of knowledge gaps that should be addressed by future research. We were unable to identify any RCTs that
evaluated the effectiveness of QI interventions for ongoing attendance for DRS. There has been considerable
debate on the optimal screening interval for diabetic retinopathy. A recent UK cost-effectiveness study
concluded that annual screening was not cost-effective and recommended the introduction of personalised
screening intervals.224 Nonetheless, periodic screening is essential to detect sight-threatening retinopathy and
future trials should be of a sufficient length to capture multiple screening episodes (e.g. over 5 years). The
longer timescale would also allow other important longer-term outcomes to be evaluated, for example the
effect of an intervention on the progression of diabetic retinopathy and the impact on visual function.
Although the included studies provided data on a large number of participants, the characteristics of the
study participants were often poorly described and data were not provided on the relative effectiveness of
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interventions in population subgroups. These data are important to illuminate health inequities. It was
disappointing that < 5% of the included trials were conducted in the UK.
Through exploratory analyses of evidence from both randomised and non-randomised studies, we identified
BCTs that we would regard as ‘best bets’ for evaluation in future RCTs, based on their theoretical coherence
with identified barriers and enablers and their clinical effectiveness and cost-effectiveness. However, the
complexity of the QI interventions made it difficult to completely disentangle the BCT components to identify
the optimal combination of BCT components that would lead to a greater likelihood of DRS attendance.
Future research could test particular BCTs and BCT combinations in adequately powered studies using
head-to-head comparisons, including those theoretically coherent BCTs identified in our mapping exercise
that have not been commonly used in previous RCTs. Particular gaps occur in relation to BCT components
that target the emotional barriers to and enablers of screening attendance.
Research priorities
The evidence from this study can be used to inform the development of a future UK-based RCT evaluating
QI interventions that use BCTs to improve DRS attendance. The design of the RCT can be framed using the
population, intervention, comparator, outcome(s) and time frame (PICOT) format. Based on our findings
we suggest the following design.
l Population: the evidence on cost-effectiveness suggests that the focus should be on groups with a low
baseline level of attendance.
l Intervention: given that we identified that general (untargeted) QI interventions were statistically
indistinguishable from targeted interventions in terms of improving DRS attendance, both types of
intervention could be considered. Ideally, the intervention should be multifaceted and utilise BCTs that
target the patient (e.g. ‘feedback on outcomes of behaviour’, ‘social support’ or ‘information about
health consequences’) or the HCP (e.g. ‘adding objects to the environment’, such as decision support
or monitoring tools such as diabetes passports). A number of additional BCTs that are not included in
existing interventions may also be relevant to addressing important theoretical determinants of
screening attendance. In particular, there are gaps around the inclusion of intervention components to
address the emotional barriers to and enablers of screening attendance (such as anxiety about the
experience of the screening test itself or fear of the screening result and sight loss).
l Comparator: the findings of our evidence synthesis were based on comparisons with usual care. However,
in included studies, usual care was either poorly described or not described at all. It is therefore important
that usual care is specified in sufficient detail so that BCTs present in the control arm can be identified.
l Outcome(s): the primary outcome should be attendance for DRS. Secondary outcomes could include
other quality indicators of diabetes care, for example HbA1c levels, screening for other microvascular
complications, ongoing attendance for DRS and the likely cost-effectiveness of the intervention.
l Time frame: the study should be of a sufficient duration to capture ongoing attendance for DRS.
The duration of the trial should be a minimum of 24 months (and ideally longer).
Before conducting the proposed RCT we recommend the following programme of research.
l Identify the population with a low rate of DRS attendance: review electronic systems for recording DRS
programme attendance, audit attendance records and analyse the characteristics of non-attenders,
with special emphasis on those who have missed several appointments as these patients might be at
the highest risk for visual loss.
l Conduct a qualitative exploration of the key determinants of attendance in subgroups of low attendees
to inform the design of meaningful interventions, with attention to ethical issues around identifying
subgroups and targeting interventions to these subgroups.
l Conduct empirical research to evaluate the validity of mapping tools to facilitate the selection of
theoretically coherent BCTs (i.e. those that target important barriers and enablers) for future research
and intervention design.
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Appendix 1 Stakeholder advisory group
membership
We established a representative stakeholder reference group to capture the views of end-users of theoutputs from this project. The group includes experts in diabetes care, representatives of the four
nations screening programme, patients, practitioners, professional organisations and policy-makers.
The following individuals were involved in the stakeholder reference group:
l Professor Peter Scanlon (Clinical Director, Diabetic Retinopathy Screening Programme, England)
l Dr Deborah Broadbent (Director of Diabetic Eye Screening, Liverpool)
l Mr Andrew Crowder (Head of Diabetic Retinopathy Screening Wales)
l Dr Caroline Styles (Lead Clinician for Diabetic Retinopathy Screening Scotland)
l Mr Raymond Curran (Assistant Director, Directorate of Integrated Care, Health & Social Care Board,
Northern Ireland)
l Grant Duncan (British Association of Retinal Screening)
l Simon O’Neil (Diabetes UK)
l Helen Lee (RNIB)
l Gozie Joe Adigwe (Eye Health Equalities Officer, RNIB Scotland).
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Appendix 2 Report of the knowledge
exchange event
Attendees
Facilitators
l Katherine Cowan (James Lind Alliance).
l Michael Bowen (College of Optometrists).
l Sally Crowe (Crowe Associates Ltd).
Research team members
l John G Lawrenson (City, University of London).
l Jill J Francis (City, University of London City).
l Fabiana Lorencatto (City, University of London).
l Ella Graham-Rowe (City, University of London).
l Tunde Peto (Queen’s University Belfast).
l Stephen Rice (Newcastle University).
l Luke Vale (Newcastle University).
l Patricia Aluko (Newcastle University).
l Jennifer M Burr (University of St Andrews).
Stakeholder members
l Andrew Crowder (Diabetes UK, Wales).
l Gozie Joe Adigwe (RNIB, Scotland).
l Simon O’Neill (Diabetes UK).
l Caroline Styles (NHS Fife, Scotland).
l Helen Lee (RNIB, London).
l David Owens (Diabetes Research Unit Cymru, Wales).
l Phil Gardner (British Association of Retinal Screening).
l Natalie Owen (Department of Health).
l David Keene (NHS City & Hackney Clinical Commissioning Group).
l David Parkins (College of Optometrists).
Patients
l Vivienne Ruddock, Sheila Burston, Melissa Louis and David Beck.
Summary of stakeholder discussions
1. Introduction
This event on the 12 January 2017 brought together the research team, people with diabetes and
experience of DRS, health professionals and service providers with an interest in DRS to hear about the
early results of this project. It was also an opportunity for participants to discuss their experiences of
barriers/enablers that affect regular DRS attendance and members of the research team were particularly
interested in hearing ideas about how low rates of attendance could be improved.
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The research team presented summaries of the methods and results in the morning, generating interesting
questions and debate, and three smaller discussion groups were facilitated in the afternoon to reflect more
deeply on the project results and capture ideas and feedback from participants. Discussion groups were
facilitated by independent (from the research team) consultants, who took notes, and all discussions were
recorded for accuracy.
This report describes these conversations and draws together the themes across the discussion groups,
using the notes and recordings as primary material. In the final section the implications of the findings for
UK screening programmes are summarised and suggestions are made for future research.
2. Discussion in groups
2.1 Group 1
The presentations were well received by this group who, although a little disappointed by the small
percentage of UK studies represented in the review, thought that there was plenty of material to consider
further. They suggested focusing on a UK breakdown of national/regional differences in barriers to and
enablers of DRS attendance; learning from local initiatives; and subgroup analysis of young people, those
from black and ethnic minority groups, those who travel extensively and stay for long periods in other
countries (e.g. Pakistan) and those with mental health issues as well as diabetes, who may be less likely to
attend screening. The overall message of the study that ‘doing something is better than doing nothing’ is
an important finding and the group was encouraged by this.
Focusing more on the group experience, agreed effective initiatives to improve DRS screening included
cleaning up patient databases, for example removing deceased people, ensuring that appointment slots
are allocated to current patients and using text message reminders. Other ideas for which experience and/or
the evidence base were less convincing included financial incentives to encourage attendance, sharing
the accumulated cost of non-attendance and getting people to sign a promise/pledge to attend screening.
It was noted that many of the interventions described in the study are behavioural or psychological
interventions yet there is a dearth of psychologists in the diabetes field to help deliver change. It was also
considered a challenge to comment on whether or not the initiatives in the study would work in the UK
given the diversity of the populations and health-care settings. One of the challenges in this area is the
diverse audiences to engage with in DRS, especially those at risk of low attendance. Another concern
identified by this group was that successful initiatives piloted by the charity sector may not be taken up by
mainstream screening services.
There was agreement in group 1 that there is varied understanding about DRS and confusion between
DRS and routine eye tests and ophthalmology appointments. Added to this is the ‘duty of candour’, that
is, telling people that screening is not foolproof may make them decide not to bother, communication
problems such as actionable messages hidden in the text of patient information or being hard to find,
overuse of medical language and the use of too-small print.
Group 1 identified those with potential low levels of attendance as working people, especially men, people
from black and ethnic minority groups, people with type 1 diabetes, especially those struggling with the
transition from paediatric to adult services, and people who do not have any symptoms and who may
think that they do not have a problem. Vulnerable groups, people on low incomes and those with multiple
conditions also need more attention with regard to screening. For example, people with many conditions
may deprioritise DRS if the symptoms of other conditions are worse than the symptoms of diabetes.
Concerns were expressed that an increase in the prevalence of type 2 diabetes has led to more people
with type 1 diabetes being missed for screening.
Experience in the group suggested that rural screening attendance rates can be higher than rates in urban
areas because people appreciate the efforts made to reach out to them. However, mobile units are not
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always popular as they can be cramped and people often have to wait in their cars as the waiting area is
so small. People also value the opportunity to use quality services that are more easily available in
urban areas.
Group members thought that screening behaviour may be reinforced when people get into good habits
within the first 3 months of a diabetes diagnosis. However, the evidence on this was questioned – is there
is a correlation between attendance and behaviour within the first 3 months of diagnosis? The ways in
which people might take responsibility for their health information were discussed, with an example
given of Scotland’s ‘my diabetes my way’ portal where people can register and manage their diabetes
appointments and processes. Other experiences of increasing screening rates included the choice of clinic
day (Fridays are better than Mondays) and holding themed clinics (London).
This group had suggestions for further research, which are included in Section 3 of this report, but in
summary their interests were in working more with groups with low attendance rates to understand their
contexts and dynamics and whether or not existing BCTs could be adapted for these groups.
2.2 Group 2
This group noted and appreciated the scope and scale of the work, especially given the large numbers of
participants from relatively few studies. Study team members clarified that the model used gave relatively
lower weighting to the results from studies with smaller numbers of participants. Those in group 2 also
wanted to know how the different UK health system might correlate with the findings, which were
somewhat dominated by US study data. The differences between the US and UK systems in health care
and screening were questioned and discussed, with the group concluding that the principal difference was
in the importance given to the cost of attending screening, which was less of a barrier in the UK studies.
Screening intervals and changes to these in the USA and UK were also discussed: although a 2-year
interval is common in the USA, a 1-year interval has been standard in the UK (by consensus since
inception), although the group noted that this was starting to vary in different areas. The other barriers/
enablers were similarly ranked across UK and US studies in the review.
A discussion about the weighting of themes in the review analysis led to input from the research team that
the frequency with which a theme occurred in the data may be a useful indicator of the importance/
impact of a theme overall, but is not the only indicator. Clinicians in the group pointed out that the risk
profile for someone who had attended two consecutive screening appointments and received a R0 result
(no sign of retinopathy) were statistically at very low risk of sight-threatening complications. This was likely
to drive the trend towards customised recall intervals in the UK and the extension of general intervals
towards 2 years. Related to this are the risks associated with informing a patient who has attended
screening that they are in the low-risk category; specifically, there was interest in whether this would make
individuals more or less likely to attend future screening appointments.
There was interest in whether or not the review indicated that there would be potential cost savings to the
system by moving from 1- to 2-year screening intervals. Clinicians and screening managers in the group
noted that the growth in absolute numbers of people living with diabetes on the registers for screening
meant that such an extension was more about delaying slightly the impact of these additional new costs
than actually saving money overall (in their view). The collective view was that the interventions described
in the review would probably work in the UK even if the majority of the data that supported them were
US based.
Moving to interventions in the charity sector there is work under way to explore the benefits of central
systems, in which a single appointment at a specialist centre could address all health screening needs for
people with diabetes. Researchers in the group pointed out that one study had explored the impact of
screening locations being geographically as close as possible to patients’ homes and the review shows that
accessibility remains a key potential barrier to screening uptake.
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The role of GPs in retinopathy screening might be less focused (not reminding patients to attend DRS or
checking with them whether or not they have attended) as they consider the screening programme to be
responsible for handling DRS. It was noted that information technology issues may prevent GPs from accessing
DRS systems or that databases are not set up to notify GPs of patients’ attendance/non-attendance. In some
areas it was possible for GPs to access screening system images for their patients using a code, but the group
experience was that few used this facility. The exception seemed to be in practices in which there was at least
one GP with a special interest in diabetes. A group member cited a review of general practices with low
did-not-attend (DNA) rates for their patients within the screening system, which found that all of these
practices had a diabetes special interest GP.149 It was noted that there was an undersupply of diabetes
specialist nurses.
Patient members of this group felt that a GP (or other trusted professional) might carry more weight than
a letter from the screening programme: ‘your GP is the one who knows you best of all’. Other barriers
from the patient perspective were having multiple appointments at different locations and the times of
available appointments (in this group the preference was for early morning, evening and weekend
appointments), but these might differ by age and across other groups.
Those with direct experience of the DRS programme felt that older women were most likely to attend for
screening. A low-attendance/at-risk group was teenagers as they approached adulthood, and then as
young adults, in other words people in transition. Group members agreed that it was easy to fall through
gaps in the system during this transition period. Although in theory it might seem easy for university
students to attend for screening, the reality was that changing GP registration presented challenges.
In terms of looking to the future and the implications of the study, the group discussed that few of the
studies had focused on interventions that sought to influence emotional and social factors that play a
role (barriers or enablers) in DRS screening and that more understanding about these would be helpful.
The role of large-scale national (television) advertising campaigns to increase public awareness of the
importance of screening was discussed, in terms of both effectiveness and cost. It is vital that evidence
from the project should inform practice and support the provision of better information for clinicians,
commissioners and patients. Finally, there was consensus that this event had been very useful, with
opportunities for patients, clinicians and representatives of stakeholder bodies to get together and talk.
This should be encouraged on a regular basis!
2.3 Group 3
This group welcomed the research and enjoyed the presentations of the results so far. They welcomed a
focus on the 20% or so who are low or non-attendees for DRS, rather than the ‘worried well’. People
were surprised that some of the interventions had a limited impact and wanted to make the distinction
between an outcome of attending screening and an outcome of improved diabetes eye health. The
researchers added that some of the studies in the review were underpowered and were thus limited and
unable to show significant outcomes. The setting of the studies (and differences in screening contexts and
costs, for example) in the USA and UK was also noted and group members were interested in whether
or not there was merit in isolating UK results. The researchers in this group suggested that it would be
beneficial to extract the UK studies and explore any differences in results to try and determine what might
be more likely to work in the UK.
People with diabetes in transition were identified as being potentially worth targeting for extra attention
with regard to DRS, including young people and children with diabetes growing into adults; older people
with diabetes (and multiple other conditions) becoming more in need of carers and who may not be able
to self-manage; and people with diabetes with dependents. People with diabetes are not static and move
through periods in their life in which there may be differing barriers and enablers affecting their awareness
of screening and their motivation and ability to be screened.
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Related to this theme was one of ‘getting lost in the DRS system’ and patients finding it hard to distinguish
between eye health hospital appointments (diabetes related or other), DRS and more routine eye tests at
high street opticians. Group members described how it can be easy to lose the thread, especially when in
transition (child to adult services) or if your care is spread over different health systems and geographical
areas. One person’s experience in the group showed how a gap of just 18 months in DRS communications
resulted in significant grading changes to R3, that is, requiring closer surveillance or treatment. Other
examples of change that might result in patients being ‘lost’ were changing GP or another significant
health-care practitioner, moving appointments from fixed to variable appointments or significantly
changing appointment times, losing the connection to a proactive system (automatic appointments and
reminders) and reliance on patients making appointments.
Group members described (sometimes first hand) how people with diabetes find the most ‘suitable way’
to be screened that fits into their schedule and lifestyle (especially if they are economically active and in
the 20–40 years age range). For example, they may experience a perfectly good interaction with DRS
provided by an accredited high street optician at a convenient time on a Saturday morning, where they
are ‘screened and get instant feedback and a picture to look at’, with this being a good user experience.
What seems to be at the heart of this high street optician experience is convenience, a good feedback
loop (compared with the DRS programme, in which patients receive a letter and are not allowed to see
their images) and the opportunity to have a useful conversation with the operative. Group members
reflected on what the DRS programme could learn from this, for example if there are ways that screeners
in the DRS programme can indicate positive or negative changes (since the last visit) without disclosing the
grading. Also, interestingly, there was a suggestion that silence on the part of the screener may be
misconstrued by those with diabetes as ‘bad news’, especially if they are not aware that it is not the
screener’s role to provide feedback. There was a sense that it is important to make every health contact
count for people with diabetes and DRS was no exception to this and could be improved.
This group was concerned that people with diabetes may think that a regular ‘sight test’ provided by a
high street optician is DRS when it is not and that they may not self-identify as not attending for the
screening programme. What they are losing is a very specific and important screening and grading
opportunity and the potential to be referred for further investigation if needed. The group felt that patient
information should include simple information about how these services differ and why it is vital to
undergo DRS in addition to other ophthalmic and eye health appointments.
The group discussed (at a researcher’s behest) the intervention and enabler of goal-setting – some group
members had positive experiences of identifying screening as an attainable goal in self-care, but there was
also caution about handling goal-setting holistically in a person-centred way, with an embedded feedback
loop to assess progress.
Another potential intervention/enabler for DRS was the ‘credible source’ intervention. The group wondered
if the DRS programme should make more of the enhanced training and skill of screeners and graders in
the programme in the patient information (without being disrespectful to other providers). Pharmacists are
also trusted professionals and potentially enablers for DRS. An example of placing business cards with
information about DRS into bags of diabetic equipment was described and cited as a low-cost intervention
(it was not clear if this was evaluated formally, but the group member was positive about the intervention).
The challenges of clinic times and locations were also discussed. One group member described the significant
extra work carried out by a general practice, which went to great lengths to physically get patients to attend
for DRS but which did not yield a higher turnout. This led the group to think about wider systems change –
what can be changed and how? Some would value greater user design of screening services (e.g. for patients
who cannot physically get to the screening equipment because of physical limitations) and exploring
opportunities for more ‘one-stop shop’ or polyclinic approaches. Accessibility was identified as a major issue
by the service providers in this group. Also, one group member had experience of a ‘learning health system’
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approach to looking at data that are collected from both people with diabetes and diabetic services, so that
more useful information can be obtained.
For the future this group felt that it had identified different ideas for further research (which are described in
Section 3) but were concerned that outputs take the form of practical recommendations and interventions
that are feasible to explore in the NHS and take account of where the DRS programme is and where it
could be, that is, what can be changed and what cannot be changed.
3. Themes across the three discussion groups
3.1 Responses to the overall project results
l Noted and appreciated the scope and scale of the work and appreciated that it is easier to identify
barriers than solutions.
l Welcomed the positive overall message that doing something is better than usual care or doing
nothing; the differences between the USA and UK (as major sources of relevant data) merit further
exploration, especially for the different contexts of screening and cost issues.
l Interest from all groups in extracting the UK data from the overall data set to better understand what
might work best in the UK.
l The possible mismatch between the predominance of behavioural and psychological interventions
and the prevalence of practitioners (specialist nurses and psychologists) able to provide support for
these interventions.
l Clarity about what really matters about outcomes of DRS – increase in overall uptake of DRS, increase
in uptake of DRS in groups identified as being low or non-attendees (who may have more severe
retinal disease), overall eye health outcomes and user experiences of DRS were suggestions.
l Interest from all groups on focusing interventions and associated research in groups who are more
likely to have low levels of attendance or to be non-attendees.
3.2 Views from diabetic retinopathy screening and other service providers
l All groups identified with, and some had experienced, initiatives that were covered in
the presentations.
l These ranged from relatively simple approaches, for example cleaning up screening databases and the
use of automatic appointment bookings, to more complex initiatives, such as GPs targeting those with
low levels of attendance (driven by targets?).
l It’s not just about interventions to and for patients, but also about systems rethink, for example
customised recall intervals depending on the level of perceived risk to patients (those with two
consecutive visits and no sign of retinopathy moving to 2-year recall) or more user input to the design
of screening programmes.
l Service providers felt (and in many cases patient representatives agreed) that there were
misunderstandings about what the DRS programme is for and about. Examples were described in
which people did not realise what sort of appointment they had had and in which there was confusion
between DRS and other ophthalmology appointments and checks.
l These issues may be a contributing factor as to why people seem to get lost in the system of DRS, with
several examples shared in which a thread of continuity was lost or a system failed to identify people
for screening.
l The introduction of different screening intervals according to risk was discussed in two groups
(evidence base for current consensus) and some participants wondered if this was within the scope of
this project. These groups were interested in the effect of duty of candour, that is, informing a patient
that he or she is in a low-risk category, and if this makes individuals more or less likely to attend future
screening appointments.
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3.3 Do the initiatives to improve attendance work in the UK?
l Groups found this a little hard to answer because of the diversity of the populations and health-care
settings in which DRS operates, for example the different cost issues and also the different recall times
for screening. They thought that extracting the UK-specific data might add additional learning.
l However, there was consensus that there are no reasons to think that any of the interventions
described would not work in the UK.
l Better evaluation of public campaigns to increase screening uptake was a theme in two groups who
were aware of poorly evaluated projects, often funded as the result of spare financial reserves.
l Two groups agreed that having access to screening close to home (or work) was important, but there
were differing views about the value of mobile services in rural areas.
3.4 Perspectives of the charitable sector
l There was some evidence across the groups of charity-funded initiatives to improve attendance, such as
single appointments at specialist centres and appointments ‘close to home’ projects.
l All groups cited accessibility of screening as a key barrier to screening uptake.
l The groups seemed to think that there was a low prevalence of charity-led projects and patient events
aimed at promoting attendance for DRS, and underfunding of such projects and events.
l When there had been successful initiatives, these struggled to be implemented into mainstream
services, which was discouraging.
3.5 Patient perspectives
l There were consistent descriptions across groups of how people with diabetes mix up DRS with routine
eye tests and maybe do not realise the important longer-term preventative nature of
screening programmes.
l The growth of the diabetic population means that there are more diverse populations with different
levels of health literacy and additional vulnerabilities and needs, adding to the complexity involved in
achieving high attendance rates for DRS.
l The role of GPs was discussed at some length in all groups – for patients this can be a crucial
relationship and when people change GP for whatever reason they can get lost in the system. This also
applies to secondary services.
l The role and effectiveness of diabetes special interest GPs and nurses were cited as important and as
having an impact on screening uptake. However, examples were described of GPs who do not think
that DRS is their responsibility, with the associated challenge of nudging them into changing
their outlook.
l Groups suggested that screeners and graders also belong to the group of people who have influence
and credibility, but patients may not know this – is this something that could be communicated more
clearly as a benefit of attending DRS?
l The timing of DRS appointments was also a topic of conversation – all agreed that it was highly
personal and contextual, but that there must be choice.
l Two groups identified the concept of patients transitioning in life and that this can present an ideal
opportunity to get ‘lost in the system’, for example moving from child to adolescent services or when
patients have too much going on in life (children, care of elderly) to prioritise their
retinopathy screening.
l Reviewing existing diabetes education programmes (e.g. DAFNE235) for DRS information and prompts
was suggested.
l Conversations about risk–benefit with regard to DRS choices seem important to improve attendance
for those with low rates of attendance or who are non-attendees.
l Communication channels about DRS also seem important – exploring social media approaches, for
example with younger people with diabetes, was suggested. It was acknowledged that the NHS is slow
to change on these fronts.
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3.6 Views on low or non-attendees
l The following list draws from the discussions in all three groups about people with diabetes with low
levels of attendance at screening or who do not attend for screening. The discussion groups felt that
these groups merit special attention and interventions that may deliver rich returns in terms of
preventing retinopathy disease (those mentioned most frequently are listed first):
1. teenagers and young people who find it hard to think in the long term, which is what a screening
programme is all about.
2. vulnerable people and those living on the margins of society, for example those who are homeless,
those in temporary accommodation, people in prison and offending units – all of these people
move about a lot and may get lost in the DRS system
3. people with diabetes who are asymptomatic and who do not perceive themselves to be ‘at risk’
of retinopathy
4. ‘highest-risk’ patients (people with type 1 diabetes)
5. linked to number 3, people with diabetes who are in denial about the long-term effects of
the disease
6. young adults who are not really engaged with their condition, until they get pregnant and
have dependents
7. people who use multiple health systems in different geographical areas
8. some black and ethnic minority groups
9. people who move for their work or who travel long distances for work and have very little time
during the week
10. people who leave the country for long periods of time to see family (e.g. Pakistan)
11. people who change from 1- to 2-year checks – will they remember?
12. people in residential health and social care accommodation
13. elderly living on their own, especially without family members living close by
14. people on low incomes.
l All groups strongly identified patients with multiple conditions requiring many appointments as being
particularly at risk of low or no attendance, not least because of the practical challenges of attending
multiple appointments at different locations, but also because of the difficulties of assimilating all of
the important information and advice provided when attending DRS.
l There was also a sense that emotional issues surrounding choices and decisions about DRS among
people with diabetes, particularly vulnerable groups, is an area in which there could be more
understanding – patients do not make information-led and rational choices, it is more complex
than that.
l There was a low awareness of particular initiatives to target vulnerable groups specifically for DRS
attendance, but group 1 suggested that other successful programmes be explored and adapted for
DRS target groups. A paper co-authored by Raj Bhopal was mentioned on adapting BCTs for ethnic
minority groups.240
3.7 Future directions
l Focusing on the profiles of those with probable low levels of attendance or non-attendees was a clear
message from this workshop – is it just DRS that they do not attend or do they show other similar
behaviours and what does that tell us?
l Can we rank the ‘best gain’ (in terms of reducing retinal disease) populations and put these central to
the strategy, rather than achieving 100% screening attendance?
l The focus on transitions in the discussions in all groups suggests that there may be a link between
these transitional life events and attendance patterns – do they change over the life course and how
can they be anticipated in reference to retinopathy screening?
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l All groups talked about the importance and role of behavioural and psychological (and knowledge
underpinning this) interventions for screening; listening to the discussion recordings you can hear
people with screening experience talking about the role of emotions and fears in choices.
l There were compelling descriptions of systems failures and reflection on how much can be changed to
target those who are less likely to attend rather than increasing the attendance of the ‘worried well’.
l Groups were interested in the role of public awareness campaigns and patient information about
screening (e.g. what it is and is not, role of specialist screeners and graders as distinct from that of
opticians) and whether or not the results from the project could be used to inform the development of
effective public (television, other media) awareness and information campaigns.
l Groups agreed that vital evidence from the project should be used to inform practice and support the
provision of better information for clinicians and commissioners, as well as patients.
l Other sectors interested in diabetes and DRS should be targeted for project dissemination (e.g. optician
services, industry, charities).
l Outputs from the project needed to be disseminated beyond scientific journals and include less
academic channels.
l Outputs from the project should encompass practical recommendations and interventions that are
feasible in the NHS.
l Outputs and recommendations from the work also need to be realistic and take account of where the
current DRS programme is, and where it could be, that is, what can be changed and what cannot
be changed.
l Final conversations highlighted how useful the event had been to participants in terms of providing an
opportunity for patients, clinicians and representatives of stakeholder bodies to get together and talk.
This should be encouraged on a regular basis.
4. Summary
4.1 What are the implications of the findings for UK screening programmes?
l There is much to be learnt from the current project for the DRS programme. There is also a need for
DRS to contribute to the further building of UK-based knowledge about screening uptake.
l There is consensus from this event that a better understanding of, and focusing more on, groups of
people with diabetes who have low levels of attendance at screening or who do not attend for
screening might yield better outcomes for the programme than attempting to achieve 100% attendance.
l Consider existing evaluated health promotion/screening programmes targeting people in the described
groups with low levels of attendance or non-attendance and assess whether or not they can be
adapted for DRS interventions.
l Sector charities and campaigning organisations should consider targeting new campaigns at key groups
at risk of low or no attendance.
l Related to this is a review of DRS patient information, given the apparent misunderstandings and
confusion about what DRS is and is not.
l Communication channels for the provision of DRS information is also an important feature for the
programme to consider.
l The role of staff in primary care in DRS uptake seems important – understanding fully the potential of
GPs, specialist nurses and pharmacists to achieve improved uptake of DRS seems a sensible output of
this process.
l The project findings should be translated into formats that make them accessible to patients/public and
which renders them easily used by screening service commissioners/managers and clinicians seeking to
optimise local services and implement interventions to improve attendance.
l Given the usefulness of this event, screening programme leaders, clinicians involved in service delivery to
those referred on from screening, patients and sector organisations with an interest in this area could
meet annually to provide a forum for sharing good practice, discussing challenges and assessing progress.
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4.2 What are the suggestions for future research?
UK perspectives
l A UK breakdown of national/regional differences in barriers to and enablers of DRS attendance.
l Gathering and learning from local initiatives (which may not be published and which may not have
been studied in RCTs).
Focusing on low or non-attendees
l Subgroup analysis of those with low levels of attendance and/or non-attendees: are they the same
people as those not attending other appointments? Or is this just about their eyes?
Diabetes-related factors
l Depression is common in diabetes and people often do not have a formal mental health diagnosis, but
their behaviours are affected – it was felt that this did not come out of the review and therefore is an
important research gap.
l Do attendance patterns change over the life course and what life events and transitions affect the
uptake of screening?
l Do attendance data differ between people with type 1 diabetes and people with type 2 diabetes, that
is, do those who have had diabetes since childhood or from a younger age develop better habits
regarding managing and monitoring their diabetes and therefore are (a) at less risk generally and
(b) more likely to be using screening services?
Behavioural interventions
l Is there a correlation between attendance and behaviour within the first 3 months of diagnosis?
Do people who do attend start attending early on?
l Is there profit in reviewing BCTs for ethnic minority groups more generally and then applying this to
DRS specifically?
l More research to inform our understanding about social and emotional factors affecting screening
uptake would be helpful.
The screening experience
l How important and effective is the discussion at the time of screening? From patient discussions it
seems that it is important and can affect subsequent screening attendance.
l Related to this are the risks associated with informing a patient who has attended screening that he or
she is in the low-risk category; specifically, there was interest in whether this would make individuals
more or less likely to attend future screening appointments.
l What can the DRS programme learn from the popular ‘high-street optician’ user experience, specifically
in terms of accessibility (high street, choice of times and days), operator feedback and the provision of
printed images that initiate conversation, feedback and advice.
Screening uptake campaigns
l More robust evaluation of screening campaigns and investigating the reasons behind the common
barrier of raising screening attendance above 80%.
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Appendix 3 Example search strategy for the
phase 1 systematic review: interventions to increase
attendance for diabetic retinopathy screening
MEDLINE (via Ovid)
1. randomized controlled trial.pt.
2. random$.ab,ti.
3. placebo.ab,ti.
4. db.’s.
5. trial.ab,ti.
6. (group or groups).ab,ti.
7. or/1-6
8. exp animals/
9. exp humans/
10. 8 not (8 and 9)
11. 7 not 10
12. exp Randomized Controlled Trials as Topic/
13. 11 or 12
14. exp Diabetes Mellitus/
15. exp Diabetes Complications/
16. exp Diabetic Retinopathy/
17. ((diabet$ or proliferative or non-proliferative) adj4 retinopath$).tw.
18. diabetic retinopathy.kw.
19. (diabet$ adj3 (eye$ or vision or visual$ or sight$)).tw.
20. (retinopath$ adj3 (eye$ or vision or visual$ or sight$)).tw.
21. (DR adj3 (eye$ or vision or visual$ or sight$)).tw.
22. or/14-21
23. exp Mass Screening/
24. exp Vision Tests/
25. exp Telemedicine/
26. exp Photography/
27. exp Ophthalmoscopes/
28. exp Ophthalmoscopy/
29. (ophthalmoscop$ or fundoscop$ or funduscop$).ti.
30. ((exam$ or photo$ or imag$) adj3 fundus).tw.
31. (photography or retinography).tw.
32. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 camera).tw.
33. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 imag$).tw.
34. screen$.tw.
35. ((eye$ or retina$ or ophthalm$) adj4 exam$).tw.
36. ((eye or vision or retinopathy or ophthalmic) adj4 test$).tw.
37. ((eye$ or retina$ or ophthalm$) adj4 visit$).tw.
38. Office Visits/
39. (telemedicine$ or telemonitor$ or telescreen$ or telehealth or teleophthalmology).tw.
40. or/23-39
41. ‘Quality of Health Care’/
42. Quality Improvement/
43. Delivery of Health Care/
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44. Delivery of Health Care, Integrated/
45. service delivery.tw.
46. decision making.tw.
47. (consensus adj3 (process$ or discuss)).tw.
48. stakeholder$.tw.
49. Quality Control/
50. Total Quality Management/
51. Quality Indicators, Health Care/
52. Quality Assurance, Health Care/
53. quality assurance.tw.
54. (quality adj2 improv$).tw.
55. total quality.tw.
56. continuous quality.tw.
57. quality management.tw.
58. (organisation$ adj3 cultur$).tw.
59. Disease Management/
60. Program Evaluation/
61. ((provider$ or program$) adj3 (monitor$ or evaluate$ or modif$ or practice)).tw.
62. (implement$ adj3 (improve$ or change$ or effort$ or issue$ or impede$ or glossary or tool$ or
innovation$ or outcome$ or driv$ or examin$ or reexamin$ or scale$ or strateg$ or advis$ or
expert$)).tw.
63. (need$ adj3 assess$).tw.
64. ((education$ or learn$) adj5 (continu$ or material$ or meeting or collaborat$)).tw.
65. exp Medical audit/
66. (audit or feedback or compliance or adherence or training or innovation).ti.
67. (guideline$ adj3 (clinical or practice or implement$ or promot$)).tw.
68. exp Health Services Accessibility/
69. (outreach adj2 (service$ or visit$)).tw.
70. (intervention$ adj3 (no or usual or routine or target$ or tailor$ or mediat$)).tw.
71. usual care.tw.
72. exp Reminder Systems/
73. remind$.tw.
74. (improve$ adj3 (attend$ or visit$ or intervention$ or adhere$)).tw.
75. (increas$ adj3 (attend$ or visit$ or intervention$ or adhere$)).tw.
76. (appointment$ adj3 (miss$ or fail$ or remind$ or follow up)).tw.
77. Telephone/
78. telephone.tw.
79. Cell Phones/
80. Mobile Applications/
81. Remote Consultation/
82. (m-health or e-health or g-health or u-health).tw.
83. (phone$ adj1 (smart or cell)).tw.
84. (smartphone$ or cellphone$).tw.
85. (hand adj1 held device$).tw.
86. (mobile adj2 (health or healthcare or phone$ or device$ or monitor$ or comput$ or app or apps
or application)).tw.
87. Internet/
88. Social Networking/
89. (email$ or text$ or message$).tw.
90. (letter or mail or mailed or print$ or brochure$ or newsletter$).tw.
91. Primary Health Care/
92. General Practitioners/ or Physicians, Family/ or Physicians, Primary Care/
93. Primary Prevention/
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94. Preventive Health Services/
95. Community Health Services/
96. Community Health Nursing/
97. Health Services, Indigenous/
98. Rural Health Services/
99. Mobile Health Units/
100. (Ophthalmologist$ or Optometrist$ or Optician$ or Orthopist$ or Refractionists).tw.
101. ((Ophthalmic or eye) adj3 (surgeon$ or nurse$ or technician$ or officer$ or assistant$ or staff$)).tw.
102. Physician’s Practice Patterns/
103. Professional Practice/
104. (professional adj3 (practice or develop$ or educat)).tw.
105. Education, Medical, Continuing/
106. exp nurses/
107. Specialties, Nursing/
108. Nurse’s Role/
109. Education, Nursing, Continuing/
110. (nurse or nurses).tw.
111. Pharmacists/
112. pharmacist$.tw.
113. ((role or roles) adj3 expan$).tw.
114. (task$ adj3 shift$).tw.
115. exp Medical Records Systems, Computerized/
116. Management Information Systems/
117. Database Management Systems/
118. Computer Systems/
119. Point-of-Care Systems/
120. Hospital Information Systems/
121. ((health or healthcare) adj4 (record or management system$)).tw.
122. (decision adj5 support).ti.
123. Economics/
124. ‘costs and cost analysis’/
125. Cost allocation/
126. Cost-benefit analysis/
127. Cost control/
128. Cost savings/
129. Cost of illness/
130. Cost sharing/
131. ‘deductibles and coinsurance’/
132. Medical savings accounts/
133. Health care costs/
134. Direct service costs/
135. Drug costs/
136. Employer health costs/
137. Hospital costs/
138. Health expenditures/
139. Capital expenditures/
140. Value of life/
141. exp economics, hospital/
142. exp economics, medical/
143. Economics, nursing/
144. Economics, pharmaceutical/
145. exp ‘fees and charges’/
146. exp budgets/
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147. (low adj cost).mp.
148. (high adj cost).mp.
149. (health?care adj cost$).mp.
150. (fiscal or funding or financial or finance).tw.
151. (cost adj estimate$).mp.
152. (cost adj variable).mp.
153. (unit adj cost$).mp.
154. (economic$ or pharmacoeconomic$ or price$ or pricing).tw.
155. Uncompensated Care/
156. Reimbursement Mechanisms/
157. Reimbursement, Incentive/
158. (insurance adj3 (health$ or scheme$)).tw.
159. (financial or economic or pay or payment or copayment or paid or fee or fees or monetary or money
or cash or incentiv$ or disincentiv$).tw.
160. or/41-159
161. exp Patient Acceptance of health Care/
162. exp Attitude to Health/
163. exp Health Behavior/
164. (barrier$ or obstacle$ or facilitat$ or enable$).tw.
165. (uptake or takeup or attend$ or accept$ or adhere$ or attitude$ or participat$ or facilitat$ or utilisat$
or utilizat$).tw.
166. (complie$ or comply or compliance$ or noncompliance$ or non compliance$).tw.
167. (encourag$ or discourage$ or reluctan$ or nonrespon$ or non respon$ or refuse$).tw.
168. (non-attend$ or non attend$ or dropout or drop out or apath$).tw.
169. Health Education/
170. exp Patient Education as Topic/
171. exp Health Promotion/
172. exp Counseling/
173. ‘Attitude of Health Personnel’/
174. (health adj2 (promotion$ or knowledge or belief$)).tw.
175. (educat$ adj2 (intervention$ or information or material or leaflet)).tw.
176. Socioeconomic Factors/
177. exp Poverty/
178. Social Class/
179. Educational Status/
180. ((school or education$) adj3 (status or level$ or attain$ or achieve$)).tw.
181. Employment/
182. Healthcare Disparities/
183. Health Status Disparities/
184. exp Medically Underserved Area/
185. Rural Population/
186. Urban Population/
187. exp Ethnic Groups/
188. Minority Groups/
189. Vulnerable Populations/
190. ((health$ or social$ or racial$ or ethnic$) adj5 (inequalit$ or inequit$ or disparit$ or equit$ or
disadvantage$ or depriv$)).tw.
191. (disadvant$ or marginali$ or underserved or under served or impoverish$ or minorit$ or racial$ or
ethnic$).tw.
192. or/161-191
193. 160 or 192
194. 13 and 22 and 40 and 193
195. (ranibizumab or bevacizumab or avastin or aflibercept).ti.
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196. (cataract$ or intraocular or glaucoma$ or phaco$ or photocoagulat$ or photodynamic or laser$ or
vitrectom$).ti.
197. (macula$ adj2 (degener$ or oedema or edema)).ti.
198. nerve fiber layer.ti.
199. (coronary or cardiac or cardio$ or heart or myocardia$ or artery or aneurysm or atrial or
echocardiography or hypertension or hypotension or stroke or pulmonary or COPD or lung$ or organ
$ or smoking).ti.
200. (pregnan$ or gestational or neonat$ or perinatal or maternal or trimester or congenital or ovary or
breast$).ti.
201. (kidney or liver or cirrhosis or renal or hepatitis or dialysis or pancrea$ or gastric or gastrectom$ or
surg$ or duoden$).ti.
202. (blood glucose or blood pressure or ketoacidosis or hypoglycemi$ or rosiglitazone).ti.
203. (lipid$ or lipase$ or statin$ or hypercholesterolemia or microalbumin$ or albumin$ or platlet$ or
plasma$ or hemoglobin$ or haemochromat$ or arterial).ti.
204. (cancer$ or carcinoma$ or neoplas$ or adenoma$ or metformin$).ti.
205. (urin$ or incontinence or bladder or constipat$ or bowel$ or faecal or colorectal or colon$).ti.
206. (gene$ or genotype$ or genome$ or genomic or phenotyp$ or biomarker$ or polymorphism$ or
interleukin$).ti.
207. (cell$ or molecular or assay).ti.
208. (cystic or fibrosis or CF or tuberculosis or TB or lupus).ti.
209. (neuropath$ or nephropath$ or prematurity).ti.
210. ($arthritis or steroid$ or osteoporosis or atherosclerosis or sclerosis).ti.
211. (apnea or sleep or limb or oral$ or celiac or coeliac or skin or MRSA or anesthesia or vitamin or HIV
or testosterone or erectile or schizophren$ or bipolar or antipsychotic$ or psychotic$).ti.
212. prevalence.ti.
213. or/195-212
214. 194 not 213
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Appendix 4 Modified Effective Practice and
Organisation of Care Group taxonomy of quality
improvement intervention components
QI component Description
QI components targeting health-care systems
Case management Any system for co-ordinating diagnosis, treatment or routine management of patients
(e.g. arrangement for referrals, follow-up of test results) by a person or multidisciplinary
team in collaboration with, or supplementary to, the primary care clinician
Team changes Changes to the structure or organisation of the primary health-care team (e.g. adding a
team member or shared care, use of multidisciplinary teams or expansion or revision of
professional roles)
Electronic patient registry General electronic medical record system or electronic tracking system for patients with
diabetes
Facilitated relay of information
to clinicians
Clinical information collected from patients and transmitted to clinicians by means other
than the existing medical record
Continuous QI Interventions explicitly identified as involving the techniques of continuous QI, total
quality management or any iterative process for assessing quality problems, developing
solutions to those problems, testing their effects and then reassessing the need for
further action
QI components targeting HCPs
Audit and feedback Summary of the clinical performance of health care delivered by an individual clinician or
clinic over a specified period, which is then transmitted back to the clinician (e.g. the
percentage of a clinician’s patients who underwent dilated eye examinations with a
specified frequency)
Clinician education Interventions designed to promote increased understanding of principles guiding clinical
care or awareness of specific recommendations for a target disorder or population of
patients
Clinician reminders Paper-based or electronic systems intended to prompt a health professional to recall
patient-specific information or carry out a specific task
Financial incentives Interventions with positive or negative financial incentives directed at providers (e.g.
linked to adherence to some process of care or achievement of some target outcome).
This strategy also includes positive or negative financial incentives directed at patients
QI components targeting patients
Education of patients Interventions designed to promote greater understanding of a target disorder or to
teach specific prevention or treatment strategies or provide specific in-person education
Promotion of self-management Provision of equipment or access to resources to promote self-management
Reminder systems Any effort (e.g. postcards or telephone calls) made to remind patients about upcoming
appointments or important aspects of self-care
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Appendix 5 Behaviour change techniques used in
included studies (Behaviour Change Technique
Taxonomy version 1)
Grouping and BCT Description
Goals and planning
Goal-setting (behaviour) Set or agree on a goal defined in terms of the behaviour to be achieved
Problem-solving Analyse, or prompt the person to analyse, factors influencing the behaviour and
generate or select strategies that include overcoming barriers and/or increasing
facilitators
Goal-setting (outcome) Set or agree on a goal defined in terms of a positive outcome of wanted behaviour
Action-planning Prompt detailed planning of performance of the behaviour. Context may be
environmental (physical or social) or internal (physical, emotional or cognitive)
Review behaviour goals Review behaviour goal(s) jointly with the person and consider modifying goal(s) or the
behaviour change strategy in light of achievements
Discrepancy between current
behaviour and goals
Draw attention to discrepancies between a person’s current behaviour (in terms of the
form, frequency, duration or intensity of that behaviour) and the person’s previously set
outcome goals, behavioural goals or action plans
Review outcome goals Review outcome goal(s) jointly with the person and consider modifying goal(s) in light of
achievements. This may lead to resetting the same goal, a small change in that goal or
setting a new goal instead of, or in addition to, the first goal
Behavioural contract Create a written specification of the behaviour to be performed, agreed on by the
person and witnessed by another
Commitment Ask the person to affirm or reaffirm statements indicating commitment to change the
behaviour
Feedback and monitoring
Monitoring of behaviour by
others without feedback
Observe or record behaviour with the person’s knowledge as part of a behaviour
change strategy
Feedback on behaviour Monitor and provide informative or evaluative feedback on performance of the
behaviour (e.g. form, frequency, duration, intensity)
Self-monitoring of behaviour Establish a method for the person to monitor and record their behaviour(s) as part of a
behaviour change strategy
Self-monitoring of outcomes of
behaviour
Establish a method for the person to monitor and record the outcome(s) of their
behaviour as part of a behaviour change strategy
Monitoring of outcomes of
behaviour by others without
feedback
Observe or record outcomes of behaviour with the person’s knowledge as part of a
behaviour change strategy
Feedback on outcomes of
behaviour/biofeedback
Monitor and provide feedback on the outcome of performance of the behaviour
Social support
Social support (unspecified) Advise on, arrange or provide social support (e.g. from friends, relatives, colleagues,
’buddies’ or staff) or non-contingent praise or reward for performance of the behaviour.
Includes encouragement and counselling, but only when it is directed at the behaviour
Social support (practical) Advise on, arrange or provide practical help (e.g. from friends, relatives, colleagues,
‘buddies’ or staff) for performance of the behaviour
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Grouping and BCT Description
Shaping knowledge
Instruction on how to perform
the behaviour
Advise or agree on how to perform the behaviour
Natural consequences
Information about health
consequences
Provide information (e.g. written, verbal, visual) about the health consequences of
performing the behaviour
Salience of consequences Use methods specifically designed to emphasise the consequences of performing the
behaviour with the aim of making them more memorable
Information about social and
environmental consequences
Provide information (e.g. written, verbal, visual) about the social and environmental
consequences of performing the behaviour
Information about emotional
consequences
Provide information (e.g. written, verbal, visual) about the emotional consequences of
performing the behaviour
Comparison of behaviour
Demonstration of the
behaviour
Provide an observable sample of the performance of the behaviour, directly in person or
indirectly (e.g. film, pictures), for the person to aspire to or imitate
Social comparison Draw attention to others’ performance to allow comparison with the person’s own
performance
Information about others’
approval
Provide information about what other people think about the behaviour. The
information clarifies whether others will like, approve of or disapprove of what the
person is doing or will do
Associations
Prompts/cues Introduce or define an environmental or a social stimulus with the purpose of prompting
or cueing the behaviour. The prompt or cue would normally occur at the time or place
of the performance
Reduce prompts/cues Withdraw gradually prompts to perform the behaviour
Repetition and substitution
Behavioural practice/rehearsal Prompt practice or rehearsal of the performance of the behaviour one or more times in
a context or at a time when the performance may not be necessary, to increase habit
and skill
Graded tasks Set easy-to-perform tasks, making them increasingly difficult but achievable, until the
behaviour is performed
Comparison of outcomes
Credible source Present verbal or visual communication from a credible source in favour of or against the
behaviour
Reward and threat
Material incentive (behaviour) Inform the person that money, vouchers or other valued objects will be delivered if and
only if there has been effort and/or progress in performing the behaviour
Social reward Arrange a verbal or non-verbal reward if and only if there has been effort and/or
progress in performing the behaviour
Non-specific reward Inform the person that a reward will be delivered if and only if there has been effort
and/or progress in performing the behaviour
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Grouping and BCT Description
Antecedents
Restructuring the physical
environment
Change, or advise to change, the physical environment to facilitate performance of the
wanted behaviour or create barriers to performance of the unwanted behaviour (other
than prompts/cues, rewards and punishments)
Restructuring the social
environment
Change, or advise to change, the social environment to facilitate performance of the
wanted behaviour or create barriers to performance of the unwanted behaviour (other
than prompts/cues, rewards and punishments)
Adding objects to the
environment
Add objects to the environment to facilitate performance of the behaviour
Scheduled consequences
Behaviour cost Arrange for withdrawal of something valued if and only if an unwanted behaviour is
performed
Self-belief
Verbal persuasion about
capability
Tell the person that they can successfully perform the wanted behaviour, arguing
against self-doubts and asserting that they can and will succeed
Focus on past success Advise the person to think about or list previous successes in performing the behaviour
(or parts of it)
Reproduced from Michie et al.36 This article is published under license to BioMed Central Ltd. This is an Open Access article
distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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Appendix 6 Summary of reported costs and
resources needed to deliver interventions
QI component Study
DRS or
GQI
Estimated costs of resources
utilised Resources utilised
Promotion of
self-management
Davis 2011;124
n= 85 patients
GQI Staff cost per person = £625.25,
costs of the other resources
used = £476.35 over 12 months,
direct cost per person = £1102
13 sessions (three individual
and 10 group session)
consisting of 15 minutes
with nurses and 4 hours
with a health educator per
person
Wagner 2001;105
n= 14 clinics,
n= 278 patients
GQI Not reported 1-hour group session with
relevant health professional
every 3–6 months
Team changes Frei 2014;69
n= 15 practices,
n= 164 patients
GQI Not reported 6-day training for nurses,
two 4-hour workshops for
physicians and nurses
Wagner 2001;105
n= 14 clinics,
n= 278 patients
GQI Not reported 1-hour group session with
relevant health professional
every 3–6 months
Litaker 2003;87
n= 79 patients
GQI Mean personnel costs for the
intervention per month per
patient = £130.15, total additional
personnel costs = £10,281.97
Average of 180 minutes
with patients
Case
management
Krein 2004;85 n= 123 GQI Not reported 2 days of training for case
managers, 20 hours per
week spent with patients.
Quarterly profiling for
24 months and subsequently
every 6 months
Patient
education
Prezio 2014;96 n= 90 GQI Physician = £48.76 per hour,
community health worker =
£12.91 per hour, cost of
intervention over 20 years =
£3646.10 per patient
Seven sessions per patients,
1 hour of physician
supervision for health
workers
Pizzi 2015;117
n= 117 for mailed
intervention, n= 120
for telephone
intervention
DRS Staff time for 120 patients for
telephone intervention over
1 month= £501.13, staff time
for 117 patients for mailed
intervention over 1 month=
£173.17; £85.24 per hour for
physician, £29.32 per hour for
health services manager, £16.72
per hour for medical assistant;
materials for telephone
intervention= £30.25, materials for
mailed intervention= £135.46;
total cost of intervention= £577.64
for 120 patients in telephone
intervention group over 1 month,
£335.48 for 117 patients in mailed
intervention group over 1 month;
total cost per patient when
appointment is made and kept:
telephone intervention= £9.47,
mailed intervention= £8.83
1 hour of supervision
for every 20 hours of
intervention delivered,
two 1-hour meetings with
medical assistants, health
services manager and
ophthalmologist
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QI component Study
DRS or
GQI
Estimated costs of resources
utilised Resources utilised
Adair 2013;59 n= 930 GQI Care guide cost for 120 patients=
£375,917 at the rate of £11.77
per hour over 1 year, cost of two
supervisory nurses= £85,847.24,
training cost= £2228.99, cost of
modular furniture and equipment
for 12 stations= £79,422.81; total
cost= £463,993; total cost of
intervention per patient= £326
12 care guides, 2 weeks of
training, two supervisory
nurses, five visits on average
to clinics, four contacts with
patients, furniture and
modular equipment
McCall 2011;89
n= approximately
20,000
GQI Not reported Not reported
Clancy 2007;62 n= 96 GQI Deposit fee for group visit= £13.40
per visit, £160.60 for 12 visits
Monthly meeting for a year
for 2 hours, including one
primary care internal
medicine physician and one
registered nurse per visit,
training for physicians and
nurses, 3 hours of training
for clinic staff
Schechter 2008;125
n= 305 for telephone
intervention, n= 298
for print intervention
DRS Health educator = £14,890.83,
training and supervision =
£2756.44, telephone
charges = £679.67 for
305 patients, printing and
mailing = £465.99 for
298 patients
Average of 3.2 calls
for about 20 minutes
+ 5-minute call for
preparation per patient
over 6 months; 20 hours
of training, 1 hour of
supervision by a diabetes
nurse educator, telephone
calls
Electronic
patient register
Eccles 2007;67
n= 30 practices,
n= 1674 patients
GQI Developing the guidelines=
£10,208, software development=
£12,519.36, educational
activities= £2148.11, additional
cost of running the system=
£9964.46; annual cost per
patient= £68.21
Cost of guideline and
software development,
average of two follow-up
contacts
Patient
reminders
Schechter 2008;125
n= 305 for telephone
intervention, n= 298
for print intervention
DRS Health educator = £14,890.83,
training and supervision =
£2756.44, telephone charges =
£679.67 for 305 patients,
printing and mailing = £465.99
for 298 patients
Average of 3.2 calls
for about 20 minutes
+ 5-minute call for
preparation per patient
over 6 months; 20 hours
of training, 1 hour of
supervision by a diabetes
nurse educator, telephone
calls
Pizzi 2015;117
n= 117 for mailed
intervention, n= 120
for telephone
intervention
DRS Staff time for 120 patients for
telephone intervention over
1 month = £501.13, staff time
for 117 patients for mailed
intervention over 1 month =
£173.17; £85.24 per hour for
physician, £29.32 per hour
for health services manager,
£16.72 per hour for medical
assistant; materials for telephone
intervention = £30.25, materials
for mailed intervention=
£135.46; total cost of
intervention = £577.64 for 120
1 hour of supervision
for every 20 hours of
intervention delivered,
two 1-hour meetings with
medical assistants, health
services manager and
ophthalmologist
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QI component Study
DRS or
GQI
Estimated costs of resources
utilised Resources utilised
patients in telephone intervention
group over 1 month, £335.48
for 117 patients in mailed
intervention group over 1 month
Audit and
feedback
Frijling 2002;70
n= 62 clusters,
n= 703 patients
GQI Clinical decision making per
practice = £341.51
80 hours of training for
facilitator, 15 1-hour visits to
the practice clinic, 3 hours of
GP time for implementation
of feedback
Clinician
reminders
Litaker 2003;87
n= 79 patients
GQI Mean personnel costs for the
intervention per month
= £130.15, total additional
personnel costs = £10,281.97
Average of 180 minutes with
patients over 12 months
Continuous QIs Piette 2001;95 n= 146 GQI Approximately £14–24 per year
for automated calls
13 nurses spending an
average of 3.8 hours per
patient, 15 automated calls
GQI, general quality improvement.
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Appendix 7 Theoretical Domains Framework:
definitions and examples
TDF domain and definition Examples related to diabetic retinopathy
Knowledge: awareness of the existence of
something
l In the context of this study, knowledge of the condition/scientific
rationale could relate to the patient’s knowledge of:
¢ diabetes, diabetic retinopathy and the link between the two
¢ knowledge about rationale for screening and frequency
of screening
¢ knowledge about the procedure and potential treatments
l Knowledge may be both correct and incorrect but must relate/link
to attendance
Skills: ability or proficiency acquired through
practice
l In the context of this study, skills/competence of the patient
may include:
¢ diabetes self-management training and education (including
about the DRS procedure and the importance of regular
attendance)
l Skills may be both present and absent
Social/professional role and identity: a
coherent set of behaviours and displayed
personal qualities of an individual in a social or
work setting
l In the context of this study, professional role may relate to the extent
that HCPs feel that providing DRS, education, prompts to attend
screening, recommendations and appointment setting is part of their
professional role
l Personal identity may relate to how a patient identifies with:
¢ their illness (diabetes)
¢ their view of a typical person who attends/does not
attend screening
Beliefs about capabilities: acceptance of the
truth/reality about or validity of an ability,
talent or facility that a person can put to
constructive use
l In the context of this study, beliefs about capabilities relate to a
patient’s judgements on their ability to attend screening, including
beliefs about their:
¢ physical/mental ability or confidence to make a screening
appointment and/or attend a screening appointment
Optimism: confidence that things will happen
for the best or that desired goals will be
attained
l In the context of this study, optimism related to a patient’s
judgement regarding:
¢ their susceptibility to diabetes-related problems, specifically
diabetic retinopathy
l This includes optimism, pessimism and unrealistic optimism
Beliefs about consequences: acceptance of the
truth/reality about or validity of outcomes of a
behaviour in a given situation
l In the context of this study, beliefs about consequences related to a
patient’s judgements on:
¢ the purpose, value and effectiveness of screening
¢ negative/positive outcomes of screening
Reinforcement: increasing the probability of
a response by arranging a dependent
relationship, or contingency, between the
response and a given stimulus
l In the context of this study, reinforcements relate to a patient’s
judgements on:
¢ receiving a reward/incentive for attending screening
¢ receiving a punishment for not attending screening
Intentions: conscious decision to perform a
behaviour or a resolve to act in a certain way
l In the context of this study, intentions relate to a patient’s
statements on:
¢ their intention to attend/not attend screening
¢ their intention to continue to attend/stop attending screening
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TDF domain and definition Examples related to diabetic retinopathy
Goals: mental representation of outcomes or
end states that an individual wants to achieve
l In the context of this study, goals relate to a patient’s statements on:
¢ the goals that they wish to achieve from attending screening
(e.g. preserve/protect vision)
¢ competing goals (goals that might conflict with
screening attendance)
Memory, attention and decision processes:
ability to retain information, focus selectively
on aspects of the environment and choose
between two or more alternatives
l In the context of this study, memory, attention and decision
processes relate to a patient’s statements on:
¢ their ability to remember to make/attend a
screening appointment
¢ how they decide whether to attend or not
¢ feeling overwhelmed with diabetes/multiple appointments or
other life circumstances
Environmental context and resources: any
circumstances of a person’s situation or
environment that discourages or encourages
the development of skills and abilities,
independence, social competence and
adaptive behaviour
l In the context of this study, environmental context and resources
relate to a patient’s perceptions of the:
¢ time that they have to attend
¢ financial resources that they have to attend
¢ accessibility of the screening service
¢ resources available within the screening service, hospital, clinic
l This can include the absence or presence of resources
Social influences: interpersonal processes that
can cause an individual to change their
thoughts, feelings or behaviours
l In the context of this study, social influences relate to a patient’s
statements on the influence of others on screening
attendance, including:
¢ the presence/absence of support from friends/family
¢ the trust in/respect for HCPs or belief in their authority
¢ past experiences with HCPs
¢ community groups/wider society
Emotion: a complex reaction pattern involving
experiential, behavioural and physiological
elements, by which the individual attempts to
deal with a personally significant matter or
event
l In the context of this study, emotions relate to a patient’s statements
on their emotional reaction/state in relation to:
¢ attending a screening attendance
¢ a potential diagnosis following a screening appointment
¢ loss of vision/sight
l This could also include expressions by or emotions of the HCP
Behavioural regulation: anything aimed at
managing or changing objectively observed or
measured actions
l In the context of this study, behavioural regulation relates to the
patients’ or HCPs’ statements about steps taken to provide or use:
¢ techniques/processes to remember/remind patients to attend
screening appointments
¢ techniques/processes to ensure that patients attend screening
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Appendix 8 Consolidated Framework for
Implementation Research: constructs and descriptions
CFIR construct Description
Intervention characteristics
Intervention source Perception of key stakeholders about whether the intervention is externally or internally
developed
Evidence strength and quality Stakeholders’ perceptions of the quality and validity of evidence supporting the belief that
the intervention will have the desired outcomes
Relative advantage Stakeholders’ perceptions of the advantages of implementing the intervention compared
with an alternative solution
Adaptability The degree to which an intervention can be adapted, tailored, refined or reinvented to
meet local needs
Trialability The ability to test the intervention on a small scale in the organisation and to be able to
reverse the course (undo implementation) if warranted
Complexity The perceived difficulty of implementation of an intervention, reflected by the duration,
scope, radicalness, disruptiveness, centrality and intricacy and number of steps required to
implement it
Design quality and packaging Perceived excellence in how the intervention is bundled, presented and assembled
Cost Cost of the intervention and costs associated with implementing the intervention,
including investment, supply and opportunity costs
Outer setting
Patient needs and resources The extent to which patient needs, as well as barriers to and facilitators of meeting those
needs, are accurately known and prioritised by the organisation
Cosmopolitanism The degree to which an organisation is networked with other external organisations
Peer pressure Mimetic or competitive pressure to implement an intervention, typically because most or
other key peer or competing organisations have already implemented or are in a bid for a
competitive edge
External policy and incentives A broad construct that includes external strategies to spread interventions, including policy
and regulations (governmental or other central entity), external mandates, recommendations
and guidelines, pay for performance, collaborative and public or benchmark reporting
Inner setting
Structural characteristics The social architecture, age, maturity and size of an organisation
Networks and
communications
The nature and quality of webs of social networks and the nature and quality of formal
and informal communication within an organisation
Culture Norms, values and basic assumptions of a given organisation
Implementation climate The absorptive capacity for change, shared receptivity of involved individuals to an
intervention and extent to which use of the intervention will be rewarded, supported and
expected within the organisation
Tension for change The degree to which stakeholders perceive the current situation to be intolerable or
needing change
Compatibility The degree of tangible fit between meaning and values attached to the intervention by
involved individuals, how those align with individuals’ own norms, values and perceived
risks and needs and how the intervention fits with existing workflows and systems
Relative priority Individuals’ shared perceptions of the importance of implementation within the organisation
Organisation incentives and
rewards
Extrinsic incentives such as goal-sharing awards, performance reviews, promotions and
raises in salary and less tangible incentives such as increased stature or respect
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CFIR construct Description
Goals and feedback The degree to which goals are clearly communicated, acted on and fed back to staff and
alignment of that feedback with goals
Learning climate A climate in which leaders express their own fallibility and need for team members’
assistance and input; team members feel that they are essential, valued and
knowledgeable partners in the change process; individuals feel psychologically safe to try
new methods; and there is sufficient time and space for reflective thinking and evaluation
Readiness for implementation Tangible and immediate indicators of organisation commitment to its decision to
implement an intervention
Leadership engagement Commitment, involvement and accountability of leaders and managers with regard to
implementation
Available resources The level of resources dedicated for implementation and ongoing operations, including
money, training, education, physical space and time
Access to knowledge and
information
Ease of access to digestible information and knowledge about the intervention and how
to incorporate it into work tasks
Characteristics of individuals
Knowledge of beliefs about
the intervention
Individuals’ attitudes towards and value placed on the intervention as well as familiarity
with facts, truths and principles related to the intervention
Self-efficacy Individuals’ belief in their own capabilities to execute the course of action to achieve
implementation goals
Individual stage of change Characterisation of the phase that an individual is in, as he or she progresses towards
skilled, enthusiastic and sustained use of the intervention
Individual identification with
the organisation
A broad construct related to how individuals perceive the organisation and their
relationship with and degree of commitment to that organisation
Other personal attributes A broad construct to include other personal traits such as tolerance of ambiguity,
intellectual ability, motivation, values, competence, capacity and learning style
Process
Planning The degree to which a scheme or method of behaviour and tasks for implementing an
intervention are developed in advance and the quality of those schemes or methods
Engaging Attracting and involving appropriate individuals in the implementation and use of the
intervention through a combined strategy of social marketing, education, role modelling,
training and other similar activities
Opinion leaders Individuals in an organisation who have formal or informal influence on the attitudes and
beliefs of their colleagues with respect to implementing the intervention
Formally appointed internal
implementation leaders
Individuals from within the organisation who have been formally appointed with
responsibility for implementing an intervention as co-ordinator, project manager, team
leader or other similar role
Champions Individuals who dedicate themselves to supporting, marketing and ‘driving through’ an
implementation, overcoming indifference or resistance that the intervention may provoke
in an organisation
External change agents Individuals who are affiliated with an outside entity that formally influences or facilitates
intervention decisions in a desirable direction
Executing Carrying out or accomplishing the implementation according to plan
Reflecting and evaluating Quantitative and qualitative feedback about the progress and quality of implementation
action accompanied with regular personal and team debriefings about progress and
experience
Reproduced from the Consolidated Framework for Implementation Research.211 This is an Open Access article distributed
in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
See: http://creativecommons.org/licenses/by/4.0/).
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Appendix 9 Example search strategy for the
phase 2 systematic review: barriers to and enablers of
diabetic retinopathy screening attendance
MEDLINE (via Ovid)
1. exp Diabetic Retinopathy/
2. ((diabet$ or proliferative or non-proliferative) adj4 retinopath$).tw.
3. diabetic retinopathy.kw.
4. (diabet$ adj3 (eye$ or vision or visual$ or sight$)).tw.
5. (retinopath$ adj3 (eye$ or vision or visual$ or sight$)).tw.
6. (DR adj3 (eye$ or vision or visual$ or sight$)).tw.
7. or/1-6)
8. exp Mass Screening/
9. exp Vision Tests/
10. exp Telemedicine/
11. exp Photography/
12. exp Ophthalmoscopes/
13. exp Ophthalmoscopy/
14. (ophthalmoscop$ or fundoscop$ or funduscop$).ti.
15. ((exam$ or photo$ or imag$) adj3 fundus).tw.
16. (photography or retinography).tw.
17. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 camera).tw.
18. ((mydriatic or digital or retina$ or fundus or steroscopic) adj3 imag$).tw.
19. screen$.tw.
20. ((eye$ or retina$ or ophthalm$) adj4 exam$).tw.
21. ((eye or vision or retinopathy or ophthalmic) adj4 test$).tw.
22. ((eye$ or retina$ or ophthalm$) adj4 visit$).tw.
23. Office Visits/
24. (telemedicine$ or telemonitor$ or telescreen$ or telehealth or teleophthalmology).tw.
25. or/8-24
26. exp Patient Acceptance of health Care/
27. exp Attitude to Health/
28. exp Health Behavior/
29. Motivation/
30. Fear/
31. exp Self Concept/
32. Personal Autonomy/
33. Self Care/
34. Behavior Therapy/
35. (barrier$ or obstacle$ or facilitat$ or enable$).tw.
36. (knowledge or skill$ or role$ or identity or capabilit$ or optimis$ or consequence$ or reinforcement or
intention$ or goal$ or memory or attention or context$ or resources or emotion$).tw.
37. (decision adj2 process$).tw.
38. (social adj2 influence$).tw.
39. (behavioural adj2 regulation).tw.
40. (competence or self-efficac$ or self-confidence or incentiv$ or reward$ or anxiety fear$ or self-monitor$
or habits).tw.
41. (outcome adj2 expectanc$).tw.
DOI: 10.3310/hta22290 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 29
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Lawrenson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
149
42. (action adj2 plan$).tw.
43. (decision adj2 mak$).tw.
44. (social adj2 (support$ or norm)).tw.
45. ((behaviour$ or behavior$) adj3 (change$ or modif$ or activat$ or control$ or amend$)).tw.
46. (uptake or takeup or attend$ or accept$ or adhere$ or attitude$ or participat$ or facilitat$ or utilisat$
or utilizat$).tw.
47. (motivat$ or satisf$ or promot$ or consent$ or self select$ or self referr$).tw.
48. (complie$ or comply or compliance$ or noncompliance$ or non compliance$).tw.
49. (encourag$ or discourage$ or reluctan$ or nonrespon$ or non respon$ or refuse$).tw.
50. (non-attend$ or non attend$ or dropout or drop out or apath$).tw.
51. Health Education/
52. exp Patient Education as Topic/
53. exp Health Promotion/
54. exp Counseling/
55. ‘Attitude of Health Personnel’/
56. (health adj2 (promotion$ or knowledge or belief$)).tw.
57. (educat$ adj2 (intervention$ or information or material or leaflet)).tw.
58. Focus groups/
59. Interviews as Topic/
60. (focus adj3 group$).tw.
61. Socioeconomic Factors/
62. exp Poverty/
63. Social Class/
64. Educational Status/
65. ((school or education$) adj3 (status or level$ or attain$ or achieve$)).tw.
66. Employment/
67. Uncompensated Care/
68. Reimbursement Mechanisms/
69. Reimbursement, Incentive/
70. (insurance adj3 (health$ or scheme$)).tw.
71. (financial or pay or payment or copayment or paid or fee or fees or monetary or incentiv$ or
disincentiv$).tw.
72. Healthcare Disparities/
73. Health Status Disparities/
74. exp Medically Underserved Area/
75. Rural Population/
76. Urban Population/
77. exp Ethnic Groups/
78. Minority Groups/
79. Vulnerable Populations/
80. ((health$ or social$ or racial$ or ethnic$) adj5 (inequalit$ or inequit$ or disparit$ or equit$ or
disadvantage$ or depriv$)).tw.
81. (disadvant$ or marginali$ or underserved or under served or impoverish$ or minorit$ or racial$ or
ethnic$).tw.
82. or/26-80
83. 7 and 25 and 82)
84. limit 83 to yr = ‘1990 -Current’
85. (ranibizumab or bevacizumab or avastin or aflibercept).ti.
86. (cataract$ or intraocular or glaucoma$ or phaco$ or photocoagulat$ or photodynamic or laser$ or
vitrectom$).ti.
87. (macula$ adj2 (degener$ or oedema or edema)).ti.
88. nerve fiber layer.ti.
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89. (coronary or cardiac or cardio$ or heart or myocardia$ or artery or aneurysm or atrial or
echocardiography or hypertension or hypotension or stroke or pulmonary or COPD or lung$ or organ$
or smoking).ti.
90. (pregnan$ or gestational or neonat$ or perinatal or maternal or trimester or congenital or ovary or
breast$).ti.
91. (kidney or liver or cirrhosis or renal or hepatitis or dialysis or pancrea$ or gastric or gastrectom$ or
surg$ or duoden$).ti.
92. (blood glucose or blood pressure or ketoacidosis or hypoglycemi$ or rosiglitazone).ti.
93. (lipid$ or lipase$ or statin$ or hypercholesterolemia or microalbumin$ or albumin$ or platlet$ or
plasma$ or hemoglobin$ or haemochromat$ or arterial).ti.
94. (cancer$ or carcinoma$ or neoplas$ or adenoma$ or metformin$).ti.
95. (urin$ or incontinence or bladder or constipat$ or bowel$ or faecal or colorectal or colon$).ti.
96. (gene$ or genotype$ or genome$ or genomic or phenotyp$ or biomarker$ or polymorphism$ or
interleukin$).ti.
97. (cell$ or molecular or assay).ti.
98. (cystic or fibrosis or CF or tuberculosis or TB or lupus).ti.
99. (neuropath$ or nephropath$ or prematurity).ti.
100. ($arthritis or steroid$ or osteoporosis or atherosclerosis or sclerosis).ti.
101. (apnea or sleep or limb or oral$ or celiac or coeliac or skin or MRSA or anesthesia or vitamin or HIV or
testosterone or erectile or schizophren$ or bipolar or antipsychotic$ or psychotic$).ti.
102. prevalence.ti.
103. or/85-102
104. 84 not 103
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Appendix 10 Results using a threshold of
£30,000 per quality-adjusted life-year
C hapter 6 reports the model results using a cost-effectiveness threshold of £20,000 per QALY.The model results using a threshold of £30,000 per QALY are reported in this appendix.
Probability that an intervention is cost-effective (compared with no
intervention) for quality improvement interventions at a £30,000 per
quality-adjusted life-year threshold
Intervention
Baseline probability of screening uptake
0.5 0.6 0.7 0.8 0.9
Audit and feedback 0.415 0.351 0.259 0.102 0.013
Case management 0.035 0.022 0.006 0.000 0.000
Team changes 0.850 0.794 0.676 0.319 0.015
Electronic patient registry 0.577 0.527 0.500 0.417 0.202
Clinician education 0.712 0.670 0.619 0.470 0.186
Clinician reminders 0.640 0.554 0.452 0.232 0.038
Patient education 0.809 0.773 0.730 0.628 0.309
Promotion of self management 0.759 0.690 0.565 0.275 0.027
Patient reminders 0.619 0.584 0.546 0.456 0.210
Probability that an intervention is cost-effective (including all
interventions) for quality improvement interventions at a £30,000 per
quality-adjusted life-year threshold
Intervention
Baseline probability of screening uptake
0.5 0.6 0.7 0.8 0.9
No intervention 0.015 0.022 0.053 0.146 0.411
Audit and feedback 0.018 0.014 0.011 0.012 0.003
Case management 0.000 0.000 0.000 0.000 0.000
Team changes 0.201 0.157 0.097 0.038 0.006
Electronic patient registry 0.111 0.132 0.151 0.162 0.144
Clinician education 0.096 0.116 0.128 0.135 0.088
Clinician reminders 0.123 0.100 0.081 0.046 0.018
Patient education 0.213 0.257 0.285 0.294 0.204
Promotion of self-management 0.174 0.138 0.107 0.043 0.012
Patient reminders 0.049 0.064 0.085 0.125 0.113
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Probability that an intervention is cost-effective (compared with no
intervention) for behaviour change technique interventions at a £30,000
per quality-adjusted life-year threshold
Intervention
Baseline probability of screening uptake
0.5 0.6 0.7 0.8 0.9
Patient-targeted interventions
Problem-solving 0.822 0.748 0.597 0.267 0.010
Goal-setting (outcome) 1.000 0.999 0.997 0.961 0.191
Feedback on outcomes of behaviour/biofeedback 1.000 1.000 1.000 0.997 0.866
Social support (unspecified) 0.991 0.989 0.986 0.980 0.937
Social support (practical) 0.884 0.843 0.742 0.404 0.050
Instruction on how to perform the behaviour 0.694 0.590 0.436 0.112 0.005
Information about health consequences 1.000 1.000 0.999 0.999 0.986
Prompts/cues 0.896 0.881 0.880 0.846 0.666
Credible source 0.705 0.682 0.651 0.568 0.364
Restructuring the social environment 0.625 0.586 0.522 0.394 0.181
HCP-targeted interventions
Feedback on outcomes of behaviour/biofeedback 0.776 0.742 0.730 0.634 0.325
Social support (practical) 0.998 0.994 0.901 0.396 0.003
Instruction on how to perform the behaviour 0.616 0.565 0.505 0.347 0.103
Prompts/cues 0.800 0.738 0.630 0.358 0.055
Credible source 0.917 0.884 0.852 0.715 0.339
Restructuring the social environment 0.964 0.879 0.459 0.168 0.002
Adding objects to the environment 0.946 0.947 0.937 0.914 0.798
Probability that an intervention is cost-effective (including all
interventions) for behaviour change technique interventions at a
£30,000 per quality-adjusted life-year threshold
Intervention
Baseline probability of screening uptake
0.5 0.6 0.7 0.8 0.9
No intervention 0.00 0.00 0.00 0.00 0.00
Patient-targeted interventions
Problem-solving 0.000 0.000 0.000 0.000 0.000
Goal-setting (outcome) 0.294 0.203 0.117 0.070 0.017
Feedback on outcomes of behaviour/biofeedback 0.282 0.292 0.313 0.253 0.158
Social support (unspecified) 0.081 0.103 0.130 0.160 0.231
Social support (practical) 0.000 0.000 0.000 0.000 0.000
Instruction on how to perform the behaviour 0.000 0.000 0.000 0.000 0.000
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Intervention
Baseline probability of screening uptake
0.5 0.6 0.7 0.8 0.9
Information about health consequences 0.268 0.353 0.411 0.486 0.528
Prompts/cues 0.000 0.001 0.002 0.002 0.011
Credible source 0.001 0.002 0.002 0.003 0.007
Restructuring the social environment 0.000 0.000 0.000 0.000 0.001
HCP-targeted interventions
Feedback on outcomes of behaviour/biofeedback 0.000 0.000 0.000 0.000 0.000
Social support (practical) 0.067 0.029 0.006 0.001 0.000
Instruction on how to perform the behaviour 0.000 0.000 0.000 0.000 0.000
Prompts/cues 0.001 0.001 0.001 0.001 0.000
Credible source 0.000 0.001 0.001 0.001 0.001
Restructuring the social environment 0.000 0.000 0.000 0.000 0.000
Adding objects to the environment 0.006 0.014 0.015 0.022 0.046
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Appendix 11 The maximum cost per patient for
the quality improvement and behaviour change
technique components
This appendix presents the maximum costs per patient given the mean RD or RR estimated from themeta-regressions for the QI and BCT factors. These results were derived from the maximum cost curves
presented in Chapter 6.
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Estimated maximum costs associated with the mean estimates of effectiveness and the lower and upper limits
of the confidence intervals for different quality improvement components for the models assuming a 1-year
screening interval, including and excluding care costs
Intervention RD (95% CI) RR (95% CI)
Maximum cost per patient (95% CI) (£)
No care costs Care costs
Per patient
Per general
practice (×1000)
England
(×1,000,000) Per patient
Per general
practice (×1000)
England
(×1,000,000)
Audit and feedback 0.00 (–0.18 to 0.16) 1.00 (0.75 to 1.23) 0 (0 to 40) 0 (0 to 2.89) 0 (0 to 117) 0 (0 to 52) 0 (0 to 3.76) 0 (0 to 152)
Case management –0.07 (–0.26 to 0.10) 0.91 (0.63 to 1.14) 0 (0 to 26) 0 (0 to 1.88) 0 (0 to 76) 0 (0 to 33) 0 (0 to 2.39) 0 (0 to 96)
Team changes 0.11 (–0.03 to 0.21) 1.16 (0.96 to 1.29) 29 (0 to 50) 2.10 (0 to 3.62) 84 (0 to 146) 37 (0 to 64) 2.68 (0 to 4.63) 108 (0 to 186)
Electronic patient registry 0.04 (–0.20 to 0.18) 1.05 (0.72 to 1.26) 10 (0 to 45) 0.72 (0 to 3.26) 29 (0 to 131) 13 (0 to 58) 0.94 (0 to 4.20) 38 (0 to 169)
Clinician education 0.09 (–0.11 to 0.18) 1.12 (0.85 to 1.25) 22 (0 to 44) 1.59 (0 to 3.18) 64 (0 to 128) 29 (0 to 57) 2.10 (0 to 4.12) 84 (0 to 166)
Clinician reminders 0.06 (–0.13 to 0.20) 1.09 (0.81 to 1.29) 17 (0 to 49) 1.23 (0 to 3.55) 50 (0 to 143) 22 (0 to 64) 1.59 (0 to 4.63) 64 (0 to 186)
Patient education 0.10 (–0.08 to 0.19) 1.14 (0.88 to 1.27) 25 (0 to 47) 1.81 (0 to 3.40) 73 (0 to 137) 32 (0 to 61) 2.32 (0 to 4.41) 93 (0 to 178)
Promotion of self-management 0.09 (–0.07 to 0.21) 1.13 (0.90 to 1.30) 24 (0 to 51) 1.74 (0 to 3.69) 70 (0 to 149) 31 (0 to 65) 2.24 (0 to 4.70) 90 (0 to 189)
Patient reminders 0.05 (–0.14 to 0.16) 1.07 (0.80 to 1.23) 13 (0 to 40) 0.94 (0 to 2.89) 38 (0 to 117) 17 (0 to 52) 1.23 (0 to 3.76) 50 (0 to 152)
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Estimated maximum costs associated with the mean estimates of effectiveness and the lower and upper limits
of the confidence intervals for different behaviour change techniques for the models assuming a 1-year
screening interval, including and excluding care costs
Intervention RD (95% CI) RR (95% CI)
Maximum cost per patient (95% CI) (£)
No care costs Care costs
Per patient
Per GP practice
(×1000)
England
(×1,000,000) Per patient
Per GP practice
(×1000)
England
(×1,000,000)
Patient-targeted interventions
Problem-solving 0.11 (–0.04 to 0.21) 1.16 (0.95 to 1.30) 30 (0 to 50) 2.17 (0 to 3.62) 87 (0 to 146) 38 (0 to 64) 2.75 (0 to 4.63) 111 (0 to 186)
Goal-setting (outcome) 0.23 (0.16 to 0.27) 1.33 (1.23 to 1.38) 58 (41 to 68) 4.20 (2.97 to 4.92) 169 (119 to 198) 72 (52 to 83) 5.21 (3.76 to 6.01) 210 (152 to 242)
Feedback on outcomes
of behaviour/biofeedback
0.21 (0.12 to 0.25) 1.30 (1.17 to 1.36) 50 (31 to 64) 3.62 (2.24 to 4.63) 146 (90 to 186) 64 (39 to 78) 4.63 (2.82 to 5.64) 186 (114 to 227)
Social support
(unspecified)
0.17 (0.04 to 0.24) 1.24 (1.06 to 1.34) 42 (11 to 59) 3.04 (0.80 to 4.27) 122 (32 to 172) 54 (14 to 73) 3.91 (1.01 to 5.28) 157 (41 to 213)
Social support (practical) 0.12 (–0.02 to 0.20) 1.17 (0.97 to 1.29) 30 (0 to 49) 2.17 (0 to 3.55) 87 (0 to 143) 39 (0 to 63) 2.82 (0 to 4.56) 114 (0 to 184)
Instruction on how to
perform the behaviour
0.09 (–0.06 to 0.18) 1.12 (0.91 to 1.26) 23 (0 to 45) 1.66 (0 to 3.26) 67 (0 to 131) 29 (0 to 58) 2.10 (0 to 4.20) 84 (0 to 169)
Information about health
consequences
0.20 (0.11 to 0.25) 1.29 (1.15 to 1.35) 48 (28 to 62) 3.47 (2.03 to 4.49) 140 (82 to 181) 63 (36 to 77) 4.56 (2.60 to 5.57) 184 (105 to 224)
Prompts/cues 0.10 (–0.05 to 0.19) 1.14 (0.93 to 1.27) 25 (0 to 46) 1.81 (0 to 3.33) 73 (0 to 134) 33 (0 to 60) 2.39 (0 to 4.34) 96 (0 to 175)
Credible source 0.06 (–0.14 to 0.19) 1.09 (0.80 to 1.27) 18 (0 to 47) 1.30 (0 to 3.40) 52 (0 to 137) 23 (0 to 60) 1.66 (0 to 4.34) 67 (0 to 175)
Restructuring the social
environment
0.05 (–0.13 to 0.17) 1.07 (0.81 to 1.25) 13 (0 to 43) 0.94 (0 to 3.11) 38 (0 to 125) 17 (0 to 55) 1.23 (0 to 3.98) 50 (0 to 160)
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Intervention RD (95% CI) RR (95% CI)
Maximum cost per patient (95% CI) (£)
No care costs Care costs
Per patient
Per GP practice
(×1000)
England
(×1,000,000) Per patient
Per GP practice
(×1000)
England
(×1,000,000)
HCP-targeted interventions
Feedback on outcomes
of behaviour/biofeedback
0.07 (–0.08 to 0.17) 1.10 (0.89 to 1.24) 19 (0 to 43) 1.37 (0 to 3.11) 55 (0 to 125) 24 (0 to 55) 1.74 (0 to 3.98) 70 (0 to 160)
Social support (practical) 0.25 (0.16 to 0.28) 1.35 (1.23 to 1.40) 61 (41 to 71) 4.41 (2.97 to 5.14) 178 (119 to 207) 76 (53 to 86) 5.50 (3.84 to 6.22) 221 (154 to 251)
Instruction on how to
perform the behaviour
0.04 (–0.12 to 0.16) 1.06 (0.83 to 1.23) 12 (0 to 40) 0.87 (0 to 2.89) 35 (0 to 117) 15 (0 to 51) 1.09 (0 to 3.69) 44 (0 to 149)
Prompts/cues 0.12 (–0.07 to 0.22) 1.17 (0.90 to 1.32) 31 (0 to 54) 2.24 (0 to 3.91) 90 (0 to 157) 40 (0 to 68) 2.89 (0 to 4.92) 117 (0 to 198)
Credible source 0.11 (–0.03 to 0.20) 1.16 (0.96 to 1.29) 30 (0 to 49) 2.17 (0 to 3.55) 87 (0 to 143) 38 (0 to 63) 2.75 (0 to 4.56) 111 (0 to 184)
Restructuring the social
environment
0.19 (0.08 to 0.25) 1.27 (1.12 to 1.35) 47 (22 to 62) 3.40 (1.59 to 4.49) 137 (64 to 181) 61 (28 to 76) 4.41 (2.03 to 5.50) 178 (82 to 221)
Adding objects to the
environment
0.13 (–0.02 to 0.21) 1.18 (0.98 to 1.31) 33 (0 to 52) 2.39 (0 to 3.76) 96 (0 to 152) 42 (0 to 66) 3.04 (0 to 4.78) 122 (0 to 192)
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